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ABSTRACT
The serotonin type-3 receptor (5 -HT3R) is widely distributed in peripheral and central 
nervous systems. This pentameric protein is a member of the Cys-loop superfamily of 
ligand gated ion channels and plays a role in mediating physiological processes in 
nervous, cardiovascular, and digestive systems. The ligand-binding domain of this 
receptor is extracellularly located and is composed of multiple putative loop structures. 
Based on structural and sequence homology with other members of the superfamily, it 
has been proposed that at least six such loops (loops A to F) contribute to the ligand- 
binding domain. Binding of agonist initiates a conformational change which is transduced 
to the channel, leading to channel opening (gating). The aim of this study was to 
elucidate the contribution of residues in loops B and E to the mechanism of channel 
gating in the 5 -HT3R. To this end, the three critical tyrosine residues in the loop E region 
were characterized employing site-directed mutagenesis, electrophysiological studies as 
well as radio-ligand binding assays involving two structural classes of 5 -HT3R agonists. 
In addition, structure/function analysis of the loop B region was carried out alanine- 
scanning mutagenesis. Experimental data were correlated with molecular modeling 
studies. These studies show that the hydroxytryptamine and phenylbiguanide class of 
compounds utilize different mechanisms of ligand binding and gating in the 5 -HT3R. 
Studies involving the loop B reveal that this region plays a critical role in ligand binding 
and channel gating. Data obtained from comparison of ground state and agonist-bound 
models of the 5 -HT3R was correlated with biochemical data. Taken together, these data 
suggest that agonist interaction with loop B region probably initiates a conformational
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
wave that results in intra- and inter- subunit hydrogen bonding interactions. Our 
suggest that these interactions play a critical role in agonist-induced channel opening.
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1Chapter 1: Introduction
Ionic concentrations inside and outside of cells, not only maintain the physiological 
homeostasis but also mediate the dynamics of various biological functions. Ion channels 
are complex membrane proteins that allow ions to flow in and out of cells in a controlled 
fashion. Literally, thousands of different ion channels from various species, including 
bacteria, have been identified and most of the physiological processes involve ion 
channels directly or indirectly. As expected, malfunction of specific type ion channels 
leads to distinct pathological states. Importance of ion channel research is amply 
illustrated by their special relevance to clinical cardiology, clinical nephrology, and 
clinical neurology.
1.1 Historical perspective
The history of ion channel research dates back to the early 18th century. Luigi Galvani 
demonstrated in 1792 that an isolated muscle from frog leg could be made to spasm with 
electric stimulation. He coined the term bioelectricity for this phenomenon. In 1902, 
Julius Bernstein proposed the membrane hypothesis. Using the Nerst equation, he 
suggested that nerves are surrounded by semi-permeable membrane, which allows 
selective passage of K+ out of the neuron, in turn generating the resting membrane 
potential. He also suggested that temporary changes in this potential, as a result of loss of 
selective K+ permeability, causes action potential. It was later revealed that not only K+ 
but other ions such as Na+, Ca++ and Cl' play a role in this phenomenon. The era of 
classical biophysics started with the work of John Young (1937), when he first attempted
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
the use of giant squid axon to measure ionic currents. In classical studies, which used the 
same experimental model of giant squid axon, Hodgkin, Huxley and Katz were able to 
show that Na+ and K+ indeed move across the neuronal membrane to produce currents 
responsible for generating the action potential. These studies were made possible due to 
the development of voltage-clamp by Kenneth Cole in 1949. However, it was not untill 
1974 that it was first demonstrated that ion channels exist as discreet protein molecules 
and conduct currents across the membrane. Using a muscle membrane preparation 
containing nicotinic acetylcholine receptor, Neher and Sakmann were able to demonstrate 
ionic currents through single nicotinic acetylcholine receptor ion channel. This 
remarkable feat was achieved though development of a novel electrophysiological 
technique called patch-clamp. Almost 70 years after the receptor hypothesis was first 
published (John Langly, 1907), it was shown conclusively that ion channels are an 
integral part of certain surface receptors (in this case for acetylcholine).
1.2 A brief classification of ion channels according to the mechanism of gating1
1) Voltage-gated ion channels: These ion channels have a voltage sensor in the trans­
membrane region, which directs the opening and closing of the channel gate. 
Members of this family include sodium, potassium, calcium, proton and anion 
conducting channels.
2) Mechamo-sensitive ion channels (Stretch-Activated ion Channels; SAC): This class of
ion channels responds to mechanical stress, such as stretch. These types of ion 
channels are involved in mediating pressure and sound sensation. CLC group of
1 This classification is a modified version o f  ion channel classification published on the World Wide Web 
at CFTR review page at http://opal.msu.montana.edu/cftr/default.htm
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mechano-sensitive chloride channels are activated by hyperpolarization and 
changes to cell volume.
4) Ligand-gated ion channels: These ion channels are gated by agonist molecules
interacting with a binding domain, which is usually located away from the actual 
channel gate. Extracellular ligand-gated ion channels, with the exception of 
glutamate receptors, are pentameric. The prototype of this superfamily is nicotinic 
acetylcholine receptor. G A BA a and GAB Ac, Glycine and 5 -HT3 receptors 
constitute other members of this superfamily.
5) Intracellular ligand-gated ion channels: Chloride conducting cystic fibrosis
transmembrane conductance regulator (CFTR), members of ABC (ATP Binding 
Cassette) family of transporters, Amiloride-sensitive sodium channels, Calcium- 
activated Chloride Channels (CICas) and several members of ASIC family form 
this group of ion channels. These ion channels are stimulated indirectly through 
G-protein coupled receptor stimulation. These ion channels can also be activated 
by intracellular entities such as ions (calcium), nucleotides (ATP, GMP, cyclic 
AMP) and phospholipid derivative phosphatidyl inositol (PI).
1.3 Physiological role of ligand-gated ion channels: Fast synaptic transmission at the 
neuro-muscular junction.
The physiological role of the two major classes of ion channels (i.e., voltage- and 
ligand-gated ion channels) can be described using the model system of muscle nicotinic 
acetylcholine receptor (muscle nAChR) mediated neuro-transmission at the nerve-muscle 
junction. The neuro-muscular junction is formed by the axon of the stimulatory motor
3
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neuron that arises in the spinal cord. The cell-body of the motor neuron is located in the 
anterior horn of the spinal gray mater. The dendrites of the motor neuron form central 
synapses with axons of central motor neurons. Action potential is generated in the central 
synapse and travels down the cell body and the axon towards the nerve-muscle junction. 
The action-potential generated by the transmission of impulse through the motor neuron 
is mediated by voltage-sensitive sodium channels. Under resting conditions, the cell 
membrane of the dendrite is held at approximately -90 mV. A local electrical disturbance, 
usually in the form of a change towards positive in the membrane potential, at the central 
synapse causes activation of voltage-sensitive sodium channels. The opening of these 
channels leads to movement of the sodium ions into the dendrite, which causes further 
changes to membrane potential. This sets into motion a train of events where the local 
electrical change in the membrane potential is propagated through the end of the axon, 
into the pre-synaptic terminal of the neuro-muscular junction. This is achieved by a wave 
of openings of voltage-sensitive sodium channels located mainly at the nodes of Ranvier. 
At the neuro-muscular junction, the arrival of an action potential leads to opening of 
calcium channels that cause a rise in the local calcium concentration. The raised calcium 
levels cause the endogenous neuro-transmitter acetylcholine (ACh) filled vesicles to 
dump large amounts of ACh in the synapse. Muscle nAChRs are hetero-pentameric 
complexes of proteins with a ligand-binding region that binds ACh. Ion channels are 
expressed on the muscle cell surface and are clustered near the post-synaptic terminal. 
The binding site for neurotransmitter the ACh is located in the extra-cellular domain, 
which probably allows easy contact with the neuro-transmitter released in the synapse.
4
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The binding of the neurotransmitter is followed by opening of the ion channel pore that 
allows a rush of cations, such as calcium and sodium, through the open ion channels into 
the interior of the sarcoplasm of the muscle cell. These events again lead to local changes 
in membrane, called ‘end-plate potentials’. The resulting change in the membrane 
potential leads to a further release of calcium from the intra-cellular calcium depots, 
causing an interaction between actin and myosin filament through complex steps, 
ultimately resulting in muscle contraction.
1.4 5-HT3 receptor is a member of ‘Cys-loop’ superfamily of ligand-gated ion 
channel receptors.
The 5 -HT3A receptor shows high degree of sequence and structural homology with the 
nicotinic acetylcholine receptor and other members of the Cys-loop family. A sequence 
alignment of all members of this family suggests that 5 -HT3A receptor subunit has a large 
extracellular N-terminal domain, four transmembrane domains (TM 1-4) and a small 
extracellular C-tail. The N-terminal domain continues as the first transmembrane domain 
(TM1). The N-terminal domain also contains the signature Cys-loop, which is a stretch of 
11 amino acids marked at both ends by a cysteine (C161-C174 in mature protein). Two 
small cytoplasmic and one small extracellular loops connect four transmembrane 
domains. Five such subunits come together to form the homopentameric receptor. The 
ion channel is an integral part of the protein and is lined by one side of five TM-2 
domains.
Seven types (5-HT1 to 7) and 14 subtypes of serotonin (5-HT) receptors have 
been discovered over last five decades. However, the realization that 5 -HT3 receptor is an
5
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ion channel is relatively recent. All other members of this family are G-protein coupled 
receptors and mediate slower forms of neuronal and non-neuronal signal transmission. 
The possibility of the existence of a neuronal type 5-HT receptor was suggested as early 
as 1957 by Gaddum and Picarelli (Gaddum and Picarelli, 1957). They suggested the 
existence of serotonin-M receptor, which was sensitive to Morphine inhibition and 
insensitive to inhibition by LSD. Although several later studies suggested the presence of 
a specific 5-HT receptor in the peripheral neuronal tissue, specific information was 
unavailable. In 1986, Bradley and colleagues renamed the serotonin-M receptor as 5- 
HT3R. Detailed pharmacological characterization of 5 -HT3R had to await the 
development of specific ligands, such as antagonists tropisetron, zacopride, granisetron, 
MDL-72222 and agonists 2-methyl 5-HT, phenylbiguanide and w-chloro 
phenylbiguanide (Costall and Naylor, 2004). In the late 80’s and the early 90’s, interest in 
5 -HT3R research was rejuvenated by the discovery that 5 -HT3R antagonists were potent 
anti-emetics, especially for post-chemotherapy nausea and vomiting. In 1989, 5 -HT3R 
was shown to be a cell membrane bound, cation-specific, ligand-gated ion channel. Using 
patch-clamp assay, Derkach et al. showed that 5-HT induced single-channel currents 
from membrane patches of guinea pig sub mucosal plexus. These unitary currents could 
be specifically blocked by 5 -HT3 receptor antagonists (Derkach et al., 1989). The full 
nucleotide and deduced protein sequence of mature murine 5 -HT3A receptor was 
published in 1991 (Maricq et al., 1991). Since then, 5 -HT3R sequences for multiple 
species e.g. porcine (Lankiewicz et al., 1998) and human (Belelli et al., 1995) have been 
reported. Splice variants of 5 -HT3A subunit have also been reported (for review, see
6
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(Reeves and Lummis, 2002). For the studies described in this thesis, we have used the 
short splice variant of murine 5 -HT3A receptor. The short form is termed 5-HT3AS 
receptor, and is six amino acids shorter than the long form (termed as 5-HT3al)- The 
missing amino acids (G385-L390) are from the second cytoplasmic loop, which connects 
M3 and M4 regions. The two splice variants show differences only in relative efficacy 
values (relative to 5-HT) for 2-methyl 5-HT and mCPBG (Niemeyer and Lummis, 1998). 
In a mutagenesis study involving the aforesaid 6 amino acids, no clear conclusion about 
their specific role in the efficacy of 2-methyl 5-HT and wCPBG could be drawn. In this 
regard, it is interesting to note that the second cytoplasmic loop plays a role in 
determining ionic conductance through the homomeric 5-HT3aR ion channel. Three 
arginine residues at positions 432, 436 and 440 in the second intracellular loop (a region 
called the HA stretch) cause an inhospitable ionic environment for cation conduction in 
the homomeric receptors. The absence of such a stretch in heteromeric 5 -HT3AB receptors 
is thought to be responsible for the higher conductance of the 5 -HT3AB receptor (Kelley et 
al., 2003). It is possible that the lack of amino acids G385-L390 causes structural changes 
in the HA stretch, which may cause 2-methyl 5-HT and mCPBG mediated channel 
opening to be modulated differently compared to the 5-HT3Al  isoform.
For both mouse and human, the sequence of the 5 -HT3B subunit has also been 
reported (Davies et ai., 1999; Stewart et al., 2003). Recent studies have identified the 
presence of 5 -HT3C, D and E subunit-like genes in human genome (Kamovsky et al., 
2003; Niesler et al., 2003). It has been suggested that 5 -HT3 receptors in the peripheral
7
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nervous system are mostly 5 -HT3AB heteropentamers, while those in central nervous 
system are 5-HT3A homopentamers (Morales and Wang, 2002).
1.5 Primary, secondary, tertiary and quaternary structure of 5 -HT3R
Mature single subunit of 5 -HT3 receptor is -480 amino acids long and weighs -50 kDa 
(-65 kDa when glycosylated) (Hovius et al., 1998; McKeman et al., 1990). N-terminal 
domain, which is predicted to exist mostly as p-strands, is extra-cellular. Similar to the 
nAChR, the binding site is contained at the subunit interface at the N-terminal (Arias, 
2000; Brejc et al., 2001; Eisele et al., 1993). Secondary structure of the 5 -HT3AR N- 
terminal domain is predicted to be very similar to that of the nAChR (Brejc et al., 2001; 
Karlin, 2002; Reeves and Lummis, 2002). These assumptions have been confirmed 
through the use of a downscaled version of Fourier transform infrared spectroscopy 
(FTIR) for both 5-HT3AR and nAChR under identical conditions (Rigler et al., 2003). The 
results of these studies predict that both receptors are 36% a-helix, 33% p-strand, 15% P- 
tum, and 16% non-regular structures. These results complement computational models 
based on the structure of the AChBP. 5 -HT3R assembles as a homo- or hetero-pentamer 
(Brejc et al., 2001; Green et al., 1995; Hovius et al., 1998; Lummis and Martin, 1992). 
Using a purified receptor preparation, electron micrographs of the murine 5 -HT3A 
receptor were obtained (Boess et al., 1995; Green et al., 1995), which show the receptor 
as a doughnut shaped pentamer of size -70X140 A with a - 2 0  A central pore.
1.6 Assembly, trafficking and cell-surface localization of the 5-HT3R
Studies using immunocytochemistry have shown that subunit A of the 5 -HT3 receptor can 
assemble as a homo-pentamer in neuronal cells as well as immortalized cell lines. This
8
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
assembly takes place in the endoplasmic reticulum with the help of a variety of chaperon 
proteins. Binding sites on homopentameric receptors are probably formed during the 
assembly process in the endoplasmic reticulum. The 5 -HT3B subunit alone cannot 
assemble into functional ion channels at the endoplasmic reticulum level; it can only co- 
assemble with 5 -HT3A subunit as a hetero-pentamer (Boyd et al., 2002). The 5 -HT3B 
subunit, when expressed alone, gets trapped in the endoplasmic reticulum, and is 
degraded therein. A sequence of amino acids in the first cytoplasmic loop of 5 -HT3B 
subunit may be responsible for this retention. Within the endoplasmic reticulum, 
chaperone proteins, BiP and calnexin interact with 5 -HT3R and probably aid in its 
assembly. These ‘helper’ proteins may also be involved in degradation of partially 
formed subunits (Boyd et al., 2002).
Both 5 -HT3A and 5 -HT3AB receptors become N-glycosylated at 3 putative sites of 
glycosylation: N109, N174; and N190 (Quirk et al., 2004). N-glycosylation adds to the 
molecular weight of the mature protein (Green et al., 1995). Early studies suggested that 
N-glycosylation does not play a role in receptor assembly or ligand-binding. However, 
Quirk et al., using site-directed mutagenesis and Tunicamycin treatment (which inhibits 
glycosylation), have shown that N109 is involved in correct receptor assembly. These 
studies also suggest a role of glycosylation at N109, N174 and N190 in membrane 
targeting of the 5-HT3 receptor as well as receptor-ligand interaction. After assembly 5- 
HT3R.S are transported to the neuronal cell surface, where they cluster at high 
concentrations at functionally important areas, such as micropodia in HEK293 cells (a
9
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non-neuronal cell-line) and dendritic spines of hippocampal neurons (Grailhe et al., 
2004).
1.7 Central and peripheral distribution of the S-HTjR
Early studies examining distribution of 5 -HT3R in rat brains utilized high affinity, 
specific binding of the antagonist [3H]GR65630. These studies suggested that 5-HT3RS 
are widely distributed in rat cortical and limbic areas (Kilpatrick et al., 1987). The 
distribution of 5 HT3R in rat brain was also studied using immunocytochemistry. In 
studies reported by the Bloom group, various polyclonal antibodies raised against 
synthetic peptides based on the primary sequence of the 5 HT3R were utilized (Morales et 
al., 1998). The 5HT3R-immunoreactive neurons could be detected in the forebrain (layers 
II-III of the neocortex, anterior olfactory nucleus, hippocampal formation, amygdala, 
caudate putamen, nucleus accumbens), brainstem (nuclei for cranial nerves trigeminal 
motor (V) and facial (V II)) and dorsal and the ventral horn of the spinal cord. A similar 
study indicated that 5 -HT3R is distributed in forebrain (isocortex, olfactory regions, 
hippocampal formation and amygdala), brainstem (sensory and motor nuclei and nuclei 
of the reticular formation) and spinal cord (dorsal and ventral horn) o f  the rat central 
nervous system (Morales et al., 1996). In rat neocortex and hippocampus, the majority of 
5 -HT3R are expressed on GABAergic neurons, suggesting a modulatory role of 5 -HT3R 
in release of GABA and it's mediation of inhibitory neurotransmission (Morales et a l, 
1996). Such a wide distribution is suggestive of a broad role played by 5 -HT3R in 
synaptic transmission. In the peripheral nervous system, 5 -HT3RS are expressed in dorsal 
root and nodose ganglia, vagus nerve and intestinal submucosal plexus. In rat
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gastrointestinal system, 5 -HT3R.S are localized to neurons of the myenteric and 
submucosal plexus, fibers in the circular and longitudinal muscles, submucosa, and 
mucosa. 5 -HT3R immuno-reactivity can also be detected in interstitial cells of Cajal 
(Glatzle et al., 2002). Interestingly, peripheral 5 -HT3R.S can be both homomeric and 
heteromeric, while central 5 -HT3R are essentially homomeric (Morales and Wang, 2002). 
These differences in composition probably reflect the differential modualtory role played 
by these receptors.
In the mouse nervous system, the distribution is very similar to that seen in the rat 
nervous system. In mouse cerebral cortex, groups of neurons in piriform, cingulate, and 
entorhinal areas are labled with 5 -HT3R specific in-situ hybridization. Areas of the limbic 
system, such as intemeurons of hippocampal formation, posteroventral hippocampal 
region and the molecular layer of CA1 also contain 5 -HT3RS. Based on this distribution 
in the hippocampal region, it was suggested that 5 -HT3 receptors inhibit pyramidal cell 
populations via excitation of inhibitory intemeurons. 5 -HT3RS are also present on 
neurons of the amygdaloid complex, the olfactory bulb, the trochlear nerve nucleus, the 
dorsal tegmental region, the facial nerve nucleus, the nucleus of the spinal tract of the 
trigeminal nerve, and the dorsal horn of spinal cord. In the murine peripheral nervous 
system, 5-HT3RS are also located on the dorsal root ganglion (Tecott et al., 1993).
Quantitative in vitro autoradiography in combination with [3H] ICS 205-930 (a 
selective 5 -HT3R antagonist) was applied to study the distribution of 5 -HT3R in post­
mortem human brain tissue. 5 -HT3RS were localized to discrete nuclei of the lower 
brainstem and the substantia gelatinosa at all levels of the spinal cord (Waeber et al.,
i l
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1989). Another study employing [3H]Zacopride revealed low levels of binding localized 
to the limbic system, perticularly to amygdala and hippocampus. These receptors were of 
a single population, probably of 5-HT3A type homomeric receptors. 5-HT3R were also 
localized with high densities in the area postrema, a finding which is in accordance with 
the proposed central mechanism of anti-emetic action of 5 -HT3R antagonists (Barnes et 
al., 1989).
L8 Gating and desensitization kinetics of LGIC coupled receptors including 5-
HT3AR
Attempts at functionally isolating 5 -HT3RS were initially limited by complications 
arising from a mixture of 5-HT receptors present in neuronal cell lines. Thus, early 
studies of receptor function were based solely on the use of 5 -HT3R specific receptor 
ligands such as the antagonist ICS 205-930 and agonist 2-Methyl 5-HT. Large quantities 
of nicotinic acetylcholine receptors can be purified from electric organ of Torpedo eel. 
Before the advent of molecular biology techniques, biochemical studies of the nAChRs 
utilized these protein preparations. However, no such source of purified protein are 
available for the 5 -HT3RS.
Initial studies indicated that 5 -HT3R caused membrane depolarization in neurons. 
These studies employed intracellular recordings made from parasympathetic neurons of 
the rabbit vesical pelvic ganglia. In such neurons 5-HT caused a membrane 
depolarization that could be competitively antagonized by ICS 205-930, a specific 5- 
HT3R antagonist. These currents were resistant to inhibition by non-specific blocker of 
non-5-HT3 5-HT receptors (e.g., 5-HT1, 5-HT2 etc) methysergide (Akasu et al., 1987).
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Membrane depolarization induced by 5 -HT3R in turn was shown to lead to the generation 
of action potential and other post-synaptic events (Surprenant and Crist, 1988). A detailed 
characterization of receptor kinetics was however obtained from whole-cell voltage- 
clamp studies using cultured hippocampal neurons, which natively express 5 -HT3R. 
Rapid application of 5-HT (the natural full agonist) to such cells caused rapid inward 
currents with rapid desensitization. The rapidity of the response suggested coupling of 5- 
HT receptor and the ion channel (Yakel and Jackson, 1988).
1.8.1 Stochastic behavior of the 5-HT3R and its relationship to the macroscopic 
events
The macroscopic events of opening and desensitization (waveform of macroscopic 
currents) are a transition of a population of receptors through various states. However, at 
the level of a single ion channel, such transitions are stochastic (random events governed 
by probability). These probabilities, however, are distinct entities which can be calculated 
from experimental observations obtained from single-channel recording. Such 
calculations are based on certain assumptions. One important assumption is that a single 
ion channel follows Markovian processes. If it is assumed that a single channel oscillates 
between a closed and an open state, then the process can be written as:
C £ = ;  O
Where C is dosed and O is open state. A Markovian process assumes that a 
constant probability exists of change in the state of ion channel (e.g. from closed to open) 
in a short period of time dt, and such probability does not depend upon how much time
13
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was spent by the channel in the closed state before beginning of ck and how it reached the 
closed state (i.e. from either the open or from desensitized state, if desensitized state is 
assumed). However, at the level of a single ion channel the probability is only predictive. 
For example, given a 0.3 probability of transition from closed to open state in 0.1 ms, an 
ion channel has a 3/10 probability of passing from closed to open state if observed for 0.1 
ms; which may or may not happen given a single observation. Based on such 
probabilities, predictions about behavior of a large number of ion channels can be easily 
made. Given a large population of ion channels, in 0.1 ms 30% of ion channels will pass 
from closed to open state in 0.1 ms and 70% will be in closed state. In next 0.1 ms the 
next 30% of closed population will change into open state. Over a period of 10 such 
periods (0.1 X 10 = 1 ms), a single exponential describing channel opening is obtained. A 
similar exponential can be obtained for channel closing. The probability of transition 
from one state to another is expressed in terms of transition rates when applied to 
macroscopic system. Such rates have units of frequency (per second, s '1). Thus 
macroscopic currents can be used as a direct reflection of probabilities of various 
lifetimes.
The functioning of 5-HT3 receptors can actually be considered in three distinct 
states; two in equilibrium conditions and one in a non-equilibrium condition. In each of 
these conditions, the passage of receptor from one state to other follows the law of mass 
action. The law of mass action states that the rate of a given reaction is proportional to the 
product of reactant concentrations at any given time. Under equilibrium conditions, the 
equilibrium constant determines the rate of reaction, since the rate of product formation
14
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and product breakdown is the same. Under non-equilibrium conditions, the forward and 
backward reaction rates determine the overall reaction rate, which keeps changing 
exponentially until equilibrium is reached.
The receptor exists in an equilibrium condition under resting conditions, with no 
contact with agonist molecules. In such conditions, the energy barriers that oppose 
transformation into the open state cannot be easily overcome, and the protein can only 
rarely venture into the open state. The receptors also exist in an equilibrium condition in 
continuous presence of the agonist. Various equilibrium constants determine the 
proportion of receptors in various states. In a receptor where there are two states; closed 
and open, continued presence of agonist will result in equilibrium condition where a 
proportion of receptors remain in the open state. This proportion will be dictated by the 
equilibrium constant. However, ligand-gated ion channels pass into a second close state 
in continuous presence of agonist, the desensitized state. Thus, in continued presence of 
agonist, the receptor population at any given time will be separated into desensitized, 
open, or closed states. For example, in continuous presence of the agonist 5-HT, 5 -HT3R 
prefers the desensitized state, which probably reflects the most stable receptor 
confirmation in presence of agonist.
A non-equilibrium or kinetic state exists when a population of receptors is 
simultaneously exposed to a quantum of agonist. Under such conditions, the macroscopic 
currents can be useful in measuring kinetic rates.
15
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1.8.2 Kinetic parameters of inward currents produced by 5-HTsa R
At supra-maximal concentrations, 5-HT is the most efficacious agonist on wild- 
type (wt) receptors. At such concentrations, mCPBG elicits only 92 (±1) % of the current 
produced by 5-HT. Agonists 2-Me5HT and PBG also behave as partial agonists; 
producing only 12 (±1) and 87 (±7) % of 5-HT induced currents. These data suggest that 
the open conformation of the wild type 5-HT3ASR channel is most efficiently stabilized 
by the endogenous agonist 5-HT, followed by mCPBG, PBG and least efficiently by 2- 
Me5HT. These values were obtained in the course of the study described in chapter 4.
Three major macroscopic states are observed with 5 -HT3R mediated inward 
currents; closed, open and desensitized. Upon fast application of agonist to cells 
expressing murine 5-HT3AR, a rapid inward current with sharp peak is observed. In 
continued presence of agonists murine 5-HT3A receptors desensitize with an apparent 
biphasic course, a rapid desensitization phase and a slow desensitization phase. A small 
percentage of the response is non-desensitizing. The response returns to the baseline with 
removal of agonist. The EC50 for 5-HT determined for recombinant murine 5-HT3A 
receptors ranges from -2-4 joM with Hill slope of 1.7-3 (Barann et al., 1997; Gunthorpe 
and Lummis, 1999; Hussy et al., 1994; Joshi et al., 2004; Maricq et a l, 1991; Mott et al., 
2001; van Hooft and Vijverberg, 1996).
Kinetics of activation can be measured by rapid pulses of agonist, where solution 
exchange is achieved in 1-5 ms. m5-HT3AR demonstrates slow activation time (mean ± 
s .e .m . 10-90 % rise time 12.5 ± 1.6 ms for 100 pM 5-HT). The rising waveform of the 
response can be fit to a single exponential waveform and yields a time constant (x) of 7.3
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ms. Given the x and the total rise time, the activation rate was calculated to be 136/s 
(Mott et al., 2001). The slow activation rate is presumably a function of slow 
conformational changes and not of slow agonist binding rates, since no significant 
difference in activation time could be detected at 2X EC50 and 20X EC50 concentrations 
of 5-HT (Yang et al., 2000). Activation rates for mCPBG-induced responses are about 2.2 
fold slower than those of 5-HT.
Kinetics of deactivation can be measured by ultra-short pulses of agonist (for 2-5 
ms). The rate of decay in maximum response amplitude in experiments measuring 
deactivation probably conveys the measure of agonist unbinding rate, and hence the rate 
of receptor deactivation. Rate of desensitization is measured simply by using longer 
agonist perfusions, which allows most of the receptors to reach desensitized state. 
Interestingly, the time constants (x) for both desensitization and deactivation of the 5- 
HT3ARs are almost identical, suggesting that agonist unbinding from the activated 
receptor occurs at the same rate as transition of activated receptor into the desensitized 
state (Bartrup and Newberry, 1996; Neijt et al., 1989). Mott et al. (Mott et al., 2001) 
report slower deactivation rates compared to desensitization rates in a population of 
patches, indicating that certain biological factors may also be controlling desensitization 
kinetics. Various studies have described the role of calcium, as well as factors controlling 
receptor phosphorylation in modulation of desensitization kinetics.
The slow activation and deactivation of the 5-HT3R is unique among all the 
ligand-gated ion channels. With the exception of NMDA receptors (Clements et a l, 
1998), all other ligand-gated ion channels demonstrate much faster rates of activation and
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deactivation i.e., nicotinic acetylcholine muscle receptors at 12000/sec (Liu and Dilger, 
1991), GABAa receptors at 6000/sec (Maconochie et al., 1994), a  1-glycine receptors at 
2200/sec (Grewer, 1999). AMP A receptors (Mosbacher et al., 1994), kainite receptors 
and purinergic P2X receptors (Evans et al., 1992) also demonstrate faster activation rates. 
The 5 -HT3R is unique among ligand-gated ion channels since it also belongs to the 5-HT 
class of receptors, which are G-protein coupled receptors. These G-protein coupled 
receptors are primarily involved in mediating slow synaptic transmission of a modulatory 
nature. It has been suggested that 5-HT3R may also be involved in mediating slower 
(among ligand-gated ion channels) types of synaptic transmission (Jackson and Yakel, 
1995).
In continued presence of agonists 5-HTsaRs desensitize, with the time constant 
(x) of -300 ms (Mott et al., 2001). The biphasic course of desensitization in can be fitted 
to the sum of two exponential components with time constants xsiow= 2300-6000 ms and 
tfast- 170-570 ms (Jones and Yakel, 1998; Mott et al., 2001; Yakel et al., 1991; Yang et 
al., 1992). Recovery from /wCPBG-induced desensitization is about 5 times slower than 
5-HT induced desensitization.
Various groups have utilized the time-course of recovery from desensitization to 
predict the number of final desensitization states induced by agonists. In such studies 
recovery of the receptor population from effects of desensitization is measured using 
double-pulse approach. The time course of desensitization can be measured by 
progressively increasing the time between two pulses, and taking the ratio of maximal
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currents at pulse 1 and pulse 2. The data obtained is fit to the equation, where ND 
indicates number of desensitization steps.
Current (I) = A(J-Qxp(-t(j!% fec(n,e[y)1'ID)) + offset.
In such experiments, the ratios obtained at each time point can be fit to a single 
exponential waveform when partial agonists are used. However, when full agonists are 
used, the waveform becomes sigmoid. These results indicate that partial agonists 
probably induce single desensitized state while full agonists induce 3-4 different 
desensitization states (van Hooft and Vijverberg, 1996). These results however are not 
unanimous. Mott et al. (Mott et al., 2001) have reported that recovery from 
desensitization induced by full agonists (5-HT and mCPBG) can be fit to a single 
exponential waveform, which indicates presence of a single desensitization state. 
Interestingly, data from kinetic modeling experiment reported by Mott et al. is in 
agreement with predictions of multiple desensitization steps.
1.8.3 A possible mechanism of gating in the 5-HT3R:
The mechanism of 5 -HT3R gating is unknown. Deciphering the gating mechanism of 5- 
HT3AR is one of the questions being addressed in this thesis. Several kinetic models for 
5-HT3R mechanism have been proposed (for a detailed description, see Appendix 1). 
However, none of these models deal with molecular dynamics of conformational changes 
associate with gating.
It is generally accepted that ligand-gated ion channels follow a cyclic path 
through various conformational stages. Interaction of agonist molecule(s) with the
19
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
receptor in resting state leads to activation with stabilization of the open state of the ion 
channel. The opening of the ion channel is followed by desensitization which is probably 
accompanied by conformational changes both at the ligand-binding domain and the ion 
channel. Various molecular processes involved in mediating these effects at the protein 
level remain unknown.
Auerbach and colleagues have utilized rate-equilibrium free energy relationship 
(REFER) analysis to map the progression of conformational changes that follow 
receptor-agonist interaction in nicotinic receptor (Chakrapani et al., 2004). This method 
utilizes measurements of changes in the energy landscape as a result o f various mutations 
along the suspected path of the conformational wave. These studies have suggested that 
protein region around the ligand-binding domain first undergoes the conformational 
change associated with agonist interaction. This conformational change is propelled 
towards the channel region through P loops 2 and 7. These regions in turn cause 
conformational changes in the extracellular M2-M3 linker region which is in direct 
contact with the ion channel. This mode of receptor action suggests that a 
“conformational wave” passes from the ligand-binding domain to the channel region and 
opens the ion channel pore.
1.9 Discovery of AChBP and it’s impact on studies pertaining to ligand-binding 
domain of LGIC receptors
The acetylcholine binding protein (AChBP) was discovered in 2001 by Sixma’s group 
(Brejc et al., 2002) while investigating mechanisms of glia-mediated synaptic 
modulation. The protein was isolated from glia of snail Lymnea stagnalis by virtue of its
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epibatidine (a nicotinic ligand) binding properties. AChBP is a soluble protein and binds 
nicotine ligands with high affinity with a pharmacological profile similar to that of homo- 
pentameric nicotinic a l  receptor. It is released from glial cells in cholinergic synapses 
and modulates acetylcholine (ACh) mediated neurotransmission by binding to ACh 
released in the synapse. The ability of AChBP to bind nicotinic ligands prompted its 
purification followed by biochemical and crystallographic characterization. These studies 
revealed that AChBP is a homo-pentameric protein. Each subunit consists of 210 amino 
acids. There exists about 31% sequence homology with nicotinic a l  receptor. AChBP 
also shares ~20% sequence homology with other members of the LGIC superfamily of 
receptors (including GABAa and GAB Ac, the glycine, and the 5 HT3 receptors). 
Although overall % homology is low, AChBP shares most of the conserved structural 
elements of the LGIC superfamily, including a 12 amino acid cysteine-cysteine loop. 
Most of the amino acids thought to be involved in binding to nicotinic ligands are also 
conserved. The crystal structure of AChBP was resolved at 2.7A resolution (Figure 1.2). 
Electron eryo-microscopic images of nAChR show a doughnut-shaped pentameric 
protein with a barrel-shaped arrangement of (3-sheets (Miyazawa et al., 2003). At the 
macromolecular level, the structure of AChBP shows remarkable similarity to the known 
structural features of torpedo eel muscle nicotinic receptor (Brejc et a l, 2001). The 
ligand-binding domain is located at the subunit interface. The crystal structure of the 
AChBP with nicotine or carmaylcholine bound was obtained at 2 .1k  resolution. The 
positions and characteristics of the amino acids involved in binding to these ligands are in
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good agreement with mutagenesis and biochemical data involving homologous residues 
from other LGIC family receptors.
The availability of a high resolution structural template has allowed preparation of 
homology models of extracellular domain of LGIC receptors. In case of 5 -HT3A receptor, 
homology models of human, rat and mouse 5 -HT3A (Maksay et al., 2003; Reeves et al.,
2003) as well as 5 -HT3AB receptor have been prepared. Homology models not only allow 
interpretation of biochemical data, but also help in formulation of novel hypotheses about 
receptor structure and function. The studies described here also utilize homology models 
of murine 5 -HT3A receptor (Figure 1.3). Preliminary homology models have been 
prepared by our research group while refined models with ligand-docking calculations 
have been provided by Dr. Zsolt Bikadi from National Academy of Sciences, Hungary.
1.10 Characterization of ligand-binding site of the 5-HT3A receptor
The majority of the studies of the putative ligand-binding site of the 5-HT3AR 
have been conducted using site-directed mutagenesis. Such studies have also employed 
diverse probe molecules (Venkataraman et al., 2002a; Venkataraman et al., 2002b), 
including fluorescent (Hovius et al., 1999; Schreiter et al., 2003) and photo-sensitive 
ligands (Lummis and Baker, 1997). Site-directed mutagenesis studies are the most 
extensively employed approach used in identification of 5 -HT3R binding site residues. 
Early biochemical studies of Cys-loop receptors suggested that the ligand-binding site 
was at the interface between adjacent subunits and was comprised of at least six binding 
loops. The discovery of the crystal structure of AChBP showed that six discontinuous 
loops contribute to the binding site; A-C from the principal face and D-F from the
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complementary face. The subsequent development of AChBP-based 5-HT3R amino 
terminal homology models provided a three dimensional framework for the 
experimentally identified residues. These residues are E129, F130 (loop A) (Boess et al., 
1997; Steward et al., 2000), W183 (loop B) (Spier and Lummis, 2000), E225, E236 (loop 
C) (Schreiter et al., 2003) W89, R91 (loop D) (Yan et al., 1999), Y141, Y143, Y153 
(loop E) (Venkataraman et al., 2002b). To date, there are no published studies on the loop 
F region of the 5-HT3R.
1.10.1 Role of loop A residues
Based on radio-ligand binding and electrophysiological studies, E129 (Boess et al., 1997) 
(E l06 according to author’s numbering) was proposed to interact with the ammonium 
group of 5-HT via an ionic or a hydrogen bond interaction. However, according to the 5- 
HT3R homology model, this residue is located distant from the binding site and does not 
contribute to binding to either agonist or antagonists.
The results of mutational analysis of F130 (Steward et al., 2000) (FI 07, according 
to the author’s numbering) of the 5-HT3R suggest that this residue is critical in 
determining recognition of the natural agonist 5-HT, and not mCPBG. F I30 is a unique 
residue, since mutation at this position specifically altered association rates of 5-HT but 
not mCPBG. It is possible that F I30 is involved in early events involved in 5-HT 
recognition. Docking calculations with 5-HT3R homology models suggest that this 
residue does not form major interactions with any docked ligand. These data suggest that 
FI 30 may not be a part of the main binding site, and initial recognition of 5-HT molecule 
by F I30 may be followed by the interaction of 5-HT with the main binding site. The
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distinct differences in action of 5-HT and mCPBG in context of F I30 mutations indicate 
that structurally distinct agonists may have distinct modes of action, including early 
events in association.
When mutated to their homologous counterpart in nicotinic acetylcholine receptor 
(asparagine), F130N receptors, could be activated by acetylcholine. It is possible that the 
role of residue at homologous position in all ligand-gated ion channels is recognition of 
specific agonist. Mu et al. have suggested that all members of the LGIC superfamily are 
activated by cation-pi interactions involving the principal face and are fairly non-specific 
(Mu et al., 2003). There also exists a large amount of cross-talk between ligands for 
nicotinic and 5 -HT3 receptors. In such a scenario, residues such as F130 may be guarding 
the ‘gate’ towards the binding site, only allowing the endogenous agonist 5-HT to 
approach the main binding site. Mutation of F130 to asparagines probably deceives the 5- 
HT3AR into accepting acetylcholine as agonist, leading to channel opening. Interestingly, 
/nCPBG does not require any such interaction at F I30.
1.10.2 Role of loop B residues
W183 from loop B region has been shown to be a critical component of the 5 -HT3R 
binding site (Spier and Lummis, 2000) Spier et al. utilized site-directed mutagenesis in 
combination with radio-ligand binding assays and whole-cell patch-clamp assay to 
decipher the role of W183 in ligand-binding. According to this study, mutation of 
tryptophan 183 to either tyrosine or phenylalanine resulted in ablation of radio-ligand 
binding. Although agonists could bind to and activate the mutant receptors, large changes 
in EC50 values for both 5-HT as well as /wCPBG are observed. Using unnatural amino
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acid substitutions, it has been postulated that this tryptophan residue forms a cation-pi 
interaction with the amino group of 5-HT (Beene et al., 2002). In such an interaction, the 
charged amino group of the ligand interacts with the pi cloud of the aromatic ring. Using 
the method of non-sense suppression, various unnatural amino acids (modified forms of 
tryptophan) with substitutions at the aromatic ring of tryptophan, were introduced at 
position 183. The mutant protein was expressed in Xenopus oocytes and assayed using 
two-voltage electrode clamp using agonist 5-HT. This technique provided a unique 
approach for examining the structure-activity relationship of a particular amino acid, 
while maintaining the biologically active form of the protein. The homologous residue in 
the nAChR has also been shown to form a cation-pi interaction with acetylcholine, but 
not nicotine (Beene et al., 2002; Zhong et al., 1998). The homologous residue in GABA 
receptors is also critical for ligand-binding. The roles of the remaining residues of the 
loop B region have not been examined in detail, and form the basis of the study described 
in chapter 5.
1.10.3 Role of loop D residues
In an alanine scanning mutagenesis study of the putative loop D region, it was shown that 
affinity for d-TC was reduced by substitution only at W90, whereas affinity for 5-HT was 
reduced only by substitution at R92 (Yan et al., 1999). Recent data suggests that d-TC 
may not be directly interacting with loop D residues. Results o f a study involving d-TC 
analogs and loop D mutant receptors suggests that the general topology of the loop D 
region is important for d-TC interaction (Yan and White, 2002). On the other hand, 
affinity for granisetron was reduced by mutations at W90, R92 and Y94. Published
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ligand-docked models for the 5 -HT3R suggest that the tertiary ammonium group of 
antagonists could interact with W90 via a cation-pi interaction (Maksay et al., 2003). This 
differential effect of substitutions on ligand affinity suggests that different ligands may 
have different points of interaction within the ligand-binding pocket. In addition, the 
‘ every-other-residue’ periodicity of the effect on affinity for granisetron indicates that 
this region of the ligand-binding site of the 5 HT3R adopted a beta-strand conformation; a 
prediction that was substantiated by structural model based on AChBP homology.
1.10.4 Role of loop E residues
Based on alanine scanning mutagenesis, three tyrosine residues (Y141, Y143 and Y153) 
have been shown to significantly alter the binding of 5 -HT3R ligands (Venkataraman et 
al., 2002b). A role for the putative E-loop region of the 5 -HT3R in the binding of 5-HT, 
mCPBG, d-TC and lerisetron was investigated using site-directed mutagenesis. 5-HT and 
wCPBG interact with Y143, d-TC with Y141 and lerisetron with both Y143 and Y153. 
This study also provided support for the hypothesis that this region of the receptor is 
present in a loop structure. Since mutations of loop E tyrosine residues affected binding 
of competitive antagonists, involvement of these residues in interaction with ligands 
(‘binding’) was suggested. On the other hand, results from preliminary 
electrophysiological assays had suggested a possible role of Y153 in mediating 
conformational changes that follow agonist binding and produce channel opening.
1.11 Medicinal chemistry of 5-HT3R ligands
The following section briefly describes the medicinal chemistry of 5-HT3AR ligands. 
Structures of ligands used in the studies described here are shown in figure 1.4
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1.11.1 5-HTjaR Agonists
Serotonin or 5-Hydroxytryptamin (5-HT) is a non-selective 5-HT3aR agonist. 5-HT is the 
most efficacious agonist for all types of 5-HT3ARs, irrespective of subclass, 5-HT 
consists of an indole ring with a hydroxyl group at 5 position. 5-HT purportedly interacts 
with amino acids in the ligand-binding domain through either cation-pi (terminal 
secondary amine) or pi-pi interaction (indole). The hydroxyl group is also an important 
determinant of agonist activity, since tryptamine is a partial agonist at 5-HT3AR (van 
Hooft and Vijverberg, 1997). Other variations of 5-HT (5-HTQ, 2-Me-5HT) also behave 
as partial agonists. Efficacy of 2-Me-5HT is different for each subclass of the 5-HT3AR. 
2-Me-5HT is a poor partial agonist with low efficacy (10% compared to 5-HT) at murine 
5-HT3asR (receptor utilized in studies described here). Partial agonists can be utilized to 
qualitatively study gating behavior of wild type and mutant receptors (see chapter 4). 
Phenylbiguanides (PBG) and phenylguanides (PG) behave as agonists of 5-HT3AR. m- 
chloro-phenylbiguanide (mCPBG) is a potent agonist at murine 5-HT3AsR, although its 
efficacy varies according to the subclass of the 5 -HT3R (Niemeyer and Lummis, 1998). 
Available evidence suggests that these agonists interact with the binding site in a fashion 
similar to that of 5-HT, although interactions at the molecular level may vary. The kinetic 
parameters of mCPBG induced responses including rise-times as well as desensitization 
are markedly different compared to those of 5-HT. There are marked differences in the 
structure of /wCPBG and 5-HT (Figure 1.4). mCPBG consists of a phenyl instead of an 
indole ring and contains a biguanide group with five nitrogens in place of the aminoethyl 
group in 5-HT. It is conceivable that the differences in action of /wCPBG and 5-HT arise
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from the differences in their chemical nature and their interactions with the ligand- 
binding domain at the molecular level. However, there are no published studies that 
address this question. For this reason, mCPBG can be a useful tool for investigations of 
biophysical aspects of 5-HT3aR gating. Other classes of ligands, such as 
piperazinylquinolines, tetrahydrothiazolopyridines and various aminoalkyl- and 
imidazoloalkyl-indenothiazoles can also behave as agonists at the 5-HT3aR.
1.11.2 S-HTsaR antagonists
Numerous selective and non-selective ligands for the 5-HT3aR have been identified. 
Selective 5-HT3aR antagonists generally confirm to the pharmacophoric model proposed 
by Hibert’s group (Hibert et al., 1990). According to this model, a ‘typical’ antagonist 
consists of carbonyl group coplanar to an aromatic ring, and a basic center 1.7 A above 
the plane of the aromatic ring, lerisetron and its analogs constitute another class of potent 
5-HT3aR antagonists (Orjales et al., 1997; Parihar et al., 2001; Venkataraman et al., 
2002a). In addition to the features described by Hibert’s model, lerisetron incorporates a 
benzimidazole ring structure. Using SAR and mutagenesis studies in tandem, we have 
demonstrated that the terminal amine is involved in a critical interaction with the ligand- 
binding domain while the benzimidazole ring structure forms a relatively minor 
component of binding interaction (Venkataraman et al., 2002a).
(+)~Tubocurarine (d-TC) and its analogs are moderately potent (-80 nM K,) 
competitive antagonists at 5-HT3aRs, and form a third structural class of antagonists. 
Curariform antagonists also inhibit the nicotinic acetylcholine receptor with similar 
affinity. Amino acids W90 and Y141 at 5-HT3aR binding domain are involved in
28
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mediating d-TC interaction, however this involvement is probably indirect (see chapter 
4) (Venkataraman et al., 2002b; Yan et ah, 1999; Yan and White, 2002). d-TC may also 
be mediating binding interactions through the loop C region of the binding site.
1.12 Modulators of S-HT3R function
In addition to specific agonists and antagonists, various non-specific atypical ligands 
interact with 5 -HT3R. Certain atypical ligands interact competitively by interacting with 
the ligand-binding domain, while others interact allosterically in a non competitive 
manner.
1.12.1 Interaction of binding site with ions
Available data suggests that divalent cations such as Ca"^ and Mg++ inhibit 5 -HT3R 
function by interfering with agonist binding, probably by binding directly at the agonist 
binding site (Niemeyer and Lummis, 2001). Zn++ potentiates 5-HT induced currents and 
reduces the rate of desensitization and apparent affinity for 5-HT (Gill et al., 1995; 
Hubbard and Lummis, 2000); 5-HTjab receptors on the other hand, may actually be 
inhibited by Z n *  (Hubbard and Lummis, 2000). The effects of Zn++ on 5 -HT3aR are 
dampened by the presence of other divalent cations Ca++ and Mg++, suggesting that these 
divalent cations may compete with each other at their site of interaction with the receptor.
1.12.2 Interaction of 5-HT3R with atypical ligands
1.12.2.1 Steroids
Glucocorticoids inhibit 5 -HT3ARs.These molecules affect receptor function by interacting 
allosterically with the protein, probably at the receptor-membrane interface (Suzuki et al.,
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2004). Glucocorticoid mediated inhibition may aid in the anti-emetic actions of 5-HT3aR 
antagonists when both are co-administered. Gonadal steroids functionally inhibit 5- 
HT3AR in a non-competitive manner. Such antagonism may have a role in 
pathophysiology of certain pregnancy-related disorders (Oz et al., 2002b; Wetzel et al.,
1998).
1.12.2.2 Neuroleptic drugs
Flupentixol, haloperidol and various phenothiazines antagonize 5-HT3AR non­
competitively in a voltage-independent manner, while clozapine antagonizes 5 -HT3R in a 
competitive manner. Chlorpromazine, also a phenothiazine may be inhibiting 5-HT3R 
competitively (Sepulveda et al., 1994). Fluphenazine and haloperidol also cause a 
change in membrane anisotropy when applied to the cell, which may also be playing a 
role in its antagonism at the 5-HT3R (Rammes et al., 2004).
1.12.2.3 Forskolln
Forskolin inhibits 5-HT3aR (Oz et al., 2002b). Forskolin acts through adenylyl cyclase to 
raise intracellular cAMP levels in a variety of cel! types. The effect of Forskolin on 5- 
HT3AR is interesting since it suggests the possibility that 5-HT3AR function is modulated 
by Forskolin through cAMP related mechanisms. However, electrophysiological analysis 
of the Forskolin effects on 5-HT3A receptors expressed in Xenopus oocytes suggests that 
Forskolin acts on the extra-cellular domain of the 5-HT3aR and inhibits its function 
through direct non-competitive inhibition (Oz et al., 2002b). Apparently the non­
competitive inhibition is not mediated through open-channel block, but through an
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interaction with the extra-cellular domain of the closed state of the receptor (Oz et al., 
2 0 0 2 b).
1.12.2.4 Toxin
Final sigma-Conotoxin from venom of a marine snail competitively inhibits 5 -HT3aR in a 
selective and competitive fashion (England et al., 1998). Nicotinic AChR is susceptible to 
several toxins (Arias, 2000). Final sigma-Conotoxin- 5-HT3R interaction was reportedly 
the first instance where 5 -HT3aR has been described to be the target of a natural toxin.
1.12.2.5 Alcohol and other drugs of abuse
Alcohols such as ethanol and butanol potentiate agonist-induced responses at the 5- 
FIT3AR (Machu and Harris, 1994; Zhou et al., 1998), but do not cause channel opening by 
themselves. This potentiation is presumably affected by increasing the rate of receptor 
activation and stabilizing the open state of the receptor and not by blocking 
desensitization (Yang et al., 2003). Arginine 222 from the pre-Ml region plays a role in 
gating. Mutation at this position cause spontaneous openings, increase rate of activation, 
increase the efficacy of full agonist and convert partial agonists into full agonists (Hu et 
al., 2003). The R222 residue thus seems to be involved in stabilizing the closed state of 
the wt receptor, presumably through its connection with the Ml region. Mutations at 
R222 also cause altered sensitivity to effects of ethanol on 5 -HT3R activation (Zhang et 
a l, 2002).
5 -HT3R antagonist ICS 205-930 at lower concentration decreases and at higher 
concentration enhances the discriminative stimulus effects associated with a lower to
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moderate dose of ethanol. 5 -HT3 antagonist ICS 205-930 enhances naltrexone's effects 
on ethanol intake (Mhatre et al., 2004; Mhatre et al., 2001). Ethanol drinking and 
deprivation shows alterered dopaminergic and serotonergic function in the nucleus 
accumbens of alcohol-preferring rats (McBride et al., 2004). Reduced 5 -HT3 receptor 
binding in the brain tissue as well as lower baseline plus maze anxiety in the alcohol- 
preferring inbred fawn-hooded rat were observed by Hensler et al. (Hensler et al., 2004). 
Subregion-specific down-regulation of 5-HT3 immunoreactivity in the nucleus 
accumbens shell during the induction of cocaine sensitization has also been observed 
(Ricci et al., 2004). These data suggest that 5-HT3R physiology can be altered by drugs 
of abuse such as alcohol and cocain.
Other potential drugs of abuse also interact with 5-H TsaR , suggesting a 
physiological role of 5-HT3aR in mediation of their action. Cocaine inhibits 5-HT3R 
competitively at low micromolar concentrations, probably by competing at the binding 
site (Carta et al., 2003; Fan et al., 1995). Nicotine and other nicotinic agonists except 3- 
(2,4)-dimethoxybenzylidene-anabaseine also inhibit 5-HT3aR competitively (Gurley and 
Lanthorn, 1998), also indicating a significant cross-talk between nAChR and 5 -HT3R 
systems. Inhaled agents of abuse 1,1,1 -trichloroethane, trichloroethylene and toluene 
potentiate 5-HT induced currents from 5-HT3AR (Lopreato et al., 2003b). Endogenous 
cannabinoid, anandamide (Oz et al., 2002a), as well as other cannabinoid agonists inhibit 
5 -HT3AR non-competitively (Barann et al., 2002; Fan, 1995). The inhibition by 
cannabinoids is stereo-selective and is probably achieved through an interaction with an 
allosteric site on the receptor (Barann et al., 2002).
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1.12.2.6 Interaction with anesthetics
Halothane, 1,2,2-trifluorocyclobutane and Isoflurane, Enflurane and Chloroform 
potentiate 5-HT-mediated currents from 5-HT3AR (Lopreato et al., 2003a; Machu and 
Harris, 1994). Interaction of Halothane with 5 -HT3R may be responsible for mediating 
some of the effects of Halothane on the spinal sensory systems (Koshizaki et al., 2003). 
Sevoflurane inhibits 5-HT3AR in noncompetitive fashion while nitrous oxide and Xenon 
competitively inhibit 5-HT-induced currents from 5-HT3AR (Machu and Harris, 1994; 
Suzuki et al., 2002). Lidocaine derivative QX222 also inhibits the receptor in a 
competitive fashion (Sepulveda et al., 1994). There is some evidence that the action of 
anesthetics may involve N-terminal domain, (Zhang et al., 1997) although trans­
membrane region 2 (TM2) may also be involved (Lopreato et al., 2003a).
1.13 Clinical (current and potential) uses of 5 -HT3R antagonists 
Specific 5-HT3A receptor antagonists have been extensively used for treatment of 
chemotherapy induced emesis. However 5 -HT3 receptor ligands are also being developed 
for treatment of certain other conditions.
• Ant-emetics: Anti-emetic action is mediated by action of 5 -HT3R antagonists on
central 5 -HT3 receptors located in chemoreceptor trigger zone (CTZ) of Area 
Postrema.
• Analgesics: possibly mediated by antagonism of 5 -HT3R located in peripheral pain
conducting fibers.
• Irritable bowel syndrome and other intestinal hypermotility disorders: Alosetron is a
potent and highly selective 5 -HT3 receptor antagonist that in large randomized
33
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
controlled clinical trials has been shown to be clinically efficient in female 
patients with diarrhea-predominant IBS (Andresen and Hollerbach, 2004). 5 -HT3 
receptor in gut may be involved in mediating secretory responses, granisetron, a 
competitive 5 -HT3R antagonist attenuates rotavirus diarrhea in mice (Kordasti et 
al., 2004), suggesting a novel approach to rotavirus therapy. 5-HT3R agonists, on 
the other hand, may prove useful for therapy of constipation, especially the 
episodic type associated with IBS.
• Anxiolytics: In animal models as well as human trials, 5 -HT3R antagonists seem to
produce anxiolysis. These results however remain largely unsubstantiated.
• Bulimia nervosa: 5 -HT3R may be involved in development of pathophysiology of
bulimia nervosa. According to some clinical studies, Ondansetron can be useful in 
modifying behavior related with Bulimia (Faris et a l, 1998; Faris et al., 2000; 
Hasler, 2000). Results from large scale clinical trials are however lacking.
• Drug abuse and drug withdrawal (Also see above): 5 -HT3R system in corticolimbic
areas (such as nucleus accumbens) plays a major role in regulation and 
modulation of dopaminergic neurotransmission. 5 -HT3RS located on pre-synaptic 
terminals to play such a role in dopamine release. Specific 5-HT3R agonist 
/mCPBG causes release of dopamine from striatal brain slices. While not leading 
to changes in behavioral patterns in control animals, drug-induced changes in 
dopamine neurotransmission can be altered by 5 -HT3R antagonists (Costall et al., 
1987). Many of the effects of a variety of drugs of abuse, including cocaine and 
alcohols, seem to be mediated through modulation of dopamine
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neurotransmission in limbic cortex. 5 -HT3R antagonists can block morphine self­
administration in rats. 5 -HT3R antagonists lead to changes in behavioral and 
neurochemical expression of cocaine sensitization that follows a period of 
withdrawal. Administration of Ondansetron with a challenge dose of cocaine in 
the withdrawal period produces an increase in locomotor activity compared to that 
produced by challenge dose alone. At the same time, attenuation in extent of 
tkCPBG induced dopamine release from striatal brain slices is also observed 
(King et al., 1997). A recent study suggests that, using Ondansetron, it is possible 
to permanently block expression of sensitization following cocaine withdrawal 
(King et al., 2000). In rats, alcohol consumption as well as alcohol related hyper­
locomotion can be blocked by 5 -HT3R antagonist administration (Kostowski et 
al., 1993; Kostowski et al., 1995). In addition, alcohol induced place preference 
under stressful conditions, in rats conditioned to fear stress can also be blocked by 
5 -HT3R antagonists (Matsuzawa et al., 1999). In human subjects, Ondansetron 
moderately reduces alcohol consumption (Naranjo and Bremner, 1993). 
Ondansetron has been shown to be efficacious in particular for the treatment of 
early onset alcoholism. The reduction in alcohol consumption seems to be 
associated with reduction in alcohol craving. The efficacy of the treatment is 
increased if Naltrexone (an opioid antagonist) is combined with Ondansetron 
(Johnson, 2003). Interestingly, late onset alcoholism does not seem to benefit 
from 5 -HT3R antagonist therapy. Many drugs of abuse directly interact with 5- 
HT3R (see above). While cocaine and canabinoids competitively inhibit 5 -HT3R,
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alcohol allosterically potentiates the action of 5-HT3R agonists. Interestingly, 
dopamine also directly interacts with 5-HT3R as a partial agonist. The 5-HT3R 
system may thus be playing a complex role in effects of drugs of abuse; indirectly 
through its modulation of dopaminergic neurotransmission and directly though 
direct interaction with the 5 -HT3R. In such a scenario, 5 -HT3R antagonists can be 
potentially used in pharmacotherapy of addiction. On the other hand, clear clinical 
efficacy of 5 -HT3R antagonists for therapy of drug-abuse has not been 
demonstrated. This is probably a reflection of complex interactions between direct 
and indirect effects of drugs of abuse on the 5-HT3R system.
• Sleep disorders: Stimulation of peripheral 5 -HT3 receptors at the nodose ganglion
can cause inhibition of respiration. Incidentally, Ondansetron and Zacopride can 
suppress sleep-related central apnea associated with ‘Obstructive sleep apnea 
hypopnea syndrome’ (OSAHS) in rat and dog models (Carley et al., 2001; 
Veasey, 2003; Veasey et al., 2001), suggesting a possible pharmaco-therapeutic 
approach for this disorder.
® Schizophrenia: A small number of studies have suggested a beneficial effect of 5-
HT3R antagonist ondansetron on schizophrenia outcome, especially the psychotic 
syndromes and tardive dyskinesia (Sirota et al., 2000).
• Cognitive enhancers: Raised 5-HT function can impair cholinergic function,
affecting cognitive processes. Antagonism of central 5 -HT3RS can prevent such 
impairment. A study in rats with deafferentation lesions of cortical cholinergic 
system was performed to assess effect of concomitant blockade of GABA and 5-
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HT3R.S. The results suggest that combined therapy of ondansetron and flumazenil 
(Gil-Bea et al., 2004) treatment probably aids restoration of a diminished 
cholinergic function. Such a treatment in patients of diminished cholinergic 
function associated with cognitive disorders may be beneficial (Gil-Bea et al., 
2004). In human subjects, 5 -HT3R antagonists cause improved cognition in 
patients with age-related impairment and scopolamine induced cognitive 
impairment in healthy subjects. On the other hand, clear benefits of 5-HT3R 
antagonists in Alzheimer ’s disease related memory impairment have not been 
reported (Eid and Rose, 1999).
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Figure 1.1: Structural features of the S-HTsaR
1.1 A: A single subunit of S-HTjaR
A large N-terminal is characterized by a disulfide loop (C-C). The four transmembrane 
regions are marked M1-M4. An extracellular loop (E) connects M2-M3 regions and may 
be interacting with the cys-loop. Two intracellular loops are marked Cl and C2. C2 is the 
larger loop and contains the ‘HA’ stretch of amino acids. Small extracellular C-terminal 
tail is marked by C.
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1.1 B: Pentameric assembly of the 5-HT3R pentamer
The binding site is marked by at the subunit interface by principal (+) and complimentary 
(-) sides. The stoichiometric make-up of the 5-HT3AB receptor is not known.
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Figure 1.2: Structure of the acetylcholine binding protein (AChBP)
Crystal structure of acetylcholine binding protein for two adjacent subunits is shown. The 
backbone of the AChBP in dimeric ribbon form is displayed. The cleft between two 
subunits forms the putative binding site, where a HEPES molecule is bound. The gross 
topology of binding loops is thought to be similar for all the members of the LGIC 
superfamily. The ‘principal’ face on left hand side contributes three discontinuous 
regions (‘loops’) to the binding site, named A, B and C. On the right hand side, the 
‘complimentary’ face contributes another three discontinuous regions (‘loops’) to the 
binding site, named D, E and F.
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Figure 1.3: 5-HT3A R homology model based on acetylcholine binding protein 
(AChBP)
The backbone of the S-HTsaR homology model in dimeric ribbon form is shown. The 
cleft between two subunits forms the binding site. The ‘principal’ face on left hand side 
contributes three discontinuous regions (‘loops’) to the binding site, named A, B and C. 
On the right hand side, the ‘complimentary’ face contributes another three discontinuous 
regions (‘loops’) to the binding site, named D, E and F. Role of region F in ligand- 
binding is yet to be demonstrated.
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Figure 1.4: 5-HTsAR ligands
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Chapter 2 : Hypotheses, research design and data analysis
2.1 Introduction
Proteins are complex macromolecules. Investigations into the nature of a protein’s 
ligand-binding site are critical to the understanding protein function. Understanding 
ligand-binding site interactions leads to better understanding of protein function in 
general and development of better ligands in particular. The structural and functional 
diversity of proteins arises mainly from differences in the primary structure, since 
primary structure is responsible for positioning both the protein backbone and amino acid 
side chains. The analysis of structure-function relationship of proteins can be achieved 
through a variety of means. Mutagenesis remains the mainstay method for structure- 
function analysis of membrane-bound proteins or receptors. Mutagenesis is used to 
investigate the role of individual amino acids in normal functioning of the protein. While 
site-directed mutagenesis is the most widely employed method, other methods such as 
photo-affinity labeling and internal fluorescence measurements can also be utilized.
2.2 Gaps in the knowledge of murine S-HTsaR structure-function correlations
The following section briefly describes some of the gaps in the knowledge of 5-HT3aR 
function at the molecular level. Some of these identified gaps form the basis of research 
presented in this thesis.
2.2.1 S-HTsa R ligand-binding domain
At the beginning of the studies described here (year 2000), the general topology of the 5- 
HT3AR binding site was unknown. It was however hypothesized that the general topology
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
of the binding domain is similar to that of the nicotinic acetylcholine receptor. Amino 
acids in the purported ligand-binding domain had been postulated on the basis of 
sequence homology with the nicotinic acetylcholine receptor. Although a few select 
residues had been confirmed by mutagenesis (D89, R91, W183, F I29), a systematic 
analysis of the binding site was not available.
The first attempt at such an analysis was made with an alanine scanning 
mutagenesis study of the purported loop E conducted in our laboratory. Using a 
systematic approach, this study identified residues Y141, Y143 and Y153. These studies 
also defined the involvement of these amino acids in purported interactions with 
antagonists lerisetron and d-TC. However, a detailed analysis of the role played by these 
amino acids in agonist action and agonist-induced conformational changes was 
unavailable.
2.2.2 S-HTjaR agonist specificities
Structurally distinct agonists of the 5 -HT3AR display distinct pharmacological (EC50 
obtained from electrophysiological assays, K, values obtained from competition radio­
ligand binding assays and maximal efficacy) as well as biophysical parameters 
(activation and desensitization parameters). The structural basis for these differences 
remains unexplored. Few studies have explored the biochemical basis of antagonist 
specificity. Utilizing structurally distinct antagonists along with mutations at the ligand- 
binding domain, our lab has probed the specificity of granisetron, lerisetron and d-TC 
(Venkataraman et al., 2002a; Venkataraman et al., 2002b). No such study involving 
structurally distinct agonists of the 5 -HT3AR had been reported.
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2.2.3 S-HTsaR mechanism of activation and desensitization.
The dynamics of S-HTjaR activation and desensitization were largely unknown. The 
available data on the ligand-binding site amino acid residues mostly described a static 
state of receptor-ligand interaction. However, the interaction of agonist with the ligand- 
binding site is followed by events that produce the conformational changes leading to 
channel opening. Channel opening is presumably followed by desensitization, which is 
accompanied by distinct conformational changes. No study had systematically explored 
the role of purported ligand-binding residues in mediating the conformational changes 
associated with channel opening and desensitization.
Use of 5-HT3AR, a homo-pentameric protein, provides a simple model for 
explorations into the functional dynamics of a ligand-gated ion channel. Since all five 
ligand-binding domains are presumably identical, it is simpler to correlate the effect of a 
mutation at a global level.
2.3 Scope for improvement in methodologies pertaining to Xenopus oocyte 
electrophysiology
Xenopus oocytes have been used extensively in the studies of ion channels. An 
exceptional amount of versatility (in terms of types of proteins expressed as well as types 
of assays performed) is provided by use of this system. In the case of ligand-gated ion 
channels, Xenopus oocytes allow sufficient receptor expression as well as measurement 
of various parameters such as activation and desensitization rates. Use of two-electrode 
voltage-clamp and Xenopus oocytes to characterize ligand-gated ion channels is relatively 
easier compared to the use of whole-cell patch-clamp assay and mammalian cells. Use of
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oocytes provides yet another advantage. The expression of various mutant proteins is 
probably better handled by oocytes compared to mammalian cells. In certain cases, it is 
possible to obtain detectable levels of receptor expression only using Xenopus oocytes.
Given the importance of oocyte electrophysiology in 5-HT3AR research, it is 
imperative that the measurements obtained be as accurate as possible. However, 
conventional methods of oocyte electrophysiology lack required fidelity, with low rates 
of drug perfusion and unstable environment preventing long term measurements from a 
single oocyte.
2.4 Protein homology in structure-function studies
Proteins can be classified on the basis of similarity in primary structure. The similarity in 
primary structure usually has an evolutionary origin. In course of evolution, structurally 
important features of the related proteins (such as structurally important amino acids 
residues proline and glycine) are conserved, since specific function of a protein is closely 
related to its structure. Such conservation probably ensures that the basic structural 
scaffold of the protein is maintained. Thus, it can be assumed that proteins sharing 
primary structure share tertiary and quaternary structure. In structure-function studies of 
protein of unknown tertiary and quaternary structure, such an assumption can be used to 
formulate primary protein models.
The structure-function studies of a protein utilizing site-directed mutagenesis as 
an approach assumes certain general hypotheses. Site-directed mutagenesis in general 
and alanine scanning mutagenesis in particular, along with molecular modeling can been
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used initially as tools to generate a basic map of the protein. Based on the results obtained 
from the initial studies, specific hypotheses can be formed and tested
When the work described in this thesis was started, how the structure of the 
presumed 5 -HT3 receptor ligand-binding domain affected interactions with various 
ligands and how the function was modulated by ligand interactions was largely unknown. 
Using the techniques described below and based on the general and specific hypotheses 
described here, we have been able to generate numerous specific hypotheses, which can 
be tested in future.
2.5 General hypothesis
Members of the ligand-gated ion channel super-family (LGICS) include 5 -HT3R, 
nicotinic acetylcholine receptor, GABA A and C receptor and glycine receptor and 
acetylcholine binding protein (AChBP). This family is also called the Cys-loop family 
due to presence of a loop of amino acids in the extracellular domain, flanked by cysteines 
on both sides. The nicotinic acetylcholine receptor is the prototype receptor. All the 
proteins are pentamers. Moderately high homology (19-31%) exists between all 
members. All major structural domains (extra-cellular N-terminal, four transmembrane 
domains and a short C-tail) are conserved. While low resolution electron micrographs are 
available for the 5 -HT3aR, the structure of the nicotinic acetylcholine receptor has been 
resolved at 4A resolution (Unwin, 2005). The crystal structure of AChBP at 2.1k  
resolution is also available. Available data suggests that 5 -HT3aR, nicotinic acetylcholine 
receptor and AChBP all share the pentameric doughnut-shaped structure In addition, 
mutagenesis data for all the members of the LGIC superfamily is available.
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All the available information suggests that members of the LGIC superfamily 
share structural and probably functional features. Based on this general hypothesis, we 
developed a primary model of the 5-HTsaR structure based on all available biochemical 
data and AChBP crystal structure. We have utilized this primary protein model to 
interpret initial studies and form specific hypothesis.
2.6 Specific hypotheses
2.6.1 Antagonist action of lerisetron is mediated mainly by the interaction of its 
terminal amine with the binding site. This interaction is probably a cation-pi 
interaction.
This hypothesis is based on data from studies on both 5-HT3AR and nicotinic 
acetylcholine receptor. For a detailed description, please refer to section 4.1 of chapter 4.
2.6.2 Different classes of S-HTjaR ligands mediate their action through distinctly 
different interactions with loop E amino acid residues.
Structurally distinct agonists and antagonists use distinctly different molecular 
interactions to mediate specific effects. This hypothesis is based on the results of initial 
studies of the loop E region (Venkataraman et al., 2002a; Venkataraman et al., 2002b). 
These studies indicate that mutations in loop E region affect different classes of 
antagonists differently. For example, a Y141A mutation specifically alters d-TC binding 
but not granisetron or lerisetron binding. For a detailed description, please refer to section
5.1 of chapter 5.
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2.6.3 Different classes of S-HTjaR agonists mediate their action through distinctly 
different modes of receptor gating
5-HT, a hydroxytryptamine, and /nCPBG, a phenylbiguanide, are structurally distinct 
classes of 5 -HT3R agonists. Preliminary electrophysiological studies of 5 -HT3A Y153A 
mutant receptor suggest that amino acid Y153 modulates action of 5-HT and mCPBG 
differentially. A Y153A mutant specifically alters characteristics of 5-HT but not 
mCPBG-elicited inward currents. Based on these results, we hypothesize that structurally 
distinct 5-HT3AR agonists differentially mediate conformational changes associated with 
channel gating. For a detailed description, please refer to section 4.1 of chapter 4.
2.6.4 Amino acids T179 to 1190 of 5-HT3aR constitute a region of the protein that 
corresponds to the purported loop B region of the nicotinic acetylcholine receptor. 
This region plays a critical role in mediating agonist action.
Previous studies support such a hypothesis. W143 of muscle nicotinic acetylcholine 
receptor and the homologous residue W183 of 5 -HT3AR have both been shown to be 
involved in mediating ligand interactions (Beene et al., 2002; Spier and Lummis, 2000). 
However, detailed analysis of the role of the putative loop B region has not been 
reported. Using site-directed mutagenesis, we have examined 12 residues of the putative 
loop B region. For a detailed description, please refer to section 6.1 of chapter 6.
2.7 Research design
The following flow-chart describes an idealized research plan (incorporating basic 
hypothesis and assumptions) that may be employed in structure-function studies of a 
protein with unknown structure. The research described in this thesis is designed to test
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the hypotheses and in general address the following question: How does the structure of 
5-HT3AR translate into maintenance of structural integrity, ligand interaction and 
mediation of conformational changes associated with channel gating?
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Research Design: Binding, Gating, Assembly or a com bination? 
Sequence and Structural homology + studies on homologous proteins
Protein model (hypothesis) ---------------------------------
Selection of region(s)
▼
Alanine scanning mutagenesis Iterative process
Radio-ligand binding + oocyte f
electrophysiology
(Ligand binding and gating, receptor number, 
receptor function)
▼
Primary Identification o f amino acids
Secondary mutants 
Protein modeling and docking
y
Determination o f role played by each amino acid Improved Model of
receptor function
- — .------------------------------— --------------------------------------------------------------------------------------------------
A detailed description of each of the methods being used follows.
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2.8 Mutagenesis
Site-directed mutagenesis is widely employed to examine the relationship of structure 
and function in proteins. Mutagenesis of a defined protein region is termed scanning 
mutagenesis, e.g. alanine scanning, cysteine scanning etc.
The following assumptions are associated with the use of mutagenesis
2.8.1 Replacement of a structurally/functionally important amino acid causes major 
changes to protein structure/function, while replacement of an unimportant amino 
acid causes minor/ no changes to protein structure/function
Site-directed mutagenesis (as opposed to random mutagenesis) involves replacement of a 
specific amino acid with another. The basic structure of all the amino acids involves a 
carbonyl group and an amino group bonded to the same carbon atom. Only the R-groups 
vary between different amino acids. Substitution of the R group of one amino acid with 
the R group of another amino acid is the basic premise of site-directed mutagenesis. If the 
R group altered is important for ligand binding then substitution will change the ligand 
binding characteristics. The mutation can be drastic such as an alanine mutation or can be 
subtle, for example a tyrosine replaced by phenylalanine. The hypothesis holds that such 
a replacement will result in a significant change to protein function if the amino acid is 
important for either ligand binding or functioning of the protein. The mutation of an 
amino acid can also lead to changes in general to protein backbone. Such structural 
changes can lead to alteration in protein functioning. Whether the effect of the mutation 
is a specific effect of the side-chain replacement or a general effect on protein backbone
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Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
can sometimes be difficult to determine. However certain guidelines can be used to 
interpret such data.
1) A specific effect of the side-chain replacement can be verified by using subtle 
mutation. Subtle mutation does not alter the local environment at the position of 
the original amino acid. A subtle mutation is thus unlikely to cause any significant 
change to protein backbone. If both drastic and subtle mutations produce 
significant changes to the receptor function, then the amino acid in question is 
probably mediating the effects on ligand binding and/or channel gating through 
side-chain involvement.
2) If a mutation leads to changes in receptor expression without changes to 
pharmacological parameters, then the amino acid is probably playing a purely 
structural role. Mere changes to receptor number will not lead to changes in the 
pharmacological parameters such as K<j, Kj, EC50 and IC50 values, while changes 
to Bmek (using radio-ligand binding) and IMax (using electrophysiology) will be 
observed. The structural role played by an amino acid can be mediated either by 
the virtue of its location in the backbone or intra-/inter-subunit interactions.
3) If a mutation leads to changes in receptor expression and pharmacological 
parameters, then the amino acid is probably playing a mixed role; both in the 
structure and function of the protein.
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2.8.2 Alanine scanning mutagenesis can be used to identify structurally/ functionally
important amino acids of a protein.
Alanine scanning mutagenesis involves sequential replacement of each amino acid (one 
amino acid at a time) with alanine. This approach is specifically used, when little or no 
structural information is available. In our studies, we have utilized this approach to verify 
the structural/functional features of a specific region (“loop B”) of the protein. Again, 
selection of the region is based on information obtained from homologous proteins, 
generally members of the same protein family. Alanine is an ideal replacement since it 
can replace amino acids both in the hydrophilic or the hydrophobic environment equally 
well (Cunningham and Wells, 1989). Alanine mutation causes complete removal of the 
side chain while maintaining the rigidity of the backbone. In such a scan, important 
amino acids are quickly identified, while unimportant amino acids are quickly 
demarcated.
2.9 Radio-ligand binding assays using mammalian cells
Radio-ligand binding is employed to assess the impact of a mutation on the high affinity 
binding to the competitive antagonist granisetron. The [3H] labeled granisetron emits beta 
particles on decay, which can be counted using a scintillation counter. Using saturation 
binding assays, the affinity of [3H] granisetron is measured (Kd), while the Bmbx allows 
evaluation of the receptor number. However, radio-ligand binding detects all of the 
receptors (including the intracellular pool) and no comment can be made about surface 
expression. A change in the Kd compared to the wt receptor indicates change in the
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affinity for granisetron, while a change in Bmjx indicates that mutation has affected 
receptor assembly.
2.10 Electrophysiology
Electrophysiological assays are used to assess the functional integrity of mutant 
receptors. Detection of electrophysiological responses indicates that the receptors are 
assembled and expressed on the cell surface. Changes in Im3x values compared to the wt 
receptor can be indicative of a change in receptor expression. On the other hand, if B^x 
data suggests little or no change to receptor assembly, or if the changes are specific to a 
particular agonist, then changes in Imox reflect alterations in efficacy of that particular 
agonist.
A change in EC50 for a mutant receptor indicates a change to in either agonist 
binding or gating of the receptor-ion channel complex. Changes to receptor number will 
not cause changes in EC50 values. Whether the changes observed in EC50 are a result of 
pure change in ligand binding or a pure change in gating or mixed effect can be 
deciphered by use of partial agonists. For a full discussion of the partial agonist approach, 
please refer to section 4.3 of this thesis.
Electrophysiological inhibition assays can also be performed. IC50 and Kj values 
for competitive antagonists can be obtained from such assays. Assuming that the 5- 
HT3AR follows the cyclic model of receptor function (i.e., closed-open-desensitized- 
closed), these values probably indicate affinity of the competitive antagonist for the 
closed state of the receptor.
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2.10.1 Electrophysiology using mammalian cells
Mammalian cells can be used to record currents using the whole-cell patch-clamp assay. 
This assay allows rapid drug delivery to the mammalian cell (given the small size of the 
cell). Using rapid drug delivery, measurements of kinetic parameters such as rise time, 
slope of the rising phase of the current, peak amplitude, desensitization time constants 
and the number of macroscopic desensitization phases can be obtained. These 
measurements allow calculation of rates e.g., ligand on/off rates, desensitization rates, 
and channel opening/closing rates. In addition to being directly informative, these values 
can also be used to prepare kinetic models of the receptor function. The whole-cell patch- 
clamp assay is technically challenging, especially in the case of mutant receptors with 
low receptor expression levels.
2.10.2 Electrophysiology using Xenopus laevis oocytes
Although it provides a non-mammalian cellular environment for protein expression, 
numerous studies have shown the fidelity of Xenopus laevis oocytes as an expression 
system. Stage IV Xenopus laevis oocytes are primed for protein expression and faithfully 
reproduce any protein of which genetic material has been introduced. All the features of 
the protein assembly and targeting of the protein are preserved. Thus, a membrane-bound 
receptor is targeted to the cell membrane. The advantages of using this system for protein 
expression and analysis are two-fold,
1) Proteins are expressed in large quantities. Thus in a case where it is difficult to 
detect currents from a mutant receptor being expressed in mammalian cells, 
expression in oocytes can make those currents detectable.
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2) Oocytes provide a more stable system for electrophysiological recording, 
allowing prolonged recording sessions.
On the other hand, drug delivery is not as rapid as whole-cell patch-damp. Also, oocytes 
may impose certain post-translational modifications, such as glycosylation, which may be 
different than those taking place in the protein’s native environment. Thus the data 
obtained from oocytes needs to be interpreted more carefully than that obtained from the 
whole-cell patch-clamp assay.
2.11 Molecular modeling
Homology-based protein modeling and the use of the protein model for ligand docking 
allows a more systematic interpretation of biochemical data by providing a three­
dimensional model. Such a model allows visualization of the inter-relation between 
various amino acids in the purported ligand-binding domain as well as between various 
amino acids and the docked ligand molecule. Corroboration of biochemical data with the 
information obtained from molecular dynamics (MD) calculations can also provide 
information about the dynamics of the protein between various conformational states. 
Information obtained from all the molecular modeling studies also aids in formulation of 
testable hypotheses.
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Chapter 3: Structure-activity relationship study of lerisetron, a
competitive antagonist at the 5-HT3AR2»
3.1 Summary
The serotonin type 3 receptor (5-HTbR) is a prototypical member of the cysteine-loop 
family of ligand-gated ion channels, lerisetron (l-phenylmethyl-2-piperizinyl 
benzimidazole) is a potent 5 -HT3R antagonist. Functional groups on this compound 
capable of forming interactions with the receptor are the terminal amino group in 4’-N 
position, an aromatic imidazole and a benzyl group in the N 1 position of the imidazole. 
The present study explored the importance of the 4’-N nitrogen by utilizing 4’-N 
substituted analogs of lerisetron. The properties of the analogs were characterized using 
murine 5-HT3AsRs expressed in Xenopus laevis oocytes. The apparent affinities of the 
analogs for 5-HT3asRS were determined using electrophysiological competition assays. 
The results obtained suggest that the terminal nitrogen of lerisetron is involved in a 
precise interaction with certain amino acid(S) in the 5-HT3AR binding site. Our results 
also indicate that the partial negative charge on the 4’-N nitrogen as well as its ability to 
participate in a cation-pi interaction are probably critical to its action as a potent 5-HT3AR 
antagonist.
2 Manuscript in preparation for submission to Neuropharmacology (Elsevier publication).
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3.2 Introduction
The serotonin type 3 as receptor (5-HT3asR) is a prototypical member of the cysteine-loop 
family of ligand-gated ion channels (LGIC) (Belelli et al., 1995; Jackson and Yakel, 
1995; Maricq et al., 1991). Other members of this family include the nicotinic 
acetylcholine receptors (Karlin and Akabas, 1995), the y-amino butyric acid type A 
receptor (G A B A a R ) (Schofield et al., 1987) and the glycine receptor (GlyR) 
(Grenningloh et al., 1987). Comprised of a pentameric quaternary structure with at least 
two ligand-binding sites present at the subunit interfaces (Arias, 2000; Celie et al., 2004; 
Miyazawa et al., 1999), this receptor family is characterized by the presence of a critical 
disulfide loop structure within the binding site and an integral ion selective channel. Like 
other members of this family, more than one subtype of the receptor can be found in the 
CNS. Both an A and B subunit have been identified and cloned (Davies et al.,
1999).Two splice variants of the A subunit have also been identified (Downie et al., 
1994; Hope et al., 1996). While both long and short splice forms are capable of forming 
functional homomeric receptors, some differences in agonist and partial agonist activity 
have been observed between the long and short splice variants of this subtype (Niemeyer 
and Lummis, 1998). A second subtype is formed by combination of the A and B subunits 
to produce a hetermomeric receptor with unknown stoichiometry (Davies et al., 1999). 
Heteromeric receptors are pharmaco 1 ogically and functional distinct from homomeric 5- 
HTsaRs (Brady et al., 2001). 5 -HT3RS are distributed throughout the central and 
peripheral nervous system, playing a significant role in phenomena such as anxiety, 
emesis and alcoholism (Ait-Daoud et al., 2001; Gandara et al., 1993). Antagonists to 5-
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HT3R.S are clinically efficacious in the treatment of chemotherapy-induced emesis and 
recent studies on human subjects have suggested they m ay be useful in treatment o f  early 
onset alcoholism (Ait-Daoud et al., 2001).
A model for the antagonist pharmacophore of the 5-HT3R was proposed by Hibert 
et al (Hibert et al., 1990). Although some modifications have been made to this model 
since that time, the common structural features of 5 -HT3R antagonists remain essentially 
the same. All 5 -HT3R antagonists contain an aromatic ring, a carbonyl oxygen or 
bioisosteric equivalent and a basic nitrogen. According to Hibert’s model, the basic 
nitrogen is located 5.2A from the centre of the aromatic ring and approximately l.?A 
above plane of the ring. The carbonyl oxygen and the aromatic ring are coplanar and 
separated by a distance of 3.3A. Additonal studies have expanded on this model to 
include another lipophilic region (Clark et al., 1993) and second hydrogen bonding 
interaction two atoms away from the first. A compound that appears to fit all 4 binding 
site regions was synthesized by Orjales et al. (Orjales et al., 1997). This compound (1- 
phenylmethyl-2-piperizinyl benzimidazole or lerisetron) is shown in figure 3.1 and is a 
potent 5 -HT3R antagonist. Functional groups on this compound capable of forming 
interactions with the receptor are the terminal amino group, an aromatic imidazole and a 
benzyl group in the N 1 position of the imidazole. While lerisetron contains no carbonyl 
group, one or both of the imidazole nitrogens could act as bioisosteres of this functional 
group (Orjales et al., 1997).
Orjales demonstrated the importance of the Ml benzyl group by synthesizing 
several N1 substituted analogs of lerisetron. Removal of the N-benzyl group produced a
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80-fold decrease in affinity, indicating a role for this group in interacting with the 5- 
HT3R. Sim ilar studies involving N 1 substituant analogs by Parihar et al. have supported 
this observation and suggest a more specific charge-charge interaction rather than a 
general lipophilic interaction (Parihar et al., 2001)
In the present study, we examined the effect of alterations at the 4’-N position 
(the terminal nitrogen group, see Figure 3.1) of lerisetron. Our results indicate that the 
terminal nitrogen is involved in a precise interaction with certain amino acid (S) in the 5- 
HT3AR binding site. Our results also indicate that the partial negative charge on the 4’-N 
nitrogen as well as its ability to participate in a cation-pi interaction are probably critical 
to its action as a potent 5 -HT3AR antagonist.
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3.3 Materials and Methods
3.3.1 Materials
Xenopus laevis frogs and frog food were purchased from Xenopus Express (FL, US). 
Sigma type II collagenase was purchased from Sigma-Aldrich (MO, US). [3H]granisetron 
was purchased from New England Nuclear (ST, US), 5-HT, 2-Me5HT from Spectrum, 
and wCPBG and d-TC from Research Biochemical International (MO, US). All other 
chemicals were obtained from Fisher Scientific (TX, US).
lerisetron and its 4’-N substituted analogs were kindly provided by Harish Parihar, who is 
a co-author of this manuscript, and Dr. Karen Kirschbaum at the University of Louisiana 
at Monroe, Monroe, LA 71203.
3.3.2 Site-directed mutagenesis
Wild-type (wt) m5-HT3As receptor cDNA was derived from N1E-115 neuroblastoma 
cells as previously described (Yan et al., 1999). All mutant receptors were constructed 
using the pAlter altered sites mutagenesis kit (Promega, CA) as described earlier 
(Venkataraman et al., 2002). All mutations were confirmed by restriction digests and 
DNA sequencing (UC Davis, CA).
3.3.3 Xenopus laevis oocyte two-electrode voltage-clamp assay
Details of the methodology employed for electrophysiological assays have been 
described earlier (Joshi et al., 2004). Ovarian lobes were surgically removed from 
Xenopus laevis frogs and washed twice in Ca+2-free Barth’s buffer [82.5 mM NaCl / 2.5 
mM KC1 / ImM MgC12 / 5 mM HEPES, pH 7.4], then gently shaken with 1.5mg/m!
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collagenase for lhour at 20-25 °C. Stage IV oocytes were selected for microinjection. 
Synthetic cRNAs for wt and mutant m5 -HT3ARs were prepared using an mMESSAGE 
mMACHINE™ High Yieid Capped RNA Transcription Kit (Ambion, TX). Each oocyte 
was injected with 50nl cRNA at a concentration of 0.2ng/nl. Oocytes were incubated at 
19°C for 2 to 4 days before electrophysiological recording. Electrical recordings were 
made using conventional two-electrode voltage-clamp at -60 mV employing an OC- 
725C oocyte clamp amplifier (Warner Instruments, CT, US) coupled to an online, 
computerized data acquisition system (DataPac 2000, RUN technologies, CA, US). 
Recording and current electrodes were filled with 3M KC1 and had resistances of 1-2 
M fl Oocytes were held in a chamber of 400pl volume and perfused with ND-96 
recording buffer (96mM NaCl / 2mM KC1 /1.8mM CaCl2 / ImM MgCl2 / 5mM HEPES, 
pH 7.4) at a rate of 15ml/min. All agonists and antagonists were prepared in ND-96 
buffer and applied at a rate of 25ml/min using an electrical pump. For competition assays 
involving lerisetron and its analogs, oocytes expressing murine 5 -HT3AsRs were pre­
exposed to varying concentrations of each antagonist for a period of 30 seconds. After 30 
seconds, the oocyte was co-exposed to a mixture of 5-HT and the antagonist. The 5-HT 
concentration in each case corresponded to the EC50 value; i.e., 4pM.
3.3.4 Xenopus laevis oocyte two-electrode voltage-clamp assay
Data was analyzed using the equation 0 = [(1+ EC50 t[A]) as previously described 
(Yan et al, 1999), where 0 is the normalized current at 5-HT concentration [A], EC50 is 
the concentration of 5-HT required to obtain half-maximal current, and n is the apparent
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Hill slope. Concentration-Response curves were obtained by non-linear regression 
analysis using GraphPad PRISM. Data were compared for significant differences using 
student’s t test.
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Results
Murine 5 -HT3as receptor expressed using X. laevis oocytes produced characteristic 
inward currents on exposure to agonist serotonin (5-HT). Iterative curve fitting of the 
doses-response data yielded an EC50 value of 3.4 + 0.3pM (n = 4). The parent compound 
lerisetron (Figure 1) potently inhibits the inward currents induced by 4 pM 5-HT, with 
concentration of 10 nM completely obliterating the response. An IC50 value 0.54 «M was 
obtained for the wt receptor.
Certain analogs were designed to study the effect of alteration of the position of 
the terminal amino group on the apparent affinity, lerisetron analog HSP-153 was tested 
in order to examine the effect of altering the position of the terminal amino group on the 
piperidine ring structure. The shift of the amino group from 4 to 5 position leads to 
significant changes to the apparent affinity of the compound, with almost 10 0 -fold 
reduction in IC50 (Table 3.1). However, alteration of the position of the terminal amino 
group addition of a carbon (analog HSP-155) produced only a minor change in the 
apparent affinity (Table 3.1). Addition of a methyl group to the terminal nitrogen also did 
not significantly change the apparent affinity of the lerisetron analog (analog HSP 93, 
Table 3.1).
Effects of the alteration of the characteristics of the terminal amino group itself 
were examined with the help of another series of analogs (Table 3.1, second group). 
Replacement of the terminal amino group with a charged quaternary amine led to a small 
but statistically significant increase in the apparent affinity of lerisetron (HSP-97, Table 
3.1). Substitution of the terminal amine by a sulfur (HSP-161) led to complete loss of the
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activity. Although substitution with a charged sulfur group (methyl sulfonium) somewhat 
restored the activity, the apparent affinity was very poor, with almost 400,000 fold 
reduction in the apparent affinity (HSP-165, Table 3.1). Surprisingly, substitution with 
oxygen (SAK-8) was better tolerated as compared to substitution with sulfur or positively 
charged sulfur (methyl sulfonium); with almost 40,000 fold reduction in the affinity. In 
any case, any substitution at the terminal nitrogen was very poorly tolerated.
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Discussion
Previous studies have supported a critical role of the terminal amino group in mediating 
the action of lerisetron, a potent antagonist of the benzimidazole group of 5-HT3R 
antagonists (Orjales et al., 1997; Parihar et al., 2001; Venkataraman et al., 2002). The 
results described here further support such a role. Our studies also indicate that proper 
positioning of the nitrogen group also plays an important role in maintaining the potency 
of lerisetron. In the case of HSP-153 and HSP-155, the terminal secondary amine of 
lerisetron has been replaced by primary amine. In the case of the secondary amine of 
lerisetron, the basicity of the terminal amino group may be contributing to the overall 
interaction with the interacting amino acid. It is conceivable that the minor decrease in 
the apparent affinity observed with HSP-155 is probably a compound effect of reduction 
in the distance as well as reduction in basicity as result of replacement with the primary 
amine. The major decrease in the apparent affinity observed with HSP153 may similarly 
reflect a compound effect of change in the position of the amino group as well as 
reduction in basicity resulting from the replacement with the primary amine. Data 
obtained from analogs HSP 161 (sulfur) and SAK-8 (oxygen) also support the 
assumption that the basic charge on the terminal group is important for its purported 
interaction.
Previous studies have indicated that addition of charge to the terminal nitrogen 
increases potency, an assumption supported by the results obtained for analog HSP-97 
(Orjales et al., 1997; Petersson et al., 2002). The terminal amino group is purportedly 
involved in a cation-pi interaction, presumably with the aromatic amino acids on the
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positive face of the 5 -HT3R binding site (Beene et al., 2002). Cation-pi interaction 
involves charge interaction of the positively charged cation with the negatively charged 
pi electron cloud of an aromatic ring, typically of an aromatic amino acid such as tyrosine 
or tryptophan (Beene et al., 2002; Zhong et al., 1998). In case of the 5-HT3aR, cation-pi 
interaction of charged terminal nitrogen of ligands with amino acids W183 or Y234 have 
been proposed (Beene, 2004). The results described here for analogs HSP-97, HSP-161 
and HSP-165 (See Table 3.1) support these assumptions. Interestingly, a charged sulfur 
(as in the case of HSP-165) cannot adequately replace the nitrogen, since it probably does 
not participate equally well in the purported cation-pi interaction.
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Figure 3.1 Parent compound, lerisetron
The terminal amino group is marked by a circle
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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Table 3.1 IC50 values obtained for the series of N-substituted lerisetron analogs
The IC50 values were obtained using Xenopus laevis oocytes expressing murine 5 -HT3A 
receptor and two-electrode voltage-clamp assay.
The number of experiments is at least 3. + indicates IC50 + the standard error. All the IC50 
values were significantly different from that obtained for the parent compound lerisetron.
Name Structure IC50 in«M
Lerisetron 0.56 +  0.19
HSP-153 57.9 +  8.9
ESP-155
— NH,
2.51+ 0 .52
HSP-93 2,46 +  0.3
HSP-97 V 0.15 +  0.04
HSP-161
No Inhibition 
up to 1 raM
HSP-165
200000 +  8000
SAZ-8
19650 +  3030
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Chapter 4: Mutations at loop E tyrosine residues differentially
modulate gating of the murine 5-HT3A Receptor3
4.1 Summary
The 5 -HT3R belongs to a superfamily of ligand-gated ion channel coupled receptors and 
shares several structural and functional features with other members including the 
nAChR, GABA and Gly receptors. Previous mutagenesis & protein modeling studies 
suggest that three tyrosine residues (Y141, Y143 and Y153) in the putative loop E region 
of the amino terminal may form part of the ligand-binding site and play a role in ligand- 
receptor interactions. Results from the molecular modeling studies suggested that 
tyrosine residues 143 and 153 are part of a dynamic H-bonding pattern and play a role in 
receptor gating. These studies also suggested that these gating interactions are 
differentially modulated by 5-HT and wCPBG through differential interactions. 
Mutations at Y143 and Y153 produced significant changes in receptor function. The 
Y143A mutation resulted in non-functional receptors; while the Y143F mutation 
produced large changes in EC50 values for four agonists; 5-HT, mCPBG, PBG and 2- 
MeSHT. In addition, relative efficacies (Imsx Agonist/lMax 5-HT) of the partial agonists 
PBG (24% vs. 87% for wt receptor) and 2-Me5HT (1.8% vs. 12% for wt receptor) were 
altered. The Y153A mutation significantly altered response kinetics for 5-HT but not 
-mCPBG and PBG. The Y153A mutation also led to drastic changes in the rank efficacy 
of four agonists compared to wt (wt: 5-HT>wCPBG>PBG»2-Me5HT, Y153A:
3 Manuscript in preparation for submission to Neuropharmacology (Elsevier publication).
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mCPBG>PBG»5-HT»2-Me5HT). The Y153F mutation produced receptors that 
displayed an efficacy profile similar to Y153A receptors. These results suggest that Y143 
is critical in general to channel gating, while Y153 mediates agonist specific gating of the 
5 -HT3A receptor.
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4.2 Introduction
The serotonin type 3 receptor (5 -HT3R) is a membrane bound, cation-selective, ion 
channel coupled, glycoprotein (Derkach et al., 1989; Maricq et al., 1991). The 5-HT3R 
belongs to a superfamily of ligand-gated ion channels (LGlCs) and shares several 
structural and functional features with other members including the nicotinic 
acetylcholine (nACh), gamma amino butyric acid (GABA) A and C, and glycine (Gly) 
receptors. The presence of a characteristic loop formed by two cysteine residues (‘cys 
loop’) in the extracellular N-terminal of these receptors has led to their designation as the 
‘Cys-loop’ superfamily of receptors. Expressed in both the central and peripheral nervous 
system (Reeves and Lummis, 2002), the 5 -HT3R mediates fast synaptic transmission 
through rapid opening and desensitization of the ion channel (Sugita et al., 1992).
Two subunits of the 5 -HT3R, A and B (Davies et al., 1999; Hanna et al., 2000) 
have been characterized, although DNA sequences coding for 5 -HT3C, D and E are 
known (Niesler et al., 2003). While the A subunit assembles in a homo-pentameric form, 
B subunit can assemble into a functional protein only if co-expressed with the A. Two 
splice variants of the A subunit of the murine receptor (1115-HT3R): As and Al are also 
known (Downie et al., 1994; Hope et al., 1993). Receptors composed of different splice 
variants demonstrate distinct pharmacological characteristics; interacting differentially 
with 5 -HT3R agonists (Hope et al., 1993).
The ligand-binding site of the 5-HT3AR is located in the extracellular N-terminal 
domain (van Hooft et al., 1998). Sequence homology with the nACh receptor and 
acetylcholine binding protein (AChBP) suggests that the ligand binding site is located in
90
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the inter-subunit interface and is formed by at least 6 ‘loop’ structures designated A to F 
(Brejc et al., 2001). Results from several site-directed mutagenesis studies have so far 
identified numerous residues from a number of these purported loop structures (Boess et 
al., 1997; Schreiter et al., 2003; Spier and Lummis, 2000; Steward et al., 2000; Yan et al., 
1999). We have previously reported that three tyrosine residues from the loop E region 
(Y141-Y153) are similarly important to ligand-receptor (L-R) interactions 
(Venkataraman et al., 2002b). These residues were identified through the use of alanine 
scanning mutagenesis of a stretch of amino acids from Y141 to K153 of the m5-HT3AR- 
Based on results obtained from radio-ligand binding assays, we have earlier proposed that 
residues Y143 and Y153 might be important in L-R interactions of both agonists (5- 
hydroxytryptamine [5-HT] and w-chlorophenylbiguanide [wCPBG]) and antagonists 
(lerisetron, its analogs and to a lesser extent, granisetron) (Venkataraman et al., 2002a; 
Venkataraman et al., 2002b). A role for Y141 in the interaction of rf-tubocurare (d-TC) 
with the ligand-binding domain was also proposed. Results from our laboratory and 
others have suggested that Y153 and Y143 may also be involved in mediating 
conformational changes in response to agonists (Beene et al., 2004; Price and Lummis, 
2004; Venkataraman et al., 2002b); however, no direct evidence has been reported in 
support of this hypothesis.
mCPBG, a selective agonist at the 5 -HT3A receptor, displays a distinct 
pharmacological profile . When assayed on murine 5 -HT3AS and 5 -HT3AL receptors, 
mCPBG displays lower efficacy compared to 5-HT(Niemeyer and Lummis, 1998) but 
higher apparent affinity (based on the EC50, Kd, K; values) (Joshi et al., 2004; Spier and
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Lummis, 2000; Venkataraman et al., 2002b). mCPBG also demonstrates higher affinity 
for the desensitized state of the 5-HT3aR (Bartrup and Newberry, 1996; Mott et al., 2001)
. Earlier studies have indicated that rwCPBG and 5-HT interact differentially with the loop 
A and loop C region of ligand binding domain of 5-HT3aR (Lankiewicz et al., 1998; 
Steward et al., 2000). However, the role of loop E region in mediating these differential 
interactions remains unexplored.
In the present study, comparison of ligand-free and ligand bound models of the 5- 
HT3AR suggested that tyrosine residues 143 and 153 are part of a dynamic H-bonding 
pattern and play a role in receptor gating. Results from ligand docking studies suggested 
that these gating interactions are differentially modulated by 5-HT and wCPBG through 
differential interactions. We explored the role of loop E tyrosines in mediating the effects 
of full and partial agonists through biochemical assays. Our results indicate that both 
Y143 and Y153 are involved in mediating the gating of the w5-HT3aR although Y153 is 
more specific to the structural class of agonist. While Y143 appears to participate in 
gating for all agonists tested, Y153 is involved only in mediating the effects of 
hydroxytryptamines (5-HT and 2-methyl 5-hydroxytryptamine [2-Me5HT]) and not 
phenylbiguanides (phenylbiguanide [PBG] and wCPBG
92
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4.3 Materials and Methods
4.3.1 Materials:
Xenopus laevis frogs and frog food were purchased from Xenopus Express (FL, US). 
Sigma type II collagenase was purchased from Sigma-Aldrich (MO, US). [3H]granisetron 
was purchased from New England Nuclear, 5-HT, 2-Me5HT from Spectrum, and 
mCPBG and d-TC from Research Biochemical International. All other chemicals were 
obtained from Fisher Scientific (TX, US).
4.3.2 Receptor modeling:
Extracellular regions of the homopentameric murine 5 -HT3R were built based on the 
crystal structure of AChBP from the snail Lymnaea stagnalis (PDB entry: 1I9B). The 
sequence of 5 -HT3R A subunit was taken from the Protein Information Resource (Wu et 
al., 2002) with an entry code of NF00508262. Multiple sequence alignments of their 
extracellular regions and AChBP were performed by ‘ClustalW’ using default parameters 
(Thompson et al., 1994). Based on this alignment, homology-model building of 5 -HT3AR 
subunit was carried out using the ‘Nest’ and ‘Loopy’ facility of the Jackal protein 
structure modeling package. ‘Nest’ predicts the experimental dihedral angles chil within 
an error range of 20 degrees for 94 % of protein side chains (Xiang and Honig, 2001). 
Protein loop predictions for amino acid insertions and deletion were done by 
‘Loopy’(Xiang et al., 2002). Homodimeric units of the pentamer were built on the basis 
of crystal structure data to reach minimal root mean standard deviation (RMSD) between 
the matched monomers. Further refinements of the resulting dimers were carried out by
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Sybyl 6.6 program (Tripos Inc., St. Louis, MO) on a Silicon Graphics Octane workstation 
under Irix 6.5 operation system. First, the all-atom model was allowed to relax during a 
short molecular dynamics run (2000 fs) using constrains for backbone atoms, not 
allowing distortions of the backbone. Finally, the entire structures were fully minimized 
without any restriction using Powell conjugate gradient method until the maximum 
derivative was less than 0.050 kcal/molA. Gasteiger-Huckel partial charges were applied 
during the calculations. The quality of the model was verified using ‘Procheck’, as 
compared with well-refined structures at the same resolution ((Laskowski, 1993). Intra- 
and interface H-bonds were analysed by HBPLUS v 3.0, an hydrogen bond calculation 
program (McDonald and Thornton, 1994). Homology model for the ground state receptor 
was constructed based on the same alignment as for the ligand-bound receptor model. 
Chain F of AChBP (Celie et al., 2004) taken from RCSB Protein Bank entry 1UV6 was 
used as a template for ground state receptor model. The loop C conformation of this 
ligand-free subunit is strikingly different from the conformation of the other crystallized 
chains with bound ligands. Side chain prediction, dimer building and structural 
minimization of the ground state receptor were carried out using the same workflow 
described above for the ligand-bound receptor model.
'AutoDock 3.0’ was applied for docking calculations, using the Lamarckian 
genetic algorithm (LGA) and the ‘pseudo-Solis and Wets’ (pSW) methods. The ligand 
docking calculations were performed independent of experimental data. The parameters 
included in Autodock are based on the ‘Assisted Model Building with Energy 
Refinement’ (AMBER) force field (Cornell, 1995). Gasteiger-Huckel partial charges
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were applied both for ligands and proteins. Solvation parameters were added to the 
protein coordinate file and the ligand torsions were defined using the ‘Addsol’ and 
‘Autotors’ utilities, respectively, in Autodock 3.0. The atomic affinity grids were 
prepared with 0.375 A spacing using the Autogrid program for a 15 x 15 x 22.5 A box 
around the interface of subunits. No constraints based on experimental data were 
employed to carry out ligand docking. Random starting positions, orientations and 
torsions (for flexible bonds) were used for the ligands. Each docking run consisted of 100 
cycles. The number of evaluations was set to 1.5 million. Final structures with RMSD 
less than 1.5 A were considered to belong to the same cluster. The structures with low 
energies and high frequencies of docking were subjected to a further minimization by 
Sybyl and were examined.
4.3.3 Site-directed Mutagenesis:
Wild type m5-HT3AS receptor cDNA was derived from N1E-115 neuroblastoma cells as 
previously described (Yan et al., 1999). All mutant receptors were constructed using the 
pAlter altered sites mutagenesis kit (Promega, CA) as described earlier (Venkataraman et 
al., 2002a). All mutations were confirmed by restriction digests and DNA sequencing 
(UC Davis, CA).
4.3.4 Cell culture and transient transfection:
/SA201 cells (a derivative of HEK 293 cells) were cultured in Dulbecco’s modified Eagle 
medium (DMEM, New Life Technologies, NY) supplemented with 10 % fetal bovine 
serum and 100 units/ml penicillin/streptomycin in a humidified 5% CO2 atmosphere at 37
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°C. For radio-ligand binding studies, fSA201 cells were plated on 90 mm culture dishes at 
a density of 5 x 106 cells/dish and grown for 9 hours prior to transfection. Cells were 
transfected with 20 jug/ dish wt or mutant plasmid DNA using a calcium phosphate 
transfection kit (New life technologies, NY). Transfected cells were supplemented with 
fresh DMEM 12-15 hours later and harvested 48 hours after transfection. For whole-cell 
patch-clamp assays, /SA201 cells were transfected using Superfect transfection reagent 
(Qiagen, CA) as described earlier (Venkataraman et al., 2002b).
The following flow-chart summarizes the use of partial agonist approach to determine 
binding vs. gating effects as a result of a mutation.
Mutation leading to changes in ECS0 values
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Role in direct interaction or gating effects or both?
Comparison of efficacy ratio (partial agonist/fbll agonist)
Molecular modeling Molecular modeling
predicts direct does not predict direct
interaction interaction
Involved in both Involved in gating effects only Involved in direct interaction only
direct interaction 
and gating
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4.3.5 Xenopus laevis oocyte two-electrode voltage-clamp assay
Details of the methodology employed for electrophysiological assays have been 
described earlier (Joshi et al., 2004). Ovarian lobes were surgically removed from 
Xenopus laevis frogs and washed twice in Ca+2 free Barth’s buffer [82.5 mM NaCl / 2.5 
mM KC1 / ImM MgCU / 5 mM HEPES, pH 7.4], then gently shaken with 1.5mg/ml 
collagenase (Sigma type II, Sigma-Aldrich) for lhour at 20-25 °C. Stage IV oocytes were 
selected for microinjection. Synthetic cRNAs for wt and mutant m 5 -HT3ARs were 
prepared using an mMESSAGE mMACHINE™ High Yield Capped RNA Transcription 
Kit (Ambion, TX). Each oocyte was injected with 50 nl cRNA at a concentration of 0.2 
ng/nl. Oocytes were incubated at 19°C for 2 to 4 days before electrophysiological 
recording. Electrical recordings were made using conventional two-electrode voltage- 
clamp at -60 mV employing an OC-725C oocyte clamp amplifier (Warner Instruments, 
CT) coupled to an online, computerized data acquisition system (DataPac 2000, RUN 
technologies). Recording and current electrodes were filled with 3M KC1 and had 
resistances of 1-2 MO. Oocytes were held in a chamber of 400 pi volume and perfused 
with ND-96 recording buffer (96 mM NaCl / 2 mM KC1 /1.8 mM CaCh /1  mM MgCh / 
5 mM HEPES, pH 7.4) at a rate of 15 ml/min. All agonists and antagonists were prepared 
in ND-96 buffer and applied at a rate of 25 ml/min using an electrical pump. For 
competition assays involving d-TC, oocytes expressing Wt or mutant receptors were pre­
exposed to varying concentrations of d-TC for a period of 30 seconds. After 30 seconds, 
the oocyte was co-exposed to a mixture of 5-HT and d-TC. The 5-HT concentration in 
each case corresponded to the EC50 value for the receptor under consideration.
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4.3.5.1 Comparison of efficacy values for various agonists on wild type and mutant
receptors:
Maximal currents were measured using supra-maximal concentrations of agonists (10-40 
X the EC50 value). iMax values were compared to those obtained using the endogenous 
agonist 5-HT. Relative efficacies for mCPBG, PBG and 2-Me5HT were calculated using 
the equation Imbx (Agonist)/lMax 5-HT X 100% (Eq. 1). Each value is indicated in the text 
as mean ± S.E and n denotes the number of experiments for each agonist. For each 
experiment, maximal currents elicited by each agonist (mCPBG, PBG and 2-Me5HT) 
were directly compared to those elicited by 5-HT on the same oocyte. Values were 
normalized separately for each experiment and the results were combined.
4.3.6 Whole-cell Patch-clamp assay:
Whole-cell patch-clamp assays were performed as described earlier (Venkataraman et al., 
2002a). Briefly, transfected cells were transferred to a recording chamber containing 
extracellular solution (140 mM NaCl, 1.7 mM MgCl2, 5 mM KC1, 1.8  mM CaCl2, 25 mM 
HEPES pH 7.4). Patch electrodes of resistance 2.5-3.0 MQ were filled with filtered 
intracellular solution containing 145 mM KC1, 2 mM MgCl2, 1 mM EGTA, 25 mM 
HEPES (pH 7.4). Cells were clamped in whole-cell configuration at a holding potential 
of -60 mV. A continuous extracellular solution flow (0.8 ml/min) was maintained 
throughout the recording procedure. 5-HT was dissolved in extracellular solution and 
delivered to cells using a rapid perfusion system (Warner Instruments, CT) at a rate 
matching the extracellular solution flow rate. The drug perfusions lasted for a period
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varying from 4 to 8 seconds. Currents elicited by agonist application were measured 
using an Axopatch 200 B amplifier (Axon Instruments, CA).
Radio-ligand Binding Assays:
Radio-ligand binding assays was performed as described earlier (Venkataraman et al., 
2002b). Briefly, transfected cells were scraped from the dishes, washed twice with PBS 
(New Life Technologies, NY), then resuspended in 1.0 ml PBS with protease inhibitor 
cocktail /100mm dish. {Complete™ protease inhibitor cocktail, Roche, Mannheim, 
Germany). Cells were either used fresh or frozen at this step until needed. Immediately 
prior to use, cells were homogenized in PBS (with protease inhibitor) using a glass tissue 
homogenizer then centrifuged at 35000 X g for 30 minutes in a Beckman JA20 rotor. 
Membranes were washed once more with PBS and resuspended in lml PBS/100 mm 
dish. Protein content was determined using Lowry assay (Sigma Diagnostics, MO). 
Binding assays were performed in PBS with protease inhibitors. For Kd determinations, 
50 pi of homogenate was incubated at 37°C for 1 hour with varying concentrations of 
[3H]granisetron. Specific binding of [JH] granisetron was determined as bound [3H] 
granisetron not displaced by a saturating concentration of a competing ligand (typically 
10 pM Tropisetron). For Kj determinations, 50 pi of homogenate was incubated at 37°C 
for 2 hours with varying concentrations of inhibitor and [3H]granisetron. Binding was 
terminated by rapid filtration onto a GF/B filters.
4.3.7 Data analysis:
Data obtained from radio-ligand binding assays was analyzed as follows. Kd values were 
determined by fitting the binding data to the following equation using GraphPad PRISM
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(San Diego, C A ):  B  = B Max [L]” / ([L]" + K ”)  (Eq.2), where B  is bound ligand, BMax is the 
maximum binding at equilibrium, L is the free ligand concentration, K is the equilibrium 
dissociation constant and n is the Hill coefficient. Statistical analysis of concentration- 
response data from electrophysiological assays was performed using the equation I  = 
ImoxK 1 + EC5o/[A] ”) (Eq.3), where I is the peak current, Im3x is the maximal response at a 
given concentration of agonist A , EC50 is the half-maximal concentration of the agonist A  
and n describes apparent Hill slope. Data from competition assays involving d -T C  was 
analyzed using the equation 0 = [(1+ EC50 /[A]) ”] '! (Eq.4) as previously described (Yan et 
al., 1999), where 0 is the normalized current at 5-HT concentration [A], EC50 is the 
concentration of 5-HT required to obtain half-maximal current, and n is the apparent Hill 
slope. Concentration-Response curves were obtained by non-linear regression analysis 
using GraphPad PRISM. Data were compared for significant differences using student’s t 
test.
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4.4 Results
4.4.1 Results from molecular modeling studies:
Ligand-docking studies were performed using the ligand-bound model of the S-HTsaR 
(Table 4.1, Figure 4.1). This model is based on the crystal structure of AChBP and 
probably indicates the activated/desensitized state of the receptor (Le Novere et al., 2002; 
Maksay et al., 2003; Reeves et al., 2003). The ligand-docking studies were originally 
performed to explore the role of loop C region in ligand-interactions. A part of the results 
from the ligand docking studies have been presented earlier (Suryanarayanan et al., 
2004). 5-HT docked model suggests that the side chain of Y153 is positioned within less 
than 4A of the hydroxyl group of 5-HT. The O-H group of 5-HT forms a hydrogen bridge 
with Y153, interfering with the H-bonding network of the receptor. In case of mCPBG- 
docked model of the receptor, the side chain or the backbone of Y153 are not within 
4Aof the docked mCPBG. There is no strong hydrogen bonding interaction possible 
between the ligand and loop E tyrosine residues, since the chloro group of wCPBG points 
toward the loop E. In case of both 5-HT and mCPBG docked models, both Y141 and 
Y143 are positioned more than 4Afrom the docked ligands. Both 5-HT and mCPBG 
seem to interact with Y234 through a cation-pi interaction.
Molecular modeling studies were performed to investigate interactions of the loop 
E tyrosine residues in the ligand-free and ligand-bound state (Table 4.2, Figure 4.1). To 
this purpose, hydrogen bonding pattern of the tyrosine residues was examined using the 
ground state model and the ligand-bound model of the murine 5 -HT3A receptor. 
Movement of loop C apparently influences the inter-subunit hydrogen bonding pattern of
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the molecule. Y141 possess only intrasubunit interactions, which remain unchanged 
during the conformational change. In the closed form model, Y234 forms an intersubunit 
hydrogen bond only with Y143. In ligand-bound state, the position of Y234 is shifted 
closer to Y153, and forms a dual hydrogen bond with Y143 and Y153. Y234 also gets 
closer to the W183, however this distance is still more than 4A even in open form. A 
reduction in the distance between Y153 main chain and W183 side chain is also 
observed. These calculations also suggest that residues Y141, Y143, Y153 and W183 
form various intra-subunit contacts with other residues. These intra-subunit contacts are 
not altered significantly by agonist binding and may indicate structural features. The 
main finding of these protein modeling results that while Y143 seems to form 
intermolecular hydrogen bonds both in closed and open state, Y153 is hydrogen bonded 
with Y234 only in 5-HT-bound form model of the receptor.
4.4.2 Results from biochemical assays:
Site directed mutagenesis studies of LGICs have been used extensively to identify amino 
acids participating in receptor-Iigand interactions. Electrophysiological assays are 
regularly employed to assess the possible role played by an amino acid in such 
interactions. EC50 measurements from electrophysiological assays can demarcate an 
amino acid as potentially important. However, these data alone cannot unequivocally 
determine whether a residue plays a role in a direct binding interaction or is involved in 
the transduction of the binding signal that leads to channel opening; i.e. gating 
(Colquhoun, 1998). A simplest form of mechanism for receptor activation (Del Castillo 
and Katz mechanism) is given as:
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KA E
A + R ^ ^  AR. ^ AR*
where the agonist A binds to the vacant closed receptor R. This interaction is governed by 
the equilibrium binding rate constant KA. The receptor-agonist complex AR then 
isomerizes to the open state AR*. The activation step is governed by equilibrium gating 
constant E. Measurement of EC50 value for the receptor R will be influenced both by the 
changes to KA and E. To address this issue of ‘binding vs. gating’ we have employed the 
“traditional partial agonist approach” (Downie et al., 1996; Downie et al., 1995; O'Shea 
and Harrison, 2000; O'Shea et al., 2000; Rajendra et al., 1995). This approach compares 
the fractional maximal currents ( I m b x )  of full and partial agonist on a single receptor 
preparation for both the wild type and mutant receptors. Changes to fractional Imbx ratios 
can be qualitatively correlated with changes in E value (Lynch, 2004). Imbx is described 
by the equation Imbx = rnPOMax, where i is the single channel conductance, n is the 
receptor number and POMax is the maximum fraction of activated receptors. The 
maximum fraction of activated receptors (POMax) is described by the equation, POm3x -  
El(l+E) (Lynch, 2004). Since the IMax values for all the agonists are being measured on 
single preparation, the receptor number n will be a constant value. Assuming that the 
single channel conductance (/) and the desensitization rates remain unchanged, 
measurement of fractional Imex ratios (relative efficacies) can be correlated with changes 
in E (Lynch, 2004).
To compare fractional maximal currents (relative efficacies) for all four agonists 
(5-HT, mCPBG, PBG and 2-Me5HT), the fractional I Max value obtained for 5-HT was
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assumed to be 100% or 1 for each of the receptor. This assumption is being solely used as 
a reference for all the IMax comparisons. We do not assume that the fractional Im3x for 5- 
HT is unchanged for any of the mutant receptors.
Xenopus oocytes expressing wt receptors produced characteristic inward currents 
when rapidly exposed to 5-HT or mCPBG (Figure 4.2A). Iterative curve fitting of the 
data yielded EC50 values that corroborate well with the published results (Figure 4.2, 
Table 4.4). 5-HT was the most efficacious agonist on wt receptors, producing maximal 
currents (IMax) of 14.8 ± 1.58 pA (n =12) at supra-maximal concentrations (Table 4.5). To 
accurately record Im3x values, drug concentrations were limited to 10-40 X EC50. Higher 
concentrations can produce erroneously low IMax values due to rapid receptor 
desensitization. To avoid such effects on maximal currents, an optimal concentration of 
each agonist for each receptor type was chosen after assaying a range of supra-maximal 
concentrations. Maximal concentration was defined using the doses-response curve. An 
optimal supra-maximal concentration was determined to be that which caused less than 
5% reduction compared to the maximal concentration. In addition, a specially designed 
perfusion chamber was employed in order to achieve faster rise times and faster solution 
changes compared to conventional perfusion chambers (Joshi et al., 2004). At such 
concentrations, mCPBG elicited only 92 (±1) % of the current produced by 5-HT. The 
ligands 2-Me5HT and PBG also behaved as partial agonists; producing only 12 (±1) and 
87 (±7) % of 5-HT induced currents (Figure 4.2B & C). These data are in agreement with 
previously published results (Downie et al., 1994; Hope et al., 1993) and suggest that the 
open conformation of the wild type 5 -HT3aSR channel is most efficiently stabilized by
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the endogenous agonist 5-HT, followed by mCPBG, PBG and least efficiently by 2- 
Me5HT.
A homogeneous population of receptors was labeled when membrane 
preparations of fSA201 mammalian cells transiently transfected with m5 -HT3AS cDNA 
were employed in a saturation ligand-binding assay. [3H] granisetron bound to wt 
receptors with high affinity (Kd =0.98 ±0.18 nM) and a Hill slope greater than one (hh=
1.6 ±0.08).
Oocytes expressing Y141A mutant receptors exhibited inward currents on 
exposure to 5-HT. Response characteristics, including rapid rise times and fast 
desensitization, were indistinguishable from those of wt receptor (Figure 4.3A). Exposure 
to mCPBG and PBG produced similar results. The EC50 for 5-HT was unaltered while a
4-fold increase for mCPBG was observed (Figure 4.3B, Table 4.4). Only a 2-fold change 
was observed in the EC50 value for PBG.
5-HT was the most efficacious agonist for the Y141A receptor, producing an Imbx 
of 0.54 ± 0.04 pA (n =9) at supra maximal concentrations. Among mutant receptors, 
Y141A produced the lowest Imbx values. At supra-maximal concentrations, mCPBG 
produced approximately 90 (±2) %, (n= 5) while PBG produces 85.4 (±2.8) % («=6) of 
currents produced by 5-HT; results that are similar to those obtained with the wild type 
receptor (Figure 4.2C). The substantially lower Imbx of 5-HT induced responses impeded 
our attempts at fully characterizing the actions of the partial agonist 2-Me5HT. We have 
previously reported that the Y141A mutation produces a 50-fold reduction in the K; for d- 
TC on the 5 -HT3A receptor, measured as a function of [3H]granisetron displacement
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(Venkataraman et al., 2002b), suggesting an altered interaction of d-TC with the 5-HT3A 
binding domain. In the present study, we performed electrophysiological competition 
assays involving 5-HT and d-TC to assess the effects of Y141A on d-TC inhibition of 5- 
HT induced responses (Figure 4.2D). d-TC inhibited 5-HT induced currents at the wt 
receptor with a high potency (2.57 ± 0.37 nM, n~3). Unexpectedly, the Y141A mutation 
led to only a 2.5 fold increase in the apparent IC50 for d-TC (Y141A d-TC IC5o= 5.9 ± 1.8 
nM, «==3). Although the value for Y141A receptor was significantly different (**p<0.01) 
from that obtained for wt receptors, the fold change was minor and was substantially less
•5
than the change in Kj observed for inhibition of [ HJgranisetron binding by d-TC 
(Venkataraman et al., 2002b)
Minor increase in Kd for [3H] granisetron was observed with Y141A mutation. 
However, a significant reduction in the receptor expression in tSA 201 cells was 
observed (Table 4.1). The low IMax values for 5-HT obtained from oocytes can be 
explained by low levels of receptor number, an assumption supported by low expression 
levels in mammalian system.
No inward currents could be elicited from oocytes injected with Y143A mutant 
cRNA in response to 1 mM of either 5-HT, mCPBG or PBG (data not shown). These 
experiments were repeated multiple times («=27) using at least six different batches of 
oocytes with identical results. In contrast, oocytes expressing Y143F mutant receptors 
produced rapid inward currents with rapid desensitization on exposure to both 5-HT and 
mCPBG. The response characteristics of Y143F receptors were thus indistinguishable 
from wt receptors (Figure 4.4A). Compared to wt receptors, the EC50 for 5-HT on Y143F
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receptors increased by 61 fold (207 ± 22.8 pM). A large increase in the EC50 value was 
also observed for 2-MeSHT (170 fold, 2.77 ±0.13 mM), while a relatively minor increase 
was seen for both raCPBG (6 fold, 5.33 ±0.19 pM, **p<0.01) and PBG (16 fold, 337 ±
14.2 pM) (Table 4.4). Only a minor change in Hill slopes was apparent (Table 4.4). 
Efficacies of all four agonists were compared using the protocol described earlier. 
mCPBG was the most efficacious agonist for the Y143F receptors, inducing maximal 
currents of 1.29 ± 0.43 pA (n =10); a value substantially lower than the IMax values 
obtained for wt receptors (Table 4.5). The maximum current induced by application of 
100 pM mCPBG was significantly different than that produced by 3mM 5HT (115 ± 5.3 
% of 5-HT current, n= 9, **p<0.01). Although average IMax values produced were in the 
range of 1 to 2 pA, some of the oocytes tested produced currents up to 3.6 pA at supra­
maximal otCPBG concentrations, allowing us to characterize action of partial agonists. 
Maximal currents induced by 3 mM PBG were 31.1 ± 3 % («=5), while maximal current 
induced by 10 mM of 2-Me5HT were only 1.8 ±0.27% (n -4) of those induced by 5- 
HT.The Y143F mutation thus resulted in significantly altered IMax PBG/lMax 5-HT and 
Iwax 2-Me5HT/ IMax 5-HT ratios (Figure 4.4C).
Both Y143A and Y143F mutations produced minor changes in Kd for [3H] 
granisetron. While receptor expression levels of Y143A in mammalian cells was 
moderately reduced, Y143F mutation did not cause any significant changes to receptor 
expression (Table 4.3).
A shift of~40 fold (136 ± 8.1 mM) was observed in the EC50 value for the agonist 
5-HT, on Y153A mutant receptors expressed in Xenopus oocytes (Table 4.4). In addition,
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responses obtained from these receptors following perfusion with 5-HT show drastically 
different characteristics when compared to wt responses. 5-HT induced responses on 
Y153A receptors were marked by both very slow rise times and very slow desensitization 
(Figure 4.5A), even at supra-maximal concentrations. The Y153A mutation produced a 
five-fold increase (-2000 msec. Vs. 400 msec. «=7) in the rise time to the peak inward 
current as compared to the wt receptor, measured at supra-maximal 5-HT concentration 
(3 mM for Y153A and 100 pM for the wt receptor). We have earlier reported similar 
results for Y153A mutant receptors expressed in fSA201 cells (Venkataraman et al., 
2002b). These findings confirm and further supplement those results.
In contrast to 5-HT, the ECso value for /wCPBG on Y153A receptor increased 
only by -9.5 fold compared to the wt receptor (Figure 4.5C). Surprisingly, mCPBG 
induced responses obtained from Y153A receptors were identical in characteristics to 
those obtained from wt receptors, with rapid rise times and fast desensitization (Figure 
4.5B). /wCPBG was the most efficacious agonist at Y153A receptors with maximal 
currents of 13.8 ± 2.2 pA («=7). In addition mCPBG elicited a -33 fold larger Imbx 
compared to that obtained with 5-HT (3284 ± 192% of 5-HT current, n -  7) at supra 
maximal concentrations (Figure 4.5D). To confirm that these results were not unique to 
receptor proteins expressed in Xenopus laevis oocytes, mCPBG’s effects on Y153A 
receptors expressed in mammalian cells (ISA 201) were characterized using whole-cell 
patch-clamp assay. Figure 4.6 shows a comparison of currents elicited from wild type and 
Y153A receptors using 5-HT and /wCPBG at maximal concentrations. Results were 
similar to those obtained from oocytes expressing Y153A receptors (Figure 4.6).
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An EC50 of 243 ± 17.1 pM was determined for PBG activation of Y153A 
receptors expressed in oocytes, a rightward shift of -12 fold compared to wt receptors. 
PBG currents were similar to those observed for mCPBG displaying rapid rise times and 
fast desensitization. Currents elicited by 3 mM PBG were -31 fold greater than those 
elicited by 5-HT (3148 ± 714 % of 5-HT current, n= 7) and slightly less than those 
obtained with mCPBG. Thus, the rank efficacy of wCPBG compared to PBG is 
unchanged by the Y153A mutation (Figure 4.5D). Maximal currents obtained with 5-HT 
produced average currents of only 0.5 pA; however, some oocytes produced up to 1.6 pA 
currents in response to 3 mM 5-HT. On these oocytes, 2-Me5HT would be expected to 
produce an Im3x o f -0.19 pA if the Y153A mutation did not alter its efficacy relative to 5- 
HT. However, no currents could be elicited with 2-Me5HT up to a concentration of 10 
mM suggesting a change in the lMax2-Me5HT/ Im&x 5-HT (efficacy) ratio. This 
conclusion is also supported by data obtained for 2-Me5-HT on Y153F receptors 
(described below). The rank efficacy of the four agonists tested on wt receptor was 5- 
HT> m€PBG> PBG »  2-Me5HT. This rank of efficacy was drastically altered for 
Y153A receptor (Figure 4.5D). For Y153A receptor, the rank efficacy was: mCPBG> 
PBG »  5 -H T »  2-Me5HT.
Mutation of Y153 to phenylalanine led to a relatively minor increase in EC50 
values for all four agonists. While a -14.5 fold increase was observed in the EC50 value 
for 5-HT, the EC50 for mCPBG increased only -3  fold (Table 4.4). Similarly, a -2  fold 
increase in the EC50 value for 2-Me5HT and -3  fold increase in the EC50 for PBG were 
observed. The Y153F mutation also produced normal kinetics for the 5-HT induced
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response, with rapid onset and rapid desensitization (Figure 4.7A). Similar to the Y153A 
mutation, mCPBG was the most efficacious agonist. Oocytes expressing Y153F receptors 
produced IMax values in response to supra-maximal concentrations of mCPBG that were 
significantly less than those expressing Y153A receptors (Table 4.5). The low Imbx values 
are in agreement with reduced receptor protein expression levels observed for the Y153F 
mutation in tSA201 cells.
A comparison of efficacies of all four agonists reveals changes in rank efficacy 
similar to the Y153A mutation. Although moderate, changes in efficacies were 
nonetheless significant. While exposure of Y153F mutant receptor to mCPBG yielded 
177 (± 11) % of IMax compared to 5-HT induced maximal current (assumed 100% in each 
case, n -22), exposure to PBG resulted in 138 (±2) % of 5-HT Imsx («=8). Most 
importantly, 2-Me5HT produced 0.7 (±0.2) % of maximal current (n=7), compared to 5- 
HT (Figure 4.7 B and C). Thus, even for the subtle Tyr to Phe mutation, the change in 
rank of efficacy observed for the Y153A mutation was preserved, i.e., mCPBG> PBG > 
5 -H T »  2-Me5HT.
Both Y153A and Y153F mutations produced minor changes in Kd for [3H] 
granisetron. While receptor expression level of Y153A in mammalian cells was 
unaltered, Y153F mutation produced moderate changes in receptor expression level 
(Table 4.3).
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4.5 Discussion
This study was primarily conducted to determine whether tyrosine residues of loop E 
region play a role in mediating gating of the 5-HT3aR channel. The theoretical 
framework for the mutagenesis experiments was provided by the molecular modeling 
studies. These studies indicated that Y143 hydroxyl forms inter-subunit contacts residues 
from the principal face of the binding domain. These studies also suggested that Id- 
bonding partner for the Y153 hydroxyl group differs depending on the class of the 
agonist bound. While 5-HT hydrogen bonds with Y153, wCPBG does not. In case of 
bound mCPBG, Y153 forms the H-bond with Y234.
The majority of the biochemical data presented here has been obtained from two- 
electrode voltage-clamping of Xenopus oocytes, although whole-cell recording was 
employed in a limited manner. To overcome limitations on slow solution exchange rates 
inherent to oocyte electrophysiology, we employed a specially designed small-volume 
oocyte chamber(Joshi et al., 2004). The method of oocytes electrophysiology was 
validated by reproduction of a complete pharmacological profile of the murine 5-H T3As 
including relative efficacies. In case of Y153, we were able to reproduce the results 
obtained from Xenopus oocytes using whole-cell recordings. Other studies have noted the 
difficulties associated with mammalian expression of loop E mutant receptors (Price and 
Lummis, 2004; Venkataraman et al., 2002b). Although oocyte based assays cannot 
replace whole-cell assays in terms of resolution and accuracy, they provide a viable 
alternative in cases where mammalian cell whole-cell recording is difficult to obtain.
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Previous competition binding studies of Y141A mutants resulted in largely 
unaltered K; values for both agonists and antagonists, suggesting a lack of any major 
interaction between Y141 and 5-HT3aR ligands. We observed no significant change in 
EC50 values, Hill slopes or relative efficacies on Y141A receptors, thus further supporting 
this conclusion. Our results also rule out involvement of Y141 in mediating 
conformational changes related to gating. The results from the molecular modeling 
studies presented here also suggest that Y141 does not interact with either 5-HT or 
mCPBG.
In contrast, expression levels of Y141A receptors appeared to decrease. Bm3x 
values observed in mammalian cells were consistent with very low I Max values for most 
efficacious agonist 5-HT, obtained in oocytes. The reduced Imbx values from oocytes 
could be a result of drastic changes to channel gating (E) mediated by 5-HT. However, 
such changes to gating would also result in drastic changes to EC50 value for 5-HT. Since 
no change to 5-HT EC50 resulted from Y141A mutation, low IMax values cannot be 
explained by assuming a disruption in 5-HT induced gating. These results suggest a role 
for Y141 in receptor assembly. Although caution should be exercised while comparing 
Iiviax and BMax values from two different expression systems, such a comparison may 
provide useful correlations between measurements of receptor expression and efficacy 
changes. Our results thus predict a structural role for Y141. Molecular models of the 5- 
HT3AR predict that Y141 forms a static intra-subunits hydrogen bond with T! 17. Such a 
hydrogen bond may play a role in either protein assembly or in maintaining proper 
receptor structure.
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Docking studies of d-TC do not predict an interaction with Y141 of the m5- 
H TsaR (Maksay et al., 2003). Consistent with this prediction, only a sm all increase in 
IC 50 value was observed for d-TC inhibition of 5-HT induced currents on Y141A 
receptors compared to wt. We previously reported a 50-fold increase in K, values for d- 
TC in competition binding assays on tSA201 cells. The basis for this discrepancy is 
unclear although a more recent study supports this finding (Price and Lummis, 2004). 
Due to differences in cell type, competing ligands and reaction conditions, binding and 
functional data cannot be directly compared. The shift of both IC50 and Ki in the same 
direction, however, suggests a minor interaction of Y141 with d-TC.
Y143F mutation produced significant changes in efficacy ratios for partial 
agonists PBG and 2-Me5HT and 5-HT (i.e., Im® PBG/Imbx 5-HT and IMax 2-Me5HT/ IMax
5-HT). These results strongly support a central role for Y143 in gating. Other 
observations also support the role of Y143 in channel gating. 1m8x values for 5-HT 
induced responses on Y143F receptors were reduced in comparison to those obtained 
from wt receptors indicating a possible decrease in 5-HT efficacy. While it is possible 
that the low IMax values obtained in oocytes were actually as a result of low receptor 
number, Bm3x values for Y143F receptors expressed in mam malian cells were comparable 
to those of wt receptors. Based on expression levels obtained in mammalian cells, a more 
parsimonious explanation for low Im® values obtained in Xenopus oocytes would be an 
alteration in gating constant for agonists in Y143F mutant receptors. Competition binding 
studies of Y143A receptors have reported large changes in Ki values for both 5-HT and 
otC P B G  (Venkataraman et al., 2002b). In the present study, no responses could be
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elicited from oocytes or mammalian cells expressing Y143A receptors, although Bmb 
values obtained from fSA201 cells (Table 4.3) were 40% of the wt values. These results 
again suggest that Y143 plays a role in channel gating and/or ligand binding in addition 
to proper receptor assembly. The results from the molecular modeling studies suggest 
that Y143 forms several inter-subunit H-bonds during the ground- as well as the agonist- 
bound state. The combined results from biochemical and modeling studies suggest that 
the involvement of Y143 in the formation of the static and probably the dynamic H- 
bonding network is responsible for its role in both maintaining the structural integrity and 
mediation of the gating effects. The results from the molecular modeling studies 
presented here also suggest that Y143 does not interact with either 5-HT or mCPBG. 
Previous studies have demonstrated the importance Y234 in mediating agonist action 
(Beene et al., 2004; Price and Lummis, 2004; Suryanarayanan et al., 2004). Y143 may be 
playing a role in mediating gating through H-bonding interactions with side chain 
hydroxyl group of Y234. Presence of such interactions in the activated state probably 
explains the severe effects of even a subtle mutation at Y143 and Y234 positions. These 
data also indicate that Y143 exerts its effect via interacting with other amino acids of the 
binding domain rather than the bound ligand.
Y143 may also be playing a role in agonist specificity. Rank efficacies of full 
agonists were altered for Y143F receptors compared to wt. Changes in efficacy parallel 
the shifts in EC50 value with the most efficacious agonist mCPBG showing the least 
change in EC50 and the least efficacious agonists 2-Me5HT showing the largest change in 
EC50. These results suggest that mCPBG induced channel gating is more tolerant to
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disruption at Y143 as compared to 5-HT induced channel gating.. Although the efficacy 
of mCPBG appeared to increase relative to 5-HT, the drastically reduced Im3x value 
associated with mCPBG responses may indicate that mCPBG effica cy  was also 
decreased.
Along with a large reduction in EC50 value, Y153A receptors have drastically 
altered 5-HT induced response characteristics, showing peculiar currents with increased 
rise times. These response characteristics suggest a major alteration in the gating 
mechanism. 2-Me5HT, an analog of 5-HT failed to produce any currents in oocytes 
expressing Y153A receptors, again reflecting a possible change in gating. At supra­
maximal concentrations, currents induced by 5-HT on Y153A receptors are strikingly 
similar in characteristics to those induced by 2-Me5HT on wt receptors, further 
suggesting that 5-HT acts in a manner similar to a low efficacy partial agonist on the 
Y153A receptor. On the other hand, the partial agonist action of 2-Me5HT on wt cannot 
be linked to a lack of involvement of Y153 since mutations at Y153 also severely alter 
the efficacy of 2-Me5HT. Mutation of Y153 to phenylalanine produced normal response 
characteristics and produced currents in response to 2-Me5HT. The efficacy profiles for 
Y153A and Y153F receptors were identical: w €PB G »PB G »5-H T »2-M e5H T . 
Compared to 5-HT and 2-Me5HT, EC50 values for mCPBG and PBG increased only 
moderately on Y153A receptors and both phenylbiguanides displayed response 
characteristics indistinguishable from wt receptors. mCPBG and PBG, produced Imbx 
amplitudes that were not significantly different than those obtained for wt receptors 
(Table 4.3). The differences in efficacy for mCPBG and PBG were also similar to wt
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receptors while EC50 values increased slightly. Expression levels of Y153A mutant 
receptor in tSA201 cells are also very similar to those o f  the wt receptor. Im® values 
identical to wt and moderate increase in the EC50 for m C P B G  and PBG, suggest that the 
efficacy of these phenylbiguanides on Y153A has not increased compared to wt. The data 
for both Y153A and Y153F receptors suggest that Y 15 3  may be differentially modulating 
the gating of the 5 -HT3aR according to structural class of the agonist. Thus, mutations at 
Y153 specifically alter responses to hydroxytryptamine and not phenylbiguanide 
agonists. Although substituting alanine with a phenylalanine restored the normal 
characteristics of 5-HT induced response, the effects on gating could not be completely 
reversed indicating that both the aromatic ring and the hydroxyl group may be involved 
in a complex interaction mediating 5-HT induced channel gating. While the effects of 
Y153 mutations appear specific for 5-HT type agonists, it should be pointed out that the 
slight increase in E C 50 values for mCPBG and PBG may also indicate a minor role for 
Y153 in mediating the interaction of these agonists.
The role played by the loop E tyrosine residues in the differential modulation of 
the gating mechanism may indicate a conserved feature of the LG1C superfamily. The 
apparent lack of conservation in this region of the protein among various members of this 
family supports such a contention (Figure 4.8). The amino acid homologous to Y153 in 
the 72 GABAa R (y2T142; Figure 4.8) is involved in differentially modulating the 
efficacy  of benzodiazepines (Mihic et al,, 1994). T142 presumably mediates these effects 
through a hydrogen bond with Y 16 0  (homologous to W183 of 5 -H T 3aR ) of cxG A B A a on 
the (+) face of the binding site (Cromer et al., 2002). Available data on the nicotinic
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acetylcholine receptors suggests that nicotine and acetylcholine interact differentially 
with the amino acids in the ligand-binding domain (Beene et a l ,  2002; Petersson et al., 
2002). Crystallographic studies of AChBP show a hydrophobic interaction between R104 
(homologus to Y143) and carbamylcholine, but not nicotine (Celie et al., 2004). Ml 14 
(homologous to Y153) on the other hand, is involved in hydrophobic contact both with 
nicotine and carbamylcholine. In addition, main chains of L102 (homologous to Y141) 
and Ml 14 (homologous to Y153) interact with nicotine but not carbamylcholine by virtue 
of a hydrogen bond. These studies provide evidence for the role of loop E region in 
mediating agonist specificity. These results also provide the most explicit evidence of 
direct interaction of agonists with the amino acids under consideration. Crystallographic 
studies can thus provide immense amount of details about protein structure. While such 
information cannot be easily obtained from electrophysiological assessment of mutant 
receptors, such assessment provides information about the dynamics of conformational 
changes and receptor gating.
Our data suggests that in the activated state, Y234 of the loop C region moves 
closer to the loop E region. Results from studies on the AChBP indicate that loop C as 
well as the other regions of the ligand-binding domain close in on the bound agonist upon 
activation (Celie et al., 2004). Modeling studies described here show that Y 143 and Y153 
play a role in forming hydrogen-bonding contacts during activation. The biochemical 
data supports such a role for Y143 and Y153. Both Y143 and Y153 form H-bonds with 
Y234, although the mode of bond formation differs according to the state of the receptor 
(ligand-free vs. ligand-bound) and the type of agonist (5-HT vs. otCPBG). While the
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Y143-Y234 hydrogen bond exists both in closed and open state, the Y153-Y234 
hydrogen bond is only seen in our m CPB G -docked open state model. Thus, Y143 
apparently forms a hydrogen bonding interaction with Y234 in the case of both 5-HT and 
m CPB G  binding. The results of our modeling studies also suggest that the specific role 
played by Y153 in 5-HT mediated gating could be the result of a direct interaction of the 
Y153 side chain with the hydroxyl group of 5-HT. This conclusion is well supported by 
the biochemical data. The lack of an interaction between Y153 and mCPBG may explain 
why mutations at Y153 are better tolerated by m CPB G -m ediated agonism. The 
biochemical data obtained from phenylbiguanides also suggest that the Y153-Y234 H- 
bond may not be critical to proper channel gating. Similar profile of the results for 
m C P B G  and PBG for mutations at Y153 suggests a similar mode of action for all 
phenylbiguanide agonists. These data thus suggest that amino acids Y143 and Y153 are 
involved in stabilization of the open state of the receptor through different mechanisms.
In the case of the nicotinic acetylcholine receptor, mutation of amino acids and 
around the purported ligand binding domain destabilizes the open state of the receptor 
(Chakrapani et al., 2004). It is conceivable that the Y153-5-HT interaction at least 
partially stabilizes the open state of the receptor. On the other hand, H-bonding 
interactions of Y143 seem to be involved in mediating agonist action in general.
The role of loop E tyrosine residues in receptor mechanism is probably not 
restricted to inter-subunit interactions. Several other lines of evidence suggest that both 
Y143 and Y153 could both be involved in direct interactions with 5-H T3aR antagonists 
(Maksay et al., 2003; Venkataraman et al., 2002a; Venkataraman et al., 2002b). The
118
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results o f  previous and present studies thus indicate a dual role for Y143 and Y153. As 
part o f  the ligand-binding domain these residues may be involved in binding interactions 
with competitive antagonists. Agonists on the other hand probably mediate channel 
gating by bringing about the local rearrangement of the H-bond network formed by these 
tyrosine residues. Our results indicate that subtle changes in this rearrangement could be 
at least partially responsible for the differential action of two structurally distinct 
agonists, 5-HT and /wCPBG.
119
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Figure 4.1 Results from molecular modeling and ligand-docking studies
4.LA Movements of the 5-HTsaR  regions surrounding the ligand-binding domain 
associated with activation:
Structures of 5-HT3A dimer units with open (ligand-free, green) and closed (ligand- 
bound, blue) binding clefts. The conformational change causes a shift in Y234 position, 
which alters its inter-subunit hydrogen bonding partners, forming a Y234-Y153 bond.
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4.1.B Docking of 5-HT to ligand-bound 5-HTsaM receptor model:
The O-H group of 5-HT forms a hydrogen bridge with Y153, interfering with the H- 
bonding network of the receptor.
4.1.C Docking of mCPBG to ligand-bound S-HTsaR receptor model:
There is no strong hydrogen bonding interaction possible between the ligand and loop E 
tyrosine residues, since the chloro- group of mCPBG points toward the loop E.
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4.2.A Characteristics of inward currents elicited by application of agonists at supra­
maximal concentration.
The set of traces shown w as obtained from a single oocyte. Traces shown are 
representative of multiple experiments. The solid bar on the top of each trace denotes 
time of drug exposure, type of agonist used and it’s concentration.
4.2.B Concentration-response curves for four agonists
Data obtained for each agonist, i.e., 2-M e5H T, /wCPBG and PBG were normalized to 
those obtained for 5-HT for each experiment separately using equation 1. Concentration- 
Response curves were obtained as described in the methods and materials section. Error 
bars indicate ± S.E.
4.2.C A comparison of efficacy values for agonists
Currents for mCPBG, PBG and 2-Me5HT were normalized to those obtained for 5-H T as 
described in methods section. Values are reported as percentages. Results from multiple 
experiments were combined to plot the bar graph. Error bars indicate S.E. Values 
obtained were 5-HT = 100% (n=9), m C P B G =  92.6 ± 0.97% (n=6), PBG=87.6 ± 3%  
(n=6), 2-Me5HT= 11.8 ± 0.2% (n=6).
Figure 4.2 Electrophysiological characterization of wt 5-HT3AS receptors expressed
in Xenopus laevis oocytes
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4.3.A Characteristics of inward currents elicited by application of agonists at supra­
maximal concentration.
The set of traces shown was obtained from a single oocyte. Traces shown are 
representative of m ultiple experiments. The solid bar on the top of each trace denotes 
time of drug exposure, along with the type of agonist used and it’s concentration.
4.3.B Concentration-response curves for four agonists
Data obtained for each agonist, i.e., 2-Me5HT, wzCPBG and PBG were normalized to 
those obtained for 5-HT for each experiment separately using equation 1. Concentration- 
Response curves were obtained as described in the methods and materials section. 
Changes both to EC50 values as w ell as efficacies (relative to 5-HT) are evident from the 
concentration-response curves. Refer to Table 4.2 for Hill slope values. Error bars 
indicate S.E.
4.3.C A comparison of efficacy values for agonists 5-HT, mCPBG and PBG
For each experiment, the maximal currents elicited by each agonist (mCPBG, PBG and 
2-Me5HT) were directly compared to those elicited by 5-HT on a single oocyte. Results 
from multiple experiments were combined to plot the bar graph comparing efficacy 
values. Error bars indicate S.E. produced approximately 5-HT= 100% (n=9), mCPBG= 
90±2 %, (n=5) PBG= 85.4±2.8% (n=6). 2-Me5HT currents could not be recorded due to 
very low Imax values.
4.3.D Inhibition of 5-HT induced responses by co-application of d-TC.
Application of d-TC was initiated 30 sec prior to co-application of 5-HT and d-TC. (i) 
3jiM 5-HT (ii) 3 pM 5-HT + 3 nM d-TC (iii) 3 pM 5-HT + 30 nM d-TC
Figure 4.3 Electrophysiological characterization of Y141A S-BTsas receptors
expressed in Xenopus laevis oocytes
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4.4.A Characteristics of inward currents elicited by application of agonists at supra­
maximal concentration.
The set of traces shown was obtained from a single oocyte. Traces shown are 
representative of multiple experiments. The solid bar on the top of each trace denotes 
time of drag exposure, along with the type of agonist used and it’s concentration.
4.4.B Concentration-response curves for four agonists
Data obtained for each agonist, i.e., 2-Me5HT, mCPBG and PBG were normalized to 
those obtained for 5-HT for each experiment separately using equation 1. Concentration- 
Response curves were obtained as described in the methods and materials section. 
Changes both to EC50 values as well as efficacies (relative to 5-HT) are evident from the 
concentration-response curves. Refer to Table 4.2 for Hill slope values. Error bars 
indicate S.E.
4.4.C Comparison of efficacies of 5-HT, mCPBG, PBG and 2-Me5HT
For each experiment, the maximal currents elicited by each agonist (mCPBG, PBG and 2- 
Me5HT) were directly compared to those elicited by 5-HT on a single oocyte. Results 
from multiple experiments were combined to plot the bar graph comparing efficacy 
values. Error bars indicate S.E. Values obtained were 5-HT = 100% (n=10), /wCPBG= 
115 ± 5.34 % (n=9), PBG= 31.1 ± 3.96 % (n=5), 2-Me5HT= 1.87 ± 0.27% (n=4).
Figure 4.4 Electrophysiological characterization of Y143F S-HTjas receptors
expressed in Xenopus laevis oocytes.
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Figure 4.5 Electrophysiological characterization of Y153A 5-HT3AS receptors
expressed in Xenopus laevis oocytes.
4.5.A Currents elicited by application of increasing concentrations of 5-HT to 
oocytes expressing Y153A mutant receptors.
Note that the time scale is different as compared to other traces shown in the Figure. All 
the traces are characterized by increased rise times and slow desensitization rates. The 
rise times do not increase significantly with increasing concentrations.
4.5.B Characteristics of inward currents elicited by application of agonists at supra­
maximal concentration
The set of traces shown was obtained from a single oocyte. Traces shown are 
representative of multiple experiments. The solid bar on the top of each trace denotes 
time of drug exposure, along with the type of agonist used and it’s concentration. 
Concentration-response curves for four agonists. Data obtained for each agonist, i.e., 2- 
MeSHT, mCPBG and PBG were normalized to those obtained for 5-HT for each 
experiment separately using equation 1. Concentration-Response curves were obtained as 
described in the methods and materials section. Changes both to EC50 values as well as 
efficacies (relative to 5-HT) are evident from the concentration-response curves. Refer to 
Table 4.2 for Hill slope values. Error bars indicate S.E.
4.5.C Comparison of efficacies of 5-HT, mCPBG, PBG and 2-Me5HT.
For each experiment, the maximal currents elicited by each agonist (mCPBG, PBG and 2- 
Me5HT) were directly compared to those elicited by 5-HT on a single oocyte. Results 
from multiple experiments were combined to plot the bar graph comparing efficacy 
values. Error bars indicate S.E. Values obtained were 5-HT = 100% (n=7), mCPBG- 
3284 ± 192% (n=7), PBG- 3148 ± 270% (n=7), 2-Me5HT= 0% (n=7).
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Figure 4.6 Whole-cell patch-clamp recording from tSA 201 cells transfected with wt 
and Y 1 5 3a  cDNA.
Data were obtained using whole-cell patch-clamp on fSA201 cells transfected with wt or 
Y 1 5 3 a  mutant 5-HT3AsR cDNA as described in methods section. The solid bar on the top 
of each trace denotes time of drug exposure, along with the type of agonist used and it’s 
concentration. T h e  responses indicated in A and B are representative examples of at least 
3 sets of experiments.
I. wt 5-HTsasR: Agonists were applied for 4 s duration.
I I . Y153A mutant receptors: Agonists were applied for 8 s duration.
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4.7.A Characteristics of inward currents elicited by application of agonists at supra­
maximal concentration.
The set of traces shown was obtained from a single oocyte. Traces shown are 
representative of multiple experiments. The solid bar on the top of each trace denotes 
time of drug exposure, along with the type o f agonist used and it’s concentration.
4.7.B Concentration-response curves for four agonists.
Data obtained for each agonist, i.e., 2-Me5HT, mCPBG and PBG were normalized to 
those obtained for 5-HT for each experiment separately using equation 1. Concentration- 
Response curves were obtained as described in the methods and materials section. 
Changes both to EC50 values as well as efficacies (relative to 5-HT) are evident from the 
concentration-response curves. Refer to Table 4.2 for Hill slope values. Error bars 
indicate S.E.
4.7.C Comparison of efficacies of 5-HT, mCPBG, PBG and 2-Me5HT.
For each experiment, the maximal currents elicited by each agonist (mCPBG, PBG and 2- 
Me5HT) were directly compared to those elicited by 5-HT on a single oocyte. Results 
from multiple experiments were combined to plot the bar graph comparing efficacy 
values. Error bars indicate S.E. 5-HT = 100% (n=22), mCPBG= 178 ± 11% (n=18), 
PBG= 136 ± 3.2% (n=8), 2-Me5HT= 0.7 ± 0.19% (n=7).
Figure 4.7 Electrophysiological characterization of Y153F S-HTsas receptors
expressed in Xenopus laevis oocytes.
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140 155
m 5 -H T 3 AS PYVY VHH- -RifEVQ NYKP
m 5 -H T 3 B PYVY V N S- - S S T IR HHKP
h 5 —HT3 A PYVY IR H - -Q & V Q NYKPh 5 -H T 3 B PW Y VNS- -Sj&TIE NYKP
T o r p e d o  nACh a lp h a T E L Z LDY- -T^K IM WTPP
m nACh a l p h a TKVL LDY- - t J h i t WTPP
m nACh a l p h a  1 t  mwz. Y N A - - s J h c q YI»PP
h nACh a lp h a ? t n v l ¥HS - - s J hcq YLPP
AChBP TPQL ARWSDGEVL YMPS
m GABAA a lp h a  1 PMKL l r it e d | t l l YfflRm GABAA B e ta  1 RSRM IRLHPD^TVL YGLR
m GABAA d e l t a ENKL IRLQPDGVIL YSIR
m GABAA gamma, 2 PNRM LRIWNDGRVL YTLR
Figure 4.8 Sequence alignment of the purported loop E region of the SHT3A 
receptor.
Murine 5-HT3asR receptor’s deduced amino acid sequence was aligned with members of 
the LGIC superfamily as well as acetylcholine binding protein sequences by employing 
multi-sequence ClustalX alignment method. Conserved residue(s) are shaded gray. 
Residues discussed in the text are marked bold. The numbers at the end indicate position 
as measured from the N-terminal of murine 5-HT3asR-
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Table 4.1 Results from ligand-docking studies
Modeling of the extracellular domain of the murine 5-HT3aR and ligand docking were 
performed as described in “Methods”. Interactions predicted for 5-HT, 2-Me5HT and 
mCPBG are shown in the table.
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Ligand
N128 T181 W I83 F226 1228
5-HTja Amino Acids 
D229 1230 S231 Y234 1236 W §0 ¥153 1207
5-HT 4 + PP CP + HB 4* CP SB + 4*
2-MeSHT 4- + PP CP + HB + + HB SB + HB 4
jkCPBG + PP CP + + CP SB +
+ Within 4 A
PP Pl-pi 
CP Cation- Pi 
HB Hydrogen bond 
SB Salt Bridge
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Table 4.2 Heteroatomic distances (Y141, Y143, Y153, W183 and their H-bonding 
partners) in ligand-bound and ligand-free receptor models
These values indicate distances in A.
Intra-subunit
Distance
Number Amino Number Amino Ligand- Ligand- Type
Acid Acid bound free
141 TYR N 117 THR OG1 3.14 3.12 MS
143 TYR OH 153 TYR OH 2 .6 6 3.04 s s
183 TRP N 124 ASP 0 3.68 2.94 MM
183 TRP N 124 ASP OD2 2.82 3.40 MS
Inter-subunit
Distance
Number Amino Number Amino Ligand- Ligand- Type
Acid Acid bound free
143 TYR OH 183 TRP 0 2.96 3.25 SM
143 TYR OH 184 LEU 0 3.86 3.06 SM
143 TYR OH 185 HIS N 3.74 4.26 SM
143 TYR OH 234 TYR OH 3.24 3.00 SS
153 TYR 0 183 TRP NE1 3.26 3.60 MS
153 TYR OH 183 TRP 0 3.71 3.83 SM
153 TYR OH 234 TRP OH 2.62 4.79 SS
M: main chain 
S: side chain
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Table 4.3 Characteristics of wt and mutant receptors expressed in tSA201 cells.
Receptors were expressed transiently in mammalian ?SA201 cells and receptor protein 
expression measured as described in the methods section. Radio-ligand binding assays 
were carried out to measure the affinity of [3H]granisetron for wt and mutant receptors. 
Each experiment was repeated 5-8 times. All values are expressed as mean ± S.E. Kd 
values for all mutant receptors were significantly different compared to wt receptors 
(**£><0 .0 1 ) although changes were minor.
Receptor
Bmox
[3F1]granisetron binding
pmol/mg o f  
total protein
Kd (nM) ^ Fold change in 
Kd
WT 12.6 ±0.23 0.98± 0.18 1.17 ± 0.08 -
Y141A 3.5 ±0.14 2.4 ±0.17 1.54 ± 0.15 2.5
Y143A 5.2 ±0.08 3.89 ±0.42 1.62 ±0.24 4.0
Y143F 12 ±0.51 3.46 ±0.31 1.34 ±0.17 3.5
Y153A 13 ±0.37 6.73 ±0.71 1 .1 2  ± 0 . 1 2 6.9
Y153F 7.0 4 ± 0.53 5.98 ±0.33 1.79 ±0.14 6.1
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Wt and mutant receptors expressed in X. laevis oocytes were assayed using two-electrode 
voltage-clamp. Each value is expressed as mean ± S.E. and is obtained from combined 
data sets of at least 4 separate experiments. With the exception of the EC50 value for 5-HT 
on Y141A receptors, all values determined for mutant receptors, were significantly 
different (**/K0.01) from wt values. The extent of change however, varied. N.D. 
indicates that no currents were detected.
Table 4.4 Electrophysiological characterization of wt and mutant receptors
expressed in Xenopus laevis oocytes.
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5-HT 2-Me5HT jbCPBG PBG
Receptor ECso (pM) m ECso (pM) m EC$o (pM) ECsfl (pM)
WT ■3.4 ±0.3 1.4 ±0.2 16.4 ±1.1 1.77 ±0.18 0.8 ±0.07 1.6 ±0.2 20.5 ±0.44 1.75 ±0.06
YI41A 2.99 ±0.17 1.28 ±0.08 N.B N.D 2.76 ± 0.17 1.46 ± 0.17 36.5 ±1.2 1.66 ±0.08
Y143A N.D N.D N.D N.D N.D N.D N.D N.D
Y143F 207 ± 22.8 1.95 ±0.36 2773 ± 134 2.01 ±0.2 5.33 ±0.19 1.93 ±0.1 337 ±14.2 2.3 ±0.26
Y153A 136 ± 8.08 2.02 ± 0.22 N.D N.D 7.62 ± 0.27 2.03 ±0,13 243 ± 17.1 1.75 ±0.2
Y153F 49.2 ±5.2 1.46 ±0.18 38 ± 3.7 1.74 ±0.26 2.2 ±0.2 1.99 ±0.3 65.7 ±2.95 2.4 ±0.19
VD
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Table 4.5 IMax values measured from oocytes expressing wt and mutant receptors
Reported values indicate currents in pA obtained for the most efficacious of the four 
agonists assayed (indicated in the last column), n indicates the number of experiments. 
Each value is expressed as mean ± S.E.
Im a x  (pA) n Agonist
WT 14.8 ± 1.58 12 5-HT
Y141A 0.54 ± 0.04 6 5-HT
Y143A 0 27 -
Y143F 1.29 ± 0.43 10 wCPBG
Y153A 13.8 ± 2.2 7 mCPBG
Y153F 7.8 ±0.5 12 wCPBG
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Chapter 5: The role of loop B amino acid residues in the
structure and function of the 5-HT3AR4
5.1 Sum mary
5 -HT3 receptors are pentameric membrane bound receptors that belong to the ligand-gated 
ion channel (LGIC) superfamily. The ligand-binding site of these receptors is located in the 
extracellular domain. Results from previous studies on nicotinic acetylcholine receptors and 
structural homology with the Acetylcholine Binding Protein (AChBP) suggest that the 
binding site of the 5-HT3aR is composed of six loops; A-F. Using site directed mutagenesis, 
we investigated the role of amino acid residues in the putative loop B region of the mouse 5- 
HT3AR in receptor function. To this end, twelve amino acids (T179-I190) of the mouse 5- 
HT3AR loop B region were sequentially mutated to alanine. Each mutant was characterized 
using radio-ligand binding and electrophysiological assays. In order to further investigate the 
roles of mutants that showed altered binding and/or function, secondary mutations were 
constructed and similarly characterized. The results were correlated with the results of 
ligand-docking studies using both ligand-free and ligand bound models of the murine 5- 
HT3AR, based on AChBP. These studies indicate that T181 and W183 are located in the 
ligand binding domain and interact directly with ligands. Intra-subunit and inter-subunit 
interactions of loop B residues on either side of ligand-binding residues seem to be involved 
in mediating conformational changes associated with receptor activation. Our studies also
4 Manuscript in preparation for subm ission to Neuropharmacology (Elsevier publication).
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indicate that the intra-subunit and inter-subunit contacts formed by loop B residues are 
involved in proper receptor expression.
5.2 Introduction
The 5 -HT3R belongs to a superfamily of ligand-gated ion channel coupled receptors and 
shares several structural and functional features with other members, including the 
nAChR, GABA and Gly receptors. An understanding of ligand-gated ion channel 
function contributes significantly to the improvement of drug development and treatment 
options. In particular, studies involving the ligand-binding site contribute tremendously to 
the development of potent and specific ligands and aid in rational drug design. The 
ligand-binding site of the 5 -HT3aR is located in the extracellular N-terminal domain. 
Based on sequence homology with the nACh receptor and acetylcholine binding protein 
(AChBP), it is assumed that the ligand binding site is located in the inter-subunit 
interface and is formed by at least 6  loop structures designated A to F. Results from site- 
directed mutagenesis studies support this assumption. Studies of 5 -HT3aR involving the 
loop B region have focused on W183. This amino acids is thought to interact with the 
quaternary ammonium group of serotinergic ligands in a cation-7r interaction. The 
homologous residue is conserved as an aromatic amino acid in all LGIC receptor subunits 
(W149 of the nAChR a-subunit, Glycine -  FI 59, GABAAa l  -  Y159) (Figure 5.1). Spier 
et al utilized site-directed mutagenesis in combination with radio-ligand binding assays 
and whole-cell patch-clamp to decipher the role of W 183 in ligand-binding (Spier and 
Lummis, 2000). According to this study, mutation of tryptophan 183 to either tyrosine or 
phenylalanine results in ablation of radio-ligand binding. Although agonists can bind to
148
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
and activate the mutant receptors, large changes in EC5o values for both serotonin and 
/nCPBG are observed. Using unnatural amino acid substitutions, it has been postulated 
that this tryptophan residue forms a cation-pi interaction with the amino group of 5-HT 
(Beene et al., 2002). In such an interaction, the charged amino group of the ligand 
interacts with the pi cloud of the aromatic ring. Using the non-sense suppression method, 
various unnatural amino acids (modified forms of tryptophan) with substitutions on the 
aromatic ring of tryptophan, were introduced at position 183. The mutant protein was 
expressed in Xenopus oocytes and assayed with two-voltage electrode clamp using 
endogenous agonist serotonin. This technique provides a unique approach for examining 
the structure-activity relationship of a particular amino acid while maintaining the 
biologically active form of the protein. The homologous residue in the nAChR has been 
shown to form a cation- pi interaction with acetylcholine, but not nicotine (Beene et al., 
2002; Zhong et al., 1998).
With the exception of W183, the structural and functional role of the purported 
loop B region remains unexplored. In the present study, we have systematically examined 
each amino acid of the purported loop B region of the murine 5 -HT3aR. These studies 
indicate that amino acids T181 and W183 probably interact directly with agonists 5-HT 
and wCPBG, while W183, H I85 and D189 seem to be involved in granisetron binding. 
Amino acids T179, F I80, H I85, 1187, and D189 probably mediate agonist-induced 
conformational changes. Our studies also indicate that intra-subunit and inter-subunit 
contacts formed by loop B residues are involved in proper receptor expression.
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5.3 Materials and Methods
5.3.1 Materials:
Xenopus laevis frogs and frog food were purchased from Xenopus Express (FL, US). 
Sigma type II collagenase was purchased from Sigma-Aldrich (MO, US). [3H]granisetron 
was purchased from New England Nuclear, 5-HT, 2-Me5HT from Spectrum, and 
wCPBG and d-TC from Research Biochemical International. All other chemicals were 
obtained from Fisher Scientific (TX, US).
5.3.2 Methods:
5.3.2.1 Site-directed Mutagenesis
Wild type m5 -HT3AS receptor cDNA was derived from N1E-115 neuroblastoma cells as 
previously described (Yan et al., 1999). All mutant receptors were constructed using the 
pAlter altered sites mutagenesis kit (Promega, CA) as described earlier (Venkataraman et 
al., 2002a). All mutations were confirmed by restriction digests and DNA sequencing 
(UC Davis, CA).
5.3.2.2 Cell culture and transient transfection
/SA201 cells (a derivative of HEK 293 cells) were cultured in Dulbecco’s modified Eagle 
medium (DMEM, New Life Technologies, NY) supplemented with 10 % fetal bovine 
serum and 100 units/ml penicillin/streptomycin in a humidified 5% CO2 atmosphere at 37 
°C. For radio-ligand binding studies, fSA201 cells were plated on 90 mm culture dishes at 
a density of 5 x 106 cells/dish and grown for 9 hours prior to transfection. Cells were
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transfected with 20 pg/ dish wt or mutant plasmid DNA using a calcium phosphate 
transfection kit (New life technologies, NY). Transfected cells were supplemented with 
fresh DMEM 12-15 hours later and harvested 48 hours after transfection. For whole-cell 
patch-clamp assays, fSA201 cells were transfected using Superfect transfection reagent 
(Qiagen, CA) as described earlier (Venkataraman et al., 2002)
S.3.2.3 Xenopus laevis oocyte two-electrode voltage-clamp assay
Details of the methodology employed for electrophysiological assays have been 
described earlier (Joshi et al., 2004). Ovarian lobes were surgically removed from 
Xenopus laevis frogs and washed twice in Ca+2 free Barth’s buffer [82.5 mM NaCl / 2.5 
mM KC1 / ImM MgCl2 / 5 mM HEPES, pH 7.4], then gently shaken with 1.5mg/ml 
collagenase (Sigma type II, Sigma-Aldrich) for lhour at 20-25 °C. Stage IV oocytes were 
selected for microinjection. Synthetic cRNAs for wt and mutant m5-HT3ARs were 
prepared using an mMESSAGE mMACHINE™ High Yield Capped RNA Transcription 
Kit (Ambion, TX). Each oocyte was injected with 50 nl cRNA at a concentration of 0.2 
ng/nl. Oocytes were incubated at 19°C for 2 to 4 days before electrophysiological 
recording. Electrical recordings were made using conventional two-electrode voltage- 
clamp at -60 mV employing an OC-725C oocyte clamp amplifier (Warner Instruments, 
CT) coupled to an online, computerized data acquisition system (DataPac 2000, RUN 
technologies). Recording and current electrodes were filled with 3M KC1 and had 
resistances of 1-2 MO. Oocytes were held in a chamber of 400 pi volume and perfused 
with ND-96 recording buffer (96 mM NaCl / 2 mM KC1 /! .8 mM CaCb /1  mM MgCh / 
5 mM HEPES, pH 7.4) at a rate of 15 ml/min. All agonists and antagonists were prepared
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in ND-96 buffer and applied at a rate of 25 ml/min using an electrical pump. For 
competition assays involving d-TC, oocytes expressing Wt or mutant receptors were pre­
exposed to varying concentrations of d-TC for a period of 30 seconds. After 30 seconds, 
the oocyte was co-exposed to a mixture of 5-HT and d-TC. The 5-HT concentration in 
each case corresponded to the EC50 value for the receptor under consideration.
5.3.2.4 Radio-ligand Binding Assays
Radio-ligand binding assays were performed as described earlier (Venkataraman et al., 
2002). Briefly, transfected cells were scraped from the dishes, washed twice with PBS 
(New Life Technologies, NY), then re-suspended in 1.0 ml PBS with protease inhibitor 
cocktail /100mm dish. (Complete™ protease inhibitor cocktail, Roche, Mannheim, 
Germany). Cells were either used fresh or frozen at this step until needed. Immediately 
prior to use, cells were homogenized in PBS (with protease inhibitor) using a glass tissue 
homogenizer then centrifuged at 35000 X g for 30 minutes in a Beckman JA20 rotor. 
Membranes were washed once more with PBS and re-suspended in lml PBS/100 mm 
dish. Protein content was determined using Lowry assay (Sigma Diagnostics, MO). 
Binding assays were performed in PBS with protease inhibitors. For Kd determinations, 
50 pi of homogenate was incubated at 37°C for 1 hour with varying concentrations of 
[3H]granisetron. Non-specific binding of [3H] granisetron was determined as bound [3H] 
granisetron not displaced by a saturating concentration of a competing ligand (typically 
10 pM Tropisetron). For Kj determinations, 50 pi of homogenate was incubated at 37°C 
for 2 hours with varying concentrations of inhibitor and [3H]granisetron. Binding was 
terminated by rapid filtration onto a GF/B filters.
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5.3.3 Data analysis
Data obtained from radio-ligand binding assays was analyzed as follows. Kd values were 
determined by fitting the binding data to the following equation using GraphPad PRISM 
(San Diego, CA): B = BMax [L]" / ([L]" + K") (Eq.2), where B is bound ligand, Bm3x is the 
maximum binding at equilibrium, L is the free ligand concentration, K is the equilibrium 
dissociation constant and n is the Hill coefficient. Statistical analysis of concentration- 
response data from electrophysiological assays was performed using the equation I  = 
IMJ (  1 + EC50/[A ]") (Eq.3), where I is the peak current, Im3x is the maximal response at a 
given concentration of agonist A, EC50 is the half-maximal concentration of the agonist A 
and n describes apparent Hill slope. Data from competition assays involving d-TC was 
analyzed using the equation 0 = [(1+ EC50 !{A\) ”] 4  as previously described (Yan et al., 
1999), where 0 is the normalized current at 5-HT concentration [A], EC50 is the 
concentration of 5-HT required to obtain half-maximal current, and n is the apparent Hill 
slope. Concentration-Response curves were obtained by non-linear regression analysis 
using GraphPad PRISM. Data were compared for significant differences using student’s t 
test.
5.3.4 Receptor modeling
Extracellular regions of the homopentameric murine 5 -HT3R were built based on the 
crystal structure of the AChBP from the snail Lymnaea stagnalis (PDB entry: 1I9B). The 
sequence of 5 -HT3R A subunit was taken from the Protein Information Resource (Wu et 
a l, 2002) with an entry code of NF00508262. Multiple sequence alignments of their
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extracellular regions and AChBP were performed by ‘ClustalW’ using default parameters 
(Thompson et al., 1994). Based on this alignment, homology-model building of the 5- 
HT3A subunit was carried out using the ‘Nest’ and ‘Loopy’ facility of the Jackal protein 
structure modeling package. ‘Nest’ predicts the experimental dihedral angles chil within 
an error range of 20 degrees for 94 % of protein side chains (Xiang and Honig, 2001). 
Protein loop predictions for amino acid insertions and deletion were done by 
‘Loopy’(Xiang et al., 2002). Homodimeric units of the pentamer were built on the basis 
of crystal structure data to reach minimal root mean standard deviation (RMSD) between 
the matched monomers. Further refinements of the resulting dimers were carried out by 
Sybyl 6.6 program (Tripos Inc., St. Louis, MO) on a Silicon Graphics Octane workstation 
under Irix 6.5 operation system. First, the all-atom model was allowed to relax during a 
short molecular dynamics run (2000 fs) using constrains for backbone atoms, not 
allowing distortions of the backbone. Finally, the entire structures were fully minimized 
without any restriction using Powell conjugate gradient method until the maximum 
derivative was less than 0.050 kcal/molA. Gasteiger-Huckel partial charges were applied 
during the calculations. The quality of the model was verified using ‘Procheck’, as 
compared with well-refined structures at the same resolution ((Laskowski, 1993). Intra- 
and interface H-bonds were analysed by HBPLUS v 3.0, an hydrogen bond calculation 
program (McDonald and Thornton, 1994). Homology model for the ground state receptor 
was constructed based on the same alignment as for the ligand-bound receptor model. 
Chain F of AChBP (Celie et al., 2004) taken from RCSB Protein Bank entry 1UV6 was 
used as a template for ground state receptor model. The loop C conformation of this
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ligand-free subunit is strikingly different from the conformation of the other crystallized 
chains with bound ligands. Side chain prediction, dimer building and structural 
minimization of the ground state receptor were carried out using the same workflow 
described above for the ligand-bound receptor model.
'AutoDock 3.0’ was applied for docking calculations, using the Lamarckian 
genetic algorithm (LGA) and the ‘pseudo-Solis and Wets’ (pSW) methods. The ligand 
docking calculations were performed independent of experimental data. The parameters 
included in Autodock are based on the ‘Assisted Model Building with Energy 
Refinement’ (AMBER) force field (Cornell, 1995). Gasteiger-Huckel partial charges 
were applied both for ligands and proteins. Solvation parameters were added to the 
protein coordinate file and the ligand torsions were defined using the ‘Addsol’ and 
‘Autotors’ utilities, respectively, in Autodock 3.0. The atomic affinity grids were 
prepared with 0.375 A spacing using the Autogrid program for a 15 x 15 x 22.5 A box 
around the interface of subunits. No constraints based on experimental data were 
employed to carry out ligand docking. Random starting positions, orientations and 
torsions (for flexible bonds) were used for the ligands. Each docking run consisted of 100 
cycles. The number of evaluations was set to 1.5 million. Final structures with RMSD 
less than 1 .5 A were considered to belong to the same cluster. The structures with low 
energies and high frequencies of docking were subjected to a further minimization by 
Sybyl and were examined.
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5.4 Results
The primary objective of alanine scanning mutagenesis is to rapidly identify functional 
and/or structural importance of each amino acid in a pre-defined region of the protein. 
Alanine substitution of both surface and buried residues is tolerated equally well. The 
structure of the protein backbone formed with the alanine substitution is similar to that 
formed with the native amino acid. Therefore a single alanine substitution is expected to 
produce little backbone distortion. Alanine substitutions on the other hand can quickly 
identify amino acids of potential importance, since the R-group of the substituted amino 
acid is replaced with a methyl group.
Wild type and mutant 5 -HT3aR receptors were expressed in two expression 
systems; mammalian tSA  cells and Xenopus laevis oocytes. The mammalian system was 
primarily used to characterize antagonist interaction with mutant receptors, while 
Xenopus laevis oocytes used to determine functional characteristics of the mutant 
receptors.
5.4.1 Electrophysiological characterization of loop B mutant receptors
Xenopus oocytes expressing wt receptors produced characteristic inward currents when 
rapidly exposed to 5-HT or mCPBG. Iterative curve fitting of the data yielded an EC50 
value of 3.4 ± 0.3 pM with a Hill slope of 1.4 ± 0.2 for 5-HT. Similar experiments 
involving mCPBG produced an EC50 value of 0.8 ± 0.07 pM and a Hill slope of 1.6 ± 0.2 
(Table 5.2). Hill slopes greater than unity indicate the cooperative nature of agonist 
induced channel opening. No inward currents could be detected when non-injected or 
mock-injected oocytes were exposed to 5-HT or otCPBG.
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Loop B mutant receptors were similarly expressed in Xenopus oocytes and 
characterized using agonists 5-HT and mCPBG. No inward currents could be elicited on 
application of either 5-HT or wCPBG from oocytes expressing T179A, F180A, L184A, 
H185A, D189 or 1190 mutant receptors. These data suggest that these amino acids 
influence agonist mediated channel opening at the wt 5 -HT3aR- However, such an 
assumption would be valid only if the mutant receptors are expressing on the cell surface. 
It is possible that mutation at each of these positions alters the ability of the receptor to be 
expressed on the cell surface, which would result in the lack of detectable response from 
these oocytes. Secondary mutations at positions L I84 (L184V), H I85 (H185F and Y) and 
1190 (1190V) resulted in detectable inward currents from the oocytes expressing these 
proteins, allowing EC 50 values to be recorded. Secondary mutants at T179, F I 80 and 
D189 are currently being evaluated in our laboratory.
5.4.1.1 Electrophysiological profile of loop B mutant receptors: 5-H T
Among loop B mutant receptors, mutations W183F and I187A resulted in large changes 
(50 and 27 fold respectively) to 5-HT EC50 (Table 5.1). The W183F mutation caused the 
largest increase in EC50. Results obtained for the W183F mutation are in tandem with 
previously reported values for 5-HT EC50 values on receptors with natural and unnatural 
substitutions at the W183 position. The LI84V mutation, a subtle mutation, resulted in 
ten-fold increase in 5-HT EC50 value. Subtle mutations at position HI 85 (H185F and 
H185Y) also resulted in a moderate (~ 6  fold) increase in the EC50 value. These results 
indicate that amino acids W183, L184, H185 and 1187 play a role in mediating the action 
of the natural agonist 5-HT.
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The T181A mutation produced a modest 7-fold increase in 5-HT EC50, suggesting 
a minor role for this amino acid in 5-HT mediated action. S182A, T186A and Q188A 
mutant receptors displayed only minor changes to 5-HT EC50 (Table 5.1). These data 
suggest that amino acids S I82, T186 and Q188 may not be playing any role in mediating 
5-HT induced channel opening.
An alanine mutation at the 1190 position resulted in mutant receptors that did not 
respond to 5-HT or otCPBG. A subtle mutation at 1190 (1190V) not only restored 
function to the 5 -HT3aR, but the EC50 value recorded for 5-HT was almost identical to 
that for the wild type receptor.
Minor but statistically significant increases in Hill number value were noted for 
mutant receptors S182A, W183F, LI84V and H185Y (p<0.05). However, the H185F 
mutation did not produce any significant change in Hill number. Similarly, reduction in 
Hill number was observed for 1190V mutant receptors.
5.4.1.2 Electrophysiological profile of loop B mutant receptors: mCPBG
Large changes in EC50 for mCPBG were noted for S182A, W183F and I187A mutant 
receptors (Table 5.1). The I187A mutation led to the largest increase in EC50 (64 fold), 
while the S182A mutation resulted in a 34-fold increase. The W183F mutation also 
produced 20-fold change. All of the remaining mutations caused only minor changes to 
mCPBG EC50 (Table 5.1). These results suggest that S I82, W183 and 1187 amino acids 
play a role either in the direct interaction of mCPBG with the ligand-binding domain or 
mCPBG mediated channel gating.
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Statistically significant increase (p<0.05) in Hill number was recorded for 
mutations T181A and H185F, while mutations S182A, H185Y and T186A led to a 
statistically significant decrease (p<0.05) in Hill number (Figure 5.3). The Hill number 
remained unchanged for all other mutant receptors.
5.4.1.3 Differential effects of the loop B mutations on action of 5-HT and mCPBG
Figures 5.2 and 5.3 show a comparison of EC50 and Hill numbers for agonists 5-HT and 
mCPBG on loop B mutant receptors. The T181A mutation led to a 5-HT specific effect 
on EC50, with mCPBG related parameters remaining almost unaffected (Table 5.2). These 
results suggest that T181 is involved in specifically mediating the action of 5-HT and not 
mCPBG. Although the W183F mutation causes an increase in EC50 for both 5-HT and 
/raCPBG, the value for 5-HT seems to be much more affected (50-fold for 5-HT vs. 20­
fold for mCPBG; Table 5.2). LI84V caused changes similar to W183F, although the 
magnitude of change was smaller (11-fold for 5-HT vs. 6-fold for mCPBG; Table 5.2). 
These results suggest that both W183 and LI 84 influence 5-HT and mCPBG induced 
channel opening. However, both amino acids may be more important for action of 5-HT 
compared to mCPBG.
The S182A mutation led to a specific effect on EC50 for mCPBG while 
parameters for 5-HT remained unchanged (no change for 5-HT vs. 30-fold change for 
mCPBG; Table 5.2). These results suggest that S182A is involved in specifically 
mediating the action of mCPBG and not 5-HT.
The waveform of inward currents induced from S I82A expressing oocytes by 
supra-maximal concentrations of 5-HT were compared to those obtained from the wild
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type receptors (Figure 5.4B). Although the first (rapid) phase of the desensitization 
appeared to be slower in case of the S182A mutant receptor, other differences in the wave 
form were not observed.
The waveform of inward currents induced from S182A expressing oocytes by 
supra-maximal concentrations of wCPBG were compared to those obtained from the wild 
type receptors (Figure 5.40). In the case of the wild type receptor, the waveform clearly 
shows the presence of a non-desensitizing phase on continued application of mCPBG 
(marked with a circle in figure 5.4 C). A similar phase in continued presence of mCPBG 
is conspicuously absent in the current waveform of S182A (marked with a circle in figure 
5.7C). The recovery phase for SI 82A mutant receptors from desensitization also appears 
to be prolonged. The wild type receptors completely recover from the state of 
desensitization induced by supra-maximal concentration of mCPBG after a period of 7 ± 
2 (« = 3) minutes. For S I82A receptors, the recovery is complete only at the end of a 30 
± 3 (n = 3) minute period.
The I187A mutation led to an increase in EC50 for both 5-HT and mCPBG. 
However, the value for otCPBG was affected to a greater extent compared to 5-HT (25­
fold for 5-HT vs. 65-fold for mCPBG; Table 5.2).
Mutations at position H185 (H185Y and H185F) produced changes of equal 
magnitude for both 5-HT and mCPBG EC50 (Table 5.2), suggesting that H I85 plays a 
general role in agonist induced channel opening.
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5.4.2 Granisetron binding to loop B mutant receptors
•2
[ H] granisetron, a 5 -HT3R specific competitive antagonist, bound with a high affinity to 
wild type receptors expressed in /SA cells (Kd 0.96 nM, Table 5.2, Figure 5.5). Un­
transfected and mock-transfected cells did not show specific binding to the radio-ligand 
(data not shown). All mutations (alanine, tyrosine and phenylalanine) at W183 position 
and the alanine mutation at H185 position resulted in receptors lacking detectable binding 
to [3H] granisetron. These results suggest that W183 and H I85 are critical to ligand- 
binding and/or receptor assembly. Although a subtle mutation at HI 85 (H185Y) restored 
binding to [3H] granisetron, a 6-fold reduction in binding affinity was noted.
An alanine mutation at position D189 (D189A) resulted in a 23 fold reduction in 
the affinity of the [3H] granisetron, suggesting that an acidic residue at this position may 
be important for antagonist binding. Alanine mutation at positions T179, F I80, T181 
caused moderate changes (from 4-8) in affinity of the receptor for [3H] granisetron (Table 
5.2, Figure 5.5), while alanine mutation at positions T186, 1187 and Q188 resulted in 
minor (1.5 to 3 fold) changes in [3H] granisetron binding.
5.4.3 Maximal binding (Bm*x) values for the loop B mutant receptors
Mutations at all positions in the loop B region except L I84 resulted in large scale 
changes in Bmbx values obtained from [3H] granisetron binding assay (Figure 5.6). 
T179A, T180, H185Y, D189A and I190A mutations each resulted in drastic reduction (5­
7 % compared to the wild type receptor) in receptor expression, as suggested by BMax 
values (Figure 5.6). Mutations T181, S I82, T186 and 1187 also resulted in significant 
changes (10-30 % compared to the wild type receptor) in BMax values.The Q188A
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mutation resulted in a 50% decline in BMax- Thus, most loop B amino acid residues 
appear critical for proper expression of the 5-HT3aR-
5.4.4 Displacement of granisetron binding to loop B m utant receptors by 5-HT and 
mCPBG
[3H] granisetron binding to the wild type receptor was displaced by both non-selective 
endogenous agonist 5-HT and selective synthetic agonist mCPBG with apparent affinity 
of 0.16 pM and 0.072 pM respectively (Table 5.2, Figure 5.7.1 and 5.7.2). Since 
competition binding assays for agonists were performed under equilibrium conditions, 
the Ki values obtained probably reflect the affinity of these agonists for the desensitized 
state of the 5 -HT3R.
Since W183A, W183F and H185A mutant receptors did not bind [3H] 
granisetron; competition binding assays involving these receptors could not be 
performed. [3H] granisetron binding to mutations T179A, T180, H185Y, and D189A 
could not be displaced by either 5-HT or mCPBG. These data suggest that mutation at 
these positions specifically alter the ability of agonists to mediate binding and/or gating. 
However, mutations T179A, T180, H185Y, and D189A also resulted in drastic reduction 
in receptor expression (5-7 % compared to the wild type receptor), as suggested by the 
Bmbx values (Figure 5.6). Such low levels of Bm3x values place limitations on the 
precision of data obtained from competition assays and results obtained need to be 
interpreted with caution. In case of 1190A mutant receptor, very low receptor expression 
prevented complete characterization of [3H] granisetron displacement.
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The L184A mutation resulted in a large decrease in apparent affinity of the 
receptor for 5-HT, resulting in a 141-fold increase in Kj. Mutation T181A also resulted in 
a 70-fold increase in Kj. On the other hand, S182A,T186A, I187A and Q188A mutations 
produced only 2-4 fold change in apparent affinity for 5-HT (Figure 5.7.1).
The T181A and I187A mutations resulted in a moderate (-14-15 fold) reduction 
in apparent affinity for mCPBG. Each of S I82A, T186A and Q188A mutations resulted 
in small but significant increase in the apparent affinity (2 to 5 fold, /?<0.05), while 
values for L I84A show a small decrease. The S182A mutation resulted in the largest (5­
fold) increase in the affinity for mCPBG.
5.4.5 Results of the molecular modeling studies
Molecular modeling studies were performed according to the protocol described in 
materials and methods section. No constrains based on experimental data were applied 
while conducting these studies. The ligand-docking studies were performed using the 
homology model of the murine 5-HT3aR. This model was built using crystal structure of 
AChBP which is presumably in the open/desensitized state. The prepared models of the 
ligand-free and ligand -bound 5-HT3aR in dimeric form were optimized in Sybyi 7,0 
molecular modeling software (Tripos Inc., St. Louise, MO). The H-bonding interactions 
of loop B residues were also calculated using Sybyl 7.0 software.
5.4.5.1 Results form the ligand-docking studies using S-HTsaR homology model. 
Docking studies of 5-HT and /wCPBG predict that 5-HT but not mCPBG interacts with 
amino acid T181. Amino acid T181 is located within 4A of the docked 5-HT molecule.
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Amino acid W183 interacts with each of the docked ligands. W183 apparently interacts 
with various ligands either through cation-pi or pi-pi interaction (Table 5.3). Other amino 
acids of the purported loop B region do not seem to be Involved directly in receptor- 
ligand interaction(s). These amino acids probably play a role in mediating either a purely 
structural role or a role in mediating conformational changes in the protein associated 
with channel gating.
S.4.5.2 Results form structural predictions obtained from S-HTsaR homology 
models.
Comparison of predicted structural features of the loop B region from the ligand-free and 
ligand (agonist)-bound state models of the 5 -HT3aR were obtained. The pattern of Id- 
bonding is strikingly different in both these models of the receptor. These differences 
have been tabulated in Table 5.4.1 and 5.4.2. Figure 5.8 summarizes the hydrogen 
bonding pattern observed in the agonist-bound state.
Following bonds remain unchanged indicating their role in maintenance of 
structural rigidity
1) T179 backbone amide - E129 (El 06) side chain oxygen
2) T179 backbone carbonyl - N128 backbone amide
3) Q188 forms no H-bonds at any time
4) D189 carbonyl backbone-T64 amide backbone
Following H-bonds form during open/desensitized state: Formation of these bonds 
during the activated state suggests that these interactions are at least partially responsible 
for stabilization of distinct confirmation(s) associated with activation/desensitization.
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1) F180 backbone carbonyl and amide -M237 backbone carbonyl and amide
2) W183 side chain nitrogen -Y153 backbone carbonyl
3) 1187 backbone amide-S232 backbone carbonyl
4) 1192 amide backbone-T186 carbonyl backbone
Complex rearrangements: These complex re-arrangements during the activated state 
suggest that these interactions are at least partially responsible for stabilization of distinct 
confirmation(s) associated with activation/desensitization.
1) T179 backbone carbonyl - N128 side chain amino group becomes T179 side chain 
hydroxyl-N128 side chain amino group.
2) T181 side chain carbonyl-S182 backbone amide becomes T181 backbone carbonyl 
and amide -1125 backbone carbonyl and amide and S I82 backbone carbonyl -H I85 
backbone amide.
3) L184 carbonyl backbone- H I85 side chain nitrogen becomes W183 backbone carbonyl 
-H185 backbone amide. L I84 forms no H-bonds during open/desensitized state.
4) In ground state T186 backbone carbonyl H bonds with both D189 backbone amide and 
1190 backbone amide. In open/desensitized state T186 backbone carbonyl shifts H bond 
from D 189/1190 amide backbone to 1192 amide backbone and T186 hydroxyl side chain 
H bonds with D189 amide backbone (left free by the shift of T186 carbonyl backbone).
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5.5 Discussion
Our studies identified several novel amino acid residues of the loop B region This region 
probably constitutes the area around the ligand-binding domain of the 5-HT3AR- Amino 
acids T179, F I80, T181, S I82, H185, 1187 as well as D189 were identified as 
contributing to either direct interaction with ligands or transduction of agonist-induced 
conformational changes.
5.5.1 Loop B region plays a r o l e  in proper receptor expression
In the ground state of the receptor, T179 and FI 80 probably maintain the integrity of the 
protein structure. In this state, the T181 side-chain may form an important stabilizing 
interaction with the backbone of S I82. Loss of such an interaction probably leads to 
altered protein stability and results in reduction in receptor expression. The L184A 
mutation does not cause any change in receptor expression. H185Y causes a severe 
change to the receptor number. A receptor model of the ground state of the 5-HT3AR 
suggests that the protein backbone at L184 forms a H-bond with the side chain nitrogen 
of HI 85 in the ground state of the receptor. If such a bond does exist, any alteration in the 
characteristics of the histidine side-chain would not be tolerated. Mutations at HI 85,1187 
and D189 also affect receptor expression. While I190A mutation results in lack of 
demonstrable responses to 5-HT or mCPBG, 1190V mutation yields EC50 values 
comparable to that of the wild type receptor. These results from I190A and 1190V mutant 
receptors suggest that amino acid 1190 may be important only in maintaining the proper 
receptor expression. In ligand-docked models, 1190 appears to be distant from the general 
ligand-binding domain and may not be involved in interactions with ligands.
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Electrophysiological studies indicate that T181A mutation disrupts 5-HT induced binding 
and/or gating, while minor changes in mCPBG action are observed. Results from radio­
ligand competition assays also suggest that T181 interacts strongly with 5-HT. Taken 
together, these data suggest that T181 specifically interacts with 5-HT in the 
activated/desensitized state of the receptor. Results from the docking studies also suggest 
that 5-HT and not mCPBG interact with T181 in open/desensitized state of the receptor.
Effects of mutation at W183 have been well characterized. We were able to 
reproduce these results using the W183F mutation. Mutation at W183 causes a 50-fold 
change in EC50 for 5-HT and a relatively smaller 20-fold change for mCPBG, suggesting 
that 5-HT and mCPBG may be interacting differentially with W183. W183 probably also 
plays a role in initiating/mediating conformational changes that lead to channel opening 
and desensitization. According to modeling studies, W183 does not form any hydrogen- 
bonding interaction at the ground state of the receptor while in the activated state; its side 
chain forms an H-bond with the side chain of Y153. In addition, backbone carbonyl 
groups of both W183 and S I82 share an H-bond with the backbone amide of H185. 
W183 may also form either a cation-pi or pi-pi interaction with all 5-HT3 receptor 
ligands. Thus, W183 seems to be critical for proper functioning of 5-HTsaR.
The principle interaction of granisetron is probably with W183. The ligand- 
docking studies also predict the interaction of W183 with granisetron. It is likely that 
H185 and S182 share a minor interaction with granisetron. Mutations at T179, F I80 and 
D189 severely affect granisetron binding. However, given their distance from the
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5.5.2 Ligand-receptor interactions
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purported ligand-binding site (marked by position of W183), it is unlikely that these 
residues interact directly with granisetron. It is more likely that these residues are merely 
involved in maintaining the proper positioning of W183. In such a scenario, mutations at 
these positions will cause disruption of granisetron interaction through alteration of 
W183 position.
5.5.3 Ligand-specific mechanisms mediated through loop B region
From the loop B region, amino acids T181A, LI 84, and 1187 mediate the action of the 
endogenous agonist 5-HT. Available biochemical and molecular modeling data suggests 
that T181 is involved in direct interaction with 5-HT, but not mCPBG. The L184A 
mutation causes a large decrease in the apparent affinity for 5-HT (140 fold), but not 
wCPBG. It is likely that the selectivity of changes observed with L I84 mutations is the 
result of a minor alteration in the position of adjacent W183. Amino acids SI 82 and 1187 
are wCPBG specific and probably play a lesser role in 5-HT mediated action. A mutation 
at S182 leads to mCPBG-specific changes to receptor desensitization while 1187 probably 
mediates mCPBG-specific channel gating. Thus, mCPBG and 5-HT seem to mediate 
agonist action through distinct domains of the 5-HT3AR.
5.5.4 Desensitization
Amino acid S I82 is specifically involved in defining affinity of wCPBG for the 
desensitized state of 5-HT3AR. Loss of the non-desensitizing phase of mCPBG-induced 
response as well as delayed recovery from desensitization suggests that mCPBG induces 
a desensitization state of heightened affinity. However, this phenomenon is not observed
168
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
with 5-HT. Increased affinity of mCPBG for the desensitized state is also reflected in 
decrease in the mCPBG Kj However, ligand-docking studies do not predict a direct 
interaction of granisetron, 5-HT or mCPBG with this amino acid, suggesting a possible 
role in mediating agonist-induced gating of the 5-HT3aR, possibly by altering post­
opening receptor mechanisms.
5.5.5 Gating mechanism of the 5-HT3AR
Biochemical data from the loop B studies suggests that the loop B region plays a critical 
role in initiating the conformational changes that lead to channel opening (see Figure 
5.8). Several mutations in the loop B region lead to loss of function or severly altered 
function. T179, F I80, T181, W183, L I84, H185, 1187 and D189 mutants display such 
characteristics. These effects on function suggest that residues T179, F I80, T181, W183, 
L I84, H I85, 1187 and D189 are involved in direct interaction with agonists or in 
mediating receptor gating. Ligand-docking studies, however, predict direct interaction of 
agonists only with residues T181 and W183. Molecular modeling studies also suggest 
that all the loop B residues except T181 and W183 are positioned outside the purported 
ligand-binding domain. These data suggest that T179, F I80, L I84, H 185,1187 and D189 
mediate receptor gating.
Molecular modeling data suggests that in the activated state of the receptor, early 
part of loop B interacts with the pre-Ml region of the 5-HT3AR through F180-M237 
interaction. On activation, the side chain of T179 possibly undergoes a complex re­
arrangement. This rearrangement may indicate a conformational change associated with 
activation. In the activated state, the HI 85 backbone shares an H-bond with both the
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W183 and S182 backbone. These data suggest that the triad of S182 W183 and H185 is 
involved in mediating changes associated with activation/desensitization. Comparison of 
ground and active state model of the receptor reveals that 1187 backbone forms an H- 
bonding interaction with the backbone of S232, an amino acid in the C loop region of the 
receptor. Crystallographic studies on AChBP indicate that the C loop region is drawn 
closer to the ligand binding domain on activation. Such a movement would be aided by 
interaction between 1187 and S232. The movement of the C loop probably plays an 
important role in mediating conformational changes associated with gating. Data 
obtained from comparison of models of the ground and activated state 5-HT3 receptor 
suggests that H-bonds between D189 and T186 undergo certain modifications during 
receptor activation. However, H-bonds between D189 and T64 remain unaltered. Thus, 
D189 seems to be playing a complex role in maintaining structural integrity and 
mediating agonist action.
Biochemical and molecular modeling data collectively suggests that amino acids 
T179, F I80, L I84, H 185,1187, and D189 probably play a role only in mediating receptor 
gating. It is also possible that the changes to EC50 values observed with mutations at these 
positions are a result of alteration in the protein backbone leading to alterations in the 
position of W183 side chain. Based on the data currently present, such a distinction 
cannot be easily made.
We have utilized molecular models of the 5 -HT3AR in both ground and activate 
state to predict interactions that may be mediating conformational changes associated 
with gating. These changes have been summarized in Figure 5.8. The major interaction
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at the ligand binding domain is mediated through W183, which is located almost at the 
center of the loop B region. Molecular modeling data suggests that agonist binding leads 
to rearrangement of hydrogen bonds between loop B region and other regions from the 
same subunit such as loop A region, loop C region, pre-loop D region and pre-Ml region. 
Agonist binding at the binding cleft between two subunits also leads to formation of 
hydrogen bonds between loop B on the principal face and loop E on the complimentary 
face. The rearrangement of hydrogen bonds oocurs in the regions on both sides of W183. 
All of these connections are probably associated with the conformational changes 
mediating channel opening. In case of other members of ligand-gated ion channel 
superfamily, it has been suggested earlier that the ‘conformational wave’ that 
accompanies channel opening travels from the ligand binding domain to the channel 
(M2) region. Our data suggests that following its initiation in the ligand binding domain, 
the conformational wave travels to all the regions surrounding the loop B region with 
W 183 forming the central reference point.
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Figure 5.1 Amino acid sequence alignment of murine S-HTjaR with other members 
of the superfamily, with a focus on the predicted loop B region.
Primary sequences of the members of the LGIC superfamily were aligned using Clustal 
X algorithm. The conserved amino acids are marked in grey. The amino acid positions 
with conserved side chain characteristics are marked in bold.
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Figure 5.2: A comparison of EC50 values for 5-HT and mCPBG
Bar graph shows comparison of fold changes in 5-HT and toCPBG EC50 values for the 
mutant receptors compared to the WT values. The WT fold-change values have been 
normalized to 1. Each fold change value was calculated based on at least 4 separate 
experiments. The error bars indicate standard error. Bars indicating 5-HT EC50 fold 
change are marked with black while those indicating mCPBG EC50 fold change are 
marked grey. The fold change values are approximations. The bars lack error bars since 
fold changes and not actual data values are displayed.
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Figure 5.3: A comparison of Hill number values for 5-HT and mCPBG
Bar graph shows comparison of fold changes in 5-HT and wCPBG «H values for the 
mutant receptors compared to the WT values. The WT fold-change values have been 
normalized to 1. Each fold change value was calculated based on at least 4 separate 
experiments. The error bars indicate standard error. Bars indicating 5-HT nH fold change 
are marked with black while those indicating mCPBG n11 fold change are marked grey. 
The fold change values are approximations. The bars lack error bars since fold changes 
and not actual data values are displayed.
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Figure 5.4: Electrophysiological characterization of S182A mutation
5.4.A Comparison of 5-HT and mCPBG induced responses from SI82A mutant 
receptor
The right and left hand column of the figure shows responses elicited by a range of 
wCPBG and 5-HT concentrations recorded from separate oocyte expressing S182A 
mutant receptors respectively. The concentrations of respective agonist utilized are 
indicated at the top of each column. The responses displayed are representative of at least 
4 separate experiments. In case of mCPBG induced responses, the return to the baseline 
following the second phase of the desensitization is rapid, while no such change is 
observed in 5-HT induced responses. The characteristics of the responses induced by 
either agonist otherwise appear normal.
5.4.B Comparison of 5-HT induced responses from WT and SI82A mutant receptor
A comparison of responses induced by supra maximal concentration of 5-HT from WT 
(top trace) and S I82A mutant receptor (bottom trace) suggests that the second phase of 
the desensitization of 5-HT induced response from S182A receptor is slower as compared 
to that of the WT receptor.
5.4.C Comparison of mCPBG induced responses from WT and SI82A m utant 
receptor
A comparison of responses induced by supra maximal concentration of mCPBG from 
WT (top trace) and S182A mutant receptor (bottom trace). The WT trace clearly shows 
second, slower phase of desensitization (marked by the first circle) followed by the third,
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non-desensitizing phase (marked by the second circle). The comparison suggests that the 
third, non-desensitizing phase of mCPBG induced response WT receptor is missing in the 
wCPBG induced response from the S18A mutant receptor. The response returns to 
baseline following the second phase of desensitization (marked by two circles). The 
traces shown here are representative of at least 4 experiments.
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Figure 5.5 [3H] granisetron binding to loop B mutant receptors
Bar graph shows comparison of [3H] granisetron Kd values for each of the loop B mutant 
receptors. The Y axis shows Kd in nanomolar (nM). Each value was calculated based on 
at least 4 separate experiments. The error bars indicate standard error. Granisetron 
binding to the H185A mutant receptor could not be detected.
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Figure 5.6 A comparison of BMax values of loop B mutant receptors
Bar graph shows comparison of BMax values for each of the loop B mutant receptors. The 
Y-axis shows Bm3x measured as Counts Per Minute (CPM). The CPM for each 
preparation is comparable since same number of cells were seeded for every experiment 
(250,000 cells/ 100 mm Petri dish). Each value was calculated based on at least 4 
separate experiments. The error bars indicate standard error. Granisetron binding to the 
H185A mutant receptor could not be detected.
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Figure 5.7 Displacement of bound radio-ligand by 5-HTsaR agonists
5.7.A Displacement of [3H] granisetron binding to loop B m utant receptors by 5-HT 
Bar graph shows comparison of 5-HT Kj values for each of the loop B mutant receptors. 
The Y axis shows K; in micromolar (pM). Each value was calculated based on at least 4 
separate experiments. The error bars indicate standard error. N.D. denotes ‘Not 
Detected’.
5.7.B Displacement of [3H] granisetron binding to loop B mutant receptors by 
mCPBG
Bar graph shows comparison of mCPBG Kj values for each of the loop B mutant 
receptors. The Y axis shows Kj in micromolar (pM). Each value was calculated based on 
at least 4 separate experiments. The error bars indicate standard error. N.D. denotes ‘Not 
Detected’.
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Figure 5.8 Intra-subunit and inter-subunit contacts of the loop B region formed in 
the agonist-bound state of the receptor
Two squares represent amino terminal domains of adjacent subunits (named subunit 1 
and subunit 2). The arrows indicate probable intra-subunit and inter-subunit interactions 
of loop B amino acids formed after agonist binds to the binding domain.
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Table 5.1 Electrophysiological characterization of loop B receptors, data obtained 
using agonists 5-HT and mCPBG.
5-HT and wCPBG EC50 and «H values in fiM for each of the loop B mutant receptors. 
Each value was calculated based on at least 4 separate experiments. The standard error is 
indicated by the ‘+’ sign. N.D. denotes ‘Not Detected’.
Receptor 5-HT mCPBG
EC50 (pM) Wh EC50 (pM) nH
WT 3.4 ±0.3 1.4 ±0.2 0.8 ±0.07 1.6 ± 0 .2
T179A N.D N.D N.D N.D
F180A N.D N.D N.D N.D
T181A 24.2 ±0.91 1.64 ±0.09 2.18 ±0.09 2.04 ±0.16
SI 82 A 3.33 ±0.18 1.86 ±0.19 27.1 ±3.7 1.18 ± 0.17
W183F 169 ±9.29 2.31 ±0.22 15.7 ± 1.51 1.29 ±0.14
L184A N.D N.D N.D N.D
LI 84 V 37.3 ± 1.6 2.14 ± 0.18 5.09 ±0.19 1.6  ± 0.08
H185A N.D N.D N.D N.D
H185F 20.9 ±1.57 1.23 ±0.10 2.49 ± 0.04 2.75 ±0.13
H185Y 17.24 ±0.83 1.9 ± 0.15 5.4 ±0.42 1.14 ± 0.08
T186A 9.56 ±0.63 1.42 ±0.12 1.70 ± 0.10 1.19 ± 0.08
I187A 90 ±6.18 1.58 ±0.16 51.9 ±4.08 1.41 ±0.13
Q188A 4.38 ±0.28 1.76 ±0.17 2.28 ±0.19 1.33 ±0.13
D189A N.D N.D N.D N.D
I190A N.D N.D N.D N.D
1190 V 4.42 ±0.58 0.89 ±0.09 1.953 ±0.09 1.86 ±0.15
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Table 5.2 Radio-ligand binding to loop B receptors, data from saturation and 
competition assays
[3H] granisetron values in nanomolar (nM), as well as 5-HT and mCPBG K, values in 
micromolar (joM) for each of the loop B mutant receptors. Each value was calculated 
based on at least 4 separate experiments. The standard error is indicated by the ‘± ’ sign. 
N.D. denotes ‘Not Detected’.
R e c e p to r f f f j  g ra n is e tro n 5 -H T m C P B G
K d(nM) nH Ki(pM) K, (pM)
WT 0.96 ±0.16 1.02 ±0.07 0.16 ±0.04 0.072 ± 0.003
T179A 6.9 ±0.49 1.26 ±0.13 N.D N.D
FI 80 A 5.9 ±0.78 1.5 ±0.22 N.D N.D
T 181A 3.35 ±0.35 1.19 ±0.14 11.4±0.91 1.14 ±0.09
S182A 5.4 ±0.31 1.68 ±0.15 0.61 ±0.07 0.016 ±0.001
W183F N.D N.D N.D N.D
W 183Y N.D N.D N.D N.D
L184A 4.7 ± 0.28 1.52 ±0.12 22.6 ±4.57 0.175 ±0.02
H185A N.D N.D N.D N.D
H 185Y 4.9 ±0.32 1.25 ±0.09 ND up to 300 pM ND up to 300 pM
T186A 2.25 ± 0.34 1.2 ±0.2 0.176 ±0.20 0.022 ± 0.005
I187A 3.4 ±0.46 1.25 ± 0.19 0.60 ± 0.15* 0.94 ± 0.17*
Q188A 1.37 ± 0.1 1.19 ± 0.08 0.48 ± 0.03 0.05 ± 0.004
D189A N.D N.D N.D N.D
I190A N.D N.D N.D N.D
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Table 5.3 Results from the ligand-docking studies using 5-HTjaR homology model
Modeling of the extracellular domain of the murine 5-HT3aR and ligand docking were 
performed as described in "Experimental procedures". The results are also represented in 
Figure 1. Interactions predicted for 5-HT, 2-Me 5-HT, granisetron and mCPBG (model T  
and model '2') are shown in the table. HB: Hydrogen bond, SB: Salt bridge, CP: Cation- 
interaction, PP: interaction +: Within 4 A of docked ligand.
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Table 5.4 A comparison of the H-bonding interactions of the loop B region in 
molecular models of the relaxed and ligand bound state of S-HTjaM.
The molecular models for the relaxed and ligand bound state of S-HTsaR were provided 
by Dr. Zsolt Bikadi, National Academy of Sciences, Hungary. The PDB files of the 
molecular models were imported in to Sybyl version 7.0 (Tripos Inc., St. Louise, MO). 
The PDB files were checked for irregularities such as incorrect molecular assignment, 
incorrect bond angles and missing amino acid side chains. All essential water molecules, 
hydrogen atoms and charges were added. The comparisons in H-bonding in relaxed and 
ligand bound state were made using these corrected models.
Table 5.4.1: Loop B H-Bonds in the ground state
H-Bonds formed by residues of Loop B in the ground state model of the m5-
h t 3Ar
T179 T179 amide backbone- side chain carbonyl of E129 (E l06)
T179 carbonyl backbone- N 128 amide backbone-N128 side chain 
carbonyl
F180 No H bond
T181 T181 side chain carbonyl-S182 backbone amide
S182 T181 side chain carbonyl-S 182 backbone amide
W183 No H bond
L184 L I84 carbonyl backbone- H I85 nitrogen
H185 LI 84 carbonyl backbone- HI 85 nitrogen
H185 Q188 No bonds
T186 T186 backbone carbonyl H bonds with both D189 backbone amide and 
1190 backbone amide
1187 No H bonds
Q188 No H bonds
D189 D189 carbonyl backbone-T64 amide backbone 
D189 backbone amide-T186 backbone carbonyl
1190 1190 backbone amide -T186 backbone carbonyl
N191 T64 carbonyl backbone-N191 amide backbone
1192 No H bonds
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Table 5.4.2: Loop B H-Boitds in the ligand-bound open/desensitized state
H-Bonds formed by residues of Loop B in the open/desensitized state model of the
5-HT3AR
T179 T179 side chain carbonyl-N128 side chain amino H bond 
T179 backbone carbonyl -N128 backbone amide 
T179 backbone amide -E129 side chain carbonyl
F180 F I80 backbone carbonyl and amide -M237 backbone carbonyl and amide
T181 T181 backbone carbonyl and amide -1125 backbone carbonyl and amide
SI 82 S I82 backbone carbonyl -W183 backbone carbonyl -H I85 
amide
backbone
W183 W183 side chain nitrogen -Y153 backbone carbonyl
S I82 backbone carbonyl -W183 backbone carbonyl -H I85 backbone
amide
LI 84 No H bonds
H185 W183 side chain nitrogen -Y153 backbone carbonyl
S I82 backbone carbonyl -W183 backbone carbonyl -H185 backbone
amide
T186 T186 carbonyl side chain -D189 amide backbone 
T186 carbonyl backbone -1192 amide backbone
1187 1187 backbone amide-S232 backbone carbonyl
Q188 No H-bonds
D189 D189carbonyl backbone -T64 amide backbone
1190 No H-bonds
N191 No H-bonds
1192 1192 amide backbone-T186 carbonyl backbone
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Chapter 6: Conclusions
6.1 An overview
5-HT3aR  is a widely distributed ion channel in peripheral and central nervous system, 
and plays a major role in mediating physiological processes in cardiovascular, nervous 
and digestive systems. Studies directed at the ligand-binding domain and dynamics of 5- 
HT3AR function at the molecular level described here serve a three-fold purpose.
Members of the LGIC superfamily include nACh, GABA a GAB Ac and Gly 
receptors. These ion channels are widely distributed the nervous system and mediate 
physiological (such as neuro-muscular neurotransmission, autonomic neurotransmission, 
excitatory and inhibitory neurotransmission, sleep), pharmacological (anesthesia) and 
pathological processes (myasthenia gravis, convulsions, cerebrovascular accidents). The 
studies described here increase the understanding of how complex multi-meric membrane 
bound ion channel coupled receptors coordinate agonist binding and conformational 
changes associated with the resulting functional response (i.e.; channel opening). Despite 
all the advances in molecular biology and molecular biochemistry, detailed knowledge of 
mechanisms governing functioning of membrane bound ion channel coupled receptors is 
unavailable. Advances in the understanding of 5 -HT3AR structure and function will 
definitely aid studies of other LGIC receptors.
5 -HT3aR antagonists have been used clinically for the last 15 years and recent 
studies have suggested that 5 -HT3aR agonists can also be employed in clinical conditions 
such as gastro-esophageal reflux disease (GED) and constipation associated with irritable
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bowel syndrome. Based on the studies of 5-H T3a R  described here, we are beginning to 
understand how agonists, partial agonists or antagonists use distinct features o f  the 
ligand-biding domain to bring about specific changes. This knowledge can be used to 
create ligands that modulate specific aspects of receptor function. For example, it may be 
possible to synthesize agonists that specifically affect the desensitization state or the open 
state stability. Such ligands can be used clinically to fine-tune 5 -HT3AR function.
The 5-HT3aR is modulated by non-specific endogenous (cations, glueocorticois, 
gonadal steroids) and exogenous (alcohols, anesthetics, neuroleptic drugs) agents (See 
Chapter 1 for details). These agents interact with the 5-HT3aR in competitive or non- 
competetive manner and modulate agonist action. These interactions with non-specific 
agents probably influence various aspects of 5 -HT3R physiology and pathophysiology. 
The influence of these agents on 5 -HT3R physiology and pathophysiology is clinically 
relevant in conditions such as alcoholism, surgical anesthesia and certain drug 
interactions (e.g. with steroids). To better understand how 5-HT3R function is modulated 
by non-specific agents at the molecular level, we need to understand the molecular 
mechanism of agonist and antagonist action on the 5 -HT3R.
6.2 Methodological advancement
The vertical flow chamber developed for these studies provides an improved platform for 
Xenopus electrophysiology (see Appendix 2). This chamber offers both a stable 
environment for long term recording and rapid solution exchange rates that result in 
reliable, reproducible data. This system has proved invaluable for the evaluation of 
mutant receptors with very low I Max values, since it enables the use of rapid solution
193
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exchange rates. The use of a novel vertical perfusion system has also allowed us to 
perform accurate evaluation of relative efficacy values for various agonists and partial 
agonists. These measurements aid in the identification of changes in the gating 
mechanism that result from mutation of some amino acids. Certain mutations lead to 
changes in ‘gating’. This approach has been successfully applied for GABAa receptor, to 
decipher changes in gating mechanism as a result of point mutations. Studies involving 
full and partial agonists described here are unique and have not been conducted for the 5- 
HT3AR previously. While other laboratories have suggested involvement of certain amino 
acids residues in the gating mechanism, biochemical evidence supporting such assertions 
has been presented solely in the studies described here. While such studies can also be 
performed using conventional perfusion chambers, the vertical perfusion confers the 
ability to accurately measure peak heights. It is also imperative that measurements for all 
agonists be carried out on the same oocyte when comparing relative efficacies. Our 
method of perfusion allows recording from a single oocyte for an extended period of time 
( 1 0 -1 2  hours); whereas such stability is not usually obtained using conventional perfusion 
chambers.
6.3 The ligand binding domain
Studies described here have identified a number of novel amino acids affecting ligand- 
binding and channel opening (T179, F I80, T181, S I82, H185, 1187 and D189); while 
detailed analyses of amino acids identified earlier have been performed (Y141, Y143 and 
Y153). These results suggest that various ligands (agonists, partial agonists and
194
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antagonists) produce specific effects on receptor function by utilizing specific features of 
the ligand binding domain.
Alanine scanning mutagenesis study of the loop B region w as based on the 
hypothesis that homologous regions of related proteins share structural and functional 
features. Previous studies of the nAChR, GABAaR and AChBP suggested that a 
conserved aromatic residue in the loop B region (homologous to W143 of AChBP) 
interacts with the amino group of interacting ligands. Our studies indicate that T181 also 
interacts directly with 5-HT and granisetron, but not mCPBG. We have also shown that 
the loop B region transduces conformational changes associated with agonist induced 
channel opening.
The role of Y143 and Y153 in direct ligand interaction is less clear. Available 
data from lerisetron and its analogs suggests that Y143 and Y153 are involved in direct 
interaction with competitive antagonists. Molecular modeling data supports a direct 
interaction of 5-HT with Y153 but not with Y143. The model does not support any 
interaction between mCPBG and either of these two tyrosine residues. It is possible that 
agonists interact with Y143 in a conformational state that is different than the one 
modeled. The ligand-bound homology model represents either the open or the 
desensitized state of the receptor. If agonists interact with Y143 as a part of early events 
in ligand-receptor interaction (i.e., the pre-open state), ligand-bound models will not 
predict such interactions. However, the role of Y143 in mediating gating by all the 
agonists is well supported.
195
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
6.4 5 - H T s a R  ligand specificities
We performed studies focusing on the role played by various parts of the ligand-binding 
domain in ligand specificity. Based on the results of previous studies involving the loop E 
region, we formed the hypothesis that structurally distinct agonists mediate specific 
actions through differential interactions with ligand binding domain. Results from studies 
of the loop E and loop B region indicate that structurally distinct agonists utilize distinct 
regions of the ligand binding domain to mediate distinct conformational changes.
Y153 appears to be selectively involved in mediating gating events promoted by 
5-HT but not mCPBG. We have utilized biochemical data in combination with molecular 
modeling to obtain insights into the dynamics of the interactions of amino acid Y143 and 
Y153. Biochemical data indicates that the hydroxyl group of Y143 is critical to both 5- 
HT and otCPBG promoted channel opening, while the hydroxyl group of Y153 is critical 
to only 5-HT promoted channel opening. Molecular models of the agonist-bound state 
suggest that the side chain of Y153 apparently interacts with 5-HT, while it interacts with 
Y234 when mCPBG is bound. Therefore, interaction with Y153 is critical to the channel 
opening promoted by 5-HT, but not mCPBG. Taken together, these data indicate that the 
direct interaction 5-HT with Y153 specifically mediates 5-HT promoted channel opening. 
T181A, W183, L I84, H185 and 1187 and D189 all affect agonist induced channel 
opening. Available biochemical and molecular modeling data suggests that T181 is 
involved in direct interaction with 5-HT, but not otCPBG. T181A, W183, L I84, H185 
and 1187 are more important for gating induced by 5-HT. Amino acids S I82 and 1187 are 
mCPBG specific and play a lesser role in 5-HT mediated action. Thus, /kCPBG and 5-HT
196
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mediate agonist action through distinct interactions at the binding domain of the 5- 
HT3aR-
6.5 M ech an ism  o f  activation and desensitization.
Our studies involving loops E and B suggest that mutations in and around he ligand 
binding domain decrease the open channel stability. These data are consistent with the 
results obtained for other members of the superfamily. In case of nicotinic acetylcholine 
receptor, mutation of amino acids in and around the purported ligand binding domain 
leads to the destabilization of open state of the receptor. Similarly in case of the 5 -HT3aR, 
amino acids Y143 and Y153 may be involved in stabilization of the open state of the 
receptor. Interestingly, the selective effect of Y153 mutations on 5-HT induced gating 
suggests that structurally distinct agonists mediate channel opening by stabilizing distinct 
open states. Such differential mechanisms for agonist action have not been yet proposed 
or demonstrated for any other member of the Cys loop LGIC family. The mechanism 
proposed here could also be evaluated in other members of the LGIC family.
Examination of the 5 -HT3aR homology model suggests a mechanism by which 
both Y143 and Y153 could mediate channel gating (Figure 6.1). A direct link between 
the E-loop region and the critical Cys loop structure is clearly evident in all models of 
LGIC receptors. It has been speculated that agonist interaction with E-loop tyrosines 
causes a conformation change in the Cys loop that is involved in channel opening of the 
S-HTjaR. Emerging evidence suggests that the Cys loop region of ligand-gated ion 
channels plays a critical role in gating mechanism. Previous studies have implicated 
W149 of a A C h R  in a cation-pi interaction with the quaternary ammonium of
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acetylcholine. Based on the crystal structure of the AChBP, it has been suggested that 
W149 of aAChR mediates its effects by the virtue of its direct connection to the Cys loop 
region through p-strand 6 , which may interact with the ion channel through M2-M3 
linker region. While W183 of the 5 -HT3aR, homologous to W149 of the aAChR, is 
directly connected to the Cys loop region, so are residues Y143 and Y153. Interestingly, 
molecular dynamic simulation studies of an a l  homology model indicate that the side 
chain of residue LI 18; homologous to Y153 of 5 -HT3aR undergoes conformational 
change during ligand binding. The same study also indicates that ligand binding leads to 
a dynamic interaction of the Cys loop with the M2-M3 linker. It can therefore be 
proposed that both Y143 and Y153 exert their effects by influencing direct ligand 
interaction with the ligand-binding domain on one hand and by effecting gating through 
their connection with the Cys loop structure. Thus E-loop tyrosines may be providing a 
connection between the ligand-binding domain of agonists and conformational changes in 
the Cys loop that subsequently induce channel opening via M2-M3 interactions. The 
connection between loop E and the Cys loop on one hand as well as the Cys loop and 
loop B on the other hand may form the basis of a functional link between adjacent 
binding sites (Figure 6.1). Such a link may be important in mediating co-operativity 
between adjacent binding sites; i.e. occupancy of one binding site with agonist may lead 
to conformational changes in the adjacent binding site. Such a change in turn may lead to 
co-operative channel opening.
Data from the loop B studies suggests that this region plays a critical role in 
initiating the conformational changes that lead to channel opening (see Figure 2). These
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data suggest that amino acids T179, F I80, L184, H185, 1187 and D189 play a role in 
mediating receptor gating. We have utilized molecular models of the 5-HT3AR in both 
ground and activate state to predict interactions that may be mediating conformational 
changes associated with gating. The results from molecular modeling suggest that loop B 
region forms a ‘point of reference’ around which a multitude of changes takes place. Our 
data suggests that agonist binding leads to formation of hydrogen bonds between loop B 
region and other regions of the same subunit, including loop A loop C, pre-loop D and 
pre-Ml regions. Agonist binding at the binding cleft between two subunits also leads to 
formation of hydrogen bonds between loop B on the principal face and loop E on the 
complimentary face. These changes have been detailed in chapter 6 (see Table 6.4) and 
are summarized in Figure 6.2 (reproduced from chapter 6). A central role played by loop 
B is not surprising since the major interaction at the ligand-binding domain is mediated 
through W183, which is located almost at the center of the loop B region. It has been 
suggested that the interaction of agonist with W183 probably triggers the conformational 
wave that eventually results in opening of the channel gate. In case of other members of 
ligand-gated ion channel superfamily, it has been previously suggested that a 
“conformational wave” accompanying channel opening travels from the ligand binding 
domain to the channel (M2) region. In the 5-HT3AR, amino acid residue R222 in the pre- 
Ml region is critical in maintaining the stability of the closed state of the receptor. This 
observation suggests that the ‘conformational wave’ could also travel down to the M2 
region through the pre-Ml region. Our data suggests that the initiation of the signal in the 
ligand-binding domain may travel down to the pre-Ml region through formation of FI 80-
■ 199
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M237 interaction. Another route for the conformational wave may be through the Cys 
ioop-M2 connection. The conformational wave could also down the Cys loop region 
through its direct connection with loops B and E. Data presented here regarding amino 
acids Y143, Y153 and W183 supports this assertion. Thus, our data suggests that the 
conformational wave that triggers the channel opening travels from the ligand-binding 
domain to the M2 region through both the Cys loop and the pre-Ml region.
200
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Figure 6.1: Loop B-Cys loop-Ioop E connection
The backbone structure connecting loops E and B through the Cys loop is displayed in 
white. This connection may be playing a role in signal transduction leading to channel 
opening.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
202
Subunit 1
Face + Face
Pre-D
LoopC
Loop E Loop B
/  /  
/  /
/  /  j Loop A
/
Cys- Loop Pre-M1 region
LBS j
Subunit 2
Face + Face
Pre-D
LoopC
Loop E Loop B
/  /
Cys- Loop
Loop A
Pre-M1 region
To channel ga e To channel gate
Figure 6.2: Interactions formed during activation of the homomeric S-HTsaR.
These interactions are supported by both biochemical as well as molecular modeling data.
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Appendix 1: Mechanistic models of the 5-HT3 receptor 
function
Multi-subunit proteins with more than one binding sites require involvement of more than 
one subunit in their functioning. The site of action that causes biological activity (such as 
channel opening) is located far from the binding site. Such proteins are called allosteric 
proteins. Allosteric proteins are multimeric proteins that demonstrate symmetry. In case 
of nicotinic-acetylcholine receptor, the pentameric structure demonstrates pseudo­
symmetry, which is also the case with 5 -HT3R. For allosteric proteins, two major theories 
of receptor function have been proposed.
1. Concerted model of receptor action and
2. Sequential model of receptor action.
A l.l Concerted model of receptor action
Nicotinic acetylcholine receptor binds two agonist molecules before it opens. 
Involvement of at least two binding sites is thus required for the opening to occur. Thus a 
mechanistic model that applies to multiple binding sites was developed based on a similar 
scheme proposed for enzyme action. This model, which is called the concerted model of 
the receptor function was originally proposed by Monod-Wyman-Changeux, and was 
adapted to describe receptor mechanisms by Karlin (Karlin, 1967), Jackson (Jackson, 
1994) and Colquhoun (Colquhoun and Hawkes, 1977). This model can also be applied to 
the 5 -HT3R. The concerted model makes following assumptions.
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A) The model assumes presence of only three distinct states for the 5 -HT3R; namely 
open, closed and desensitized. No intermediate states are assumed.
B) In the absence of agonist at equilibrium, the receptor can exist all three states, 
although the closed state is preferred as it is energetically most favored. Such an 
equilibrium can be shifted by addition of agonists
C) Agonists preferentially bind with higher affinity to the active or the desensitized 
state of the receptor.
D) Addition of agonist shifts the equilibrium towards the active state/desensitized 
state depending on the equilibrium constants of the reaction.
E) Symmetry in the protein molecule is maintained at all confirmations.
The receptor exists in an equilibrium condition in resting conditions with no contact with 
agonist molecules. In such conditions, the energy barriers that oppose transformation into 
the open state cannot be easily overcome, and the protein can only rarely venture into the 
open state. 5 -HT3R protein is designed to carry out multiple functions. The multimeric 
protein with a total of 2400 amino acids (480 X 5) held together of thousands of chemical 
bonds. These bonds are in constantly being stretched, rotated, broken and newly formed 
on a picoseconds time-scale. The collective energy change that leads to a lower and more 
stable energy state as a result of these changes results in passage of the protein from one 
confirmation to another. Each confirmation may not be greatly different than the previous 
one or the one following. A protein may thus pass through literally hundreds of 
confirmations with very small amounts of change in energy, and it is sometimes difficult 
to experimentally detect such confirmations. Certain confirmations are however
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Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
associated with major changes in the energy landscape and associated alteration in 
physical state. Such confirmations are also associated with distinct states of functional 
importance, and can be usually detected. In case of ligand-gated ion channels, the 
opening of the ion channel is greatly facilitated by presence of agonist molecules. The 
binding of agonist molecule(s) probably helps overcome the energy barrier propelling the 
channel into open and subsequent confirmations.
Certain observations about nicotinic acetylcholine receptor are in tandem with the 
concerted model. At single channel level a clear open and closed state of the receptor 
with unitary conductance is observed. Although no experimental evidence exists that 
indicates that 5 -HT3R opens in absence of agonist, studies of nicotinic acetylcholine 
receptor indicate such to be the case. Opening of the nicotinic acetylcholine receptor in 
absence of agonist can again be observed using single-channel recording, although the 
frequency of such openings is very low (1 in 107 receptors open/ sec) (Jackson, 1994). In 
case of the 5-HT3R, spontaneous opening of mutant receptors has been observed (Zhang 
et al., 2002). The mutation in such a case presumably lowers the energy of ‘activation’, 
allowing spontaneous openings.
Also, both in the case of nicotinic and 5 -HT3R, there exists a (pseudo) symmetry 
around the central axis. Taken together, these observations suggest that concerted model 
of receptor action may be suitable for the ligand-gated ion channels in general and 5- 
HT3R in particular.
Methods used for analysis of the electrophysiological and radio-ligand binding 
data (obtained from studies described here) are based on mathematical expressions of
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concerted model. Various parameters of the drug-ligand interactions for a protein with 
multiple binding sites can be derived from Hill equation. This equation can be used to 
calculate both receptor saturation as well as maximal response with agonist.
B = (Bmax [L]n) / ([L]n + Kn)
Where, B is the occupancy at ligand concentration L, Bmax is the maximum receptor 
occupancy, L is the ligand concentration. K is the dissociation constant or the apparent 
affinity, n indicates the Hill coefficient. Hill coefficient puts a lower limit on the number 
of binding steps. Thus n value of 2.1 indicated that there are at least two agonist 
molecules bound, but the actual number could be higher.
Three models, all based on the concerted mechanism of receptor action, have been 
published to date.
A1.2 A concerted model of 5-HT3R function
Mott et al. used data obtained from kinetic experiments to generate a kinetic model of 
murine 5 -HT3AR function. The kinetic model suggested is based on cyclic model of 
receptor function originally proposed by Katz and Thesleff (Katz and Thesleff, 1957). 
This model is shown in figure above.
This model predicts 3 different open states, and three different desensitized states. The 
model also predicts that the ion channel opens when there are at least three agonist 
molecules occupying the 3 out of 5 5-HT3aR binding sites. The probability of being in 
open state increases when 4 agonists are bound. With binding of 5 agonist molecules, the 
probability of being in the desensitized state increases, which in turn results in reduced 
probability o f opening.
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Al.2.1 Alternate model of 5-H TsR function-1
Zhou et al. proposed a sequential kinetic model, which was built using a kinetic model 
for the nicotinic acetylcholine receptor (Zhou et al., 1998). The model assumes that two 
agonist molecules needed to open the channel.
This model was proposed in an attempt to explain the potentiation of 5 -HT3R currents by 
trichloroethanol (TCEt) at low concentrations and channel blockade at higher 
concentrations. The model suggests that TCEt, at lower concentrations, potentiates 5-HT 
induced currents by altering the stability of the open state. This stabilization of the open 
state is achieved both by decreasing dissociation and desensitization rates and increasing 
activation rates. The kinetic model suggested by authors successfully simulated 
experimental data from studies using 1 pM 5-HT and TCEt, and represents a simple 
model for receptor action. However, it is not known whether such a model can 
successfully simulate receptor behavior at all concentrations of 5-HT, especially supra­
maximal concentrations. Such models on the other hand provide a starting point for 
development of more complex models of receptor action.
A l.2 .3  Alternate model of 5-HT3R function-2
Based on Hill number obtained from dose-response curves, Hapfelmeier et al. and others 
have predicted that 2 (Hapfelmeier et al., 2003) and not 3 molecules of agonist are 
required to open the channel. When a specially designed solution exchange system is 
used to record 5-H or wCPBG induced responses from 5-HT3aR, rapid removal of 
agonist induces tail currents. These tail currents probably result from removal of 5-HT
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molecules causing channel blockade. Thus, 5-HT induced channel blockade may be at 
least partially responsible for 5-HT3aR desensitization. Hapfelmeier et al. have proposed 
sequential kinetic model for 5 -HT3A receptor based on their findings. The authors predict 
that the biphasic desensitization waveform is a result of channel block resulting from 
binding of 5-HT to a combination of high or low affinity binding sites in the channel 
region producing high and low affinity block. According to this model, 3rd agonist 
molecule actually induces desensitization by binding to either high or low channel 
blocking site.
The authors report experimental findings suggestive of multiple desensitization states, 
while their reported kinetic model supports single final desensitization state for both 5- 
HT3A and 5 -HT3AB receptors.
On the other hand, currents induced from 5-H T3Ab receptors using 5-HT do not show tail 
currents, based on which it was suggested that 5-HT3AB receptor follows a more standard 
model of receptor function. The kinetic model suggested is based on cyclic model of 
receptor function originally proposed by Katz and Thesleff (Katz and Thesleff, 1957).
Interestingly, mCPBG was able to induce tail currents even in 5-HT3Ab receptors, 
suggesting a complex mechanism of desensitization for these heteromeric receptors. Co­
expression of B subunit also confers biophysical parameters to the heteromers, which are 
not observed with homomers. The deactivation rate of the 5-HT induced currents 
becomes significantly faster than the desensitization rate. This feature is also evident in 
recordings from neural cells natively expressing 5-HT3R, suggesting that most of 5-HT3R 
is expressed in neural tissues as a heteromer and not homomer.
208
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
While the models proposed by Hapfelmeier et al. for 5-HT and mCPBG action on 
5 -HT3A and 5-HT3Ab receptors are simplistic, the suggestion that 5-HT and mCPBG 
induce desensitization in S-HTjab receptor through different mechanisms is intriguing. 
mCPBG is also unusual in demonstrating high apparent affinity (EC50) for the receptor, 
and still have almost 8% lower efficacy compared to 5-HT. wCPBG also shows delayed 
recovery from desensitization, which probably accounts for the lower efficacy. Other 
studies have proposed that structurally diverse agonists induce distinct desensitization 
states and recognize distinct confirmations of receptors recovering from desensitization. 
These data are in agreement with the suggestion that 5-HT and mCPBG follow different 
paths in and out of desensitization for the heteromeric 5 -HT3AB receptor.
A1.3 Sequential model of receptor action 
The sequential model assumes that
1) Intermediate states between closed and open are possible.
2) The successive binding of agonist molecules drives the conformational change.
3) Cooperatively emanates from sequential conformational changes in subunits. 
Conformational change in one subunit affects its subunit contact with 
neighbouring subunit and changes binding characteristics of the neighboring 
subunit.
4) Symmetry in the protein molecule is not necessarily maintained. The protein goes 
through sequential changes in confirmation as a result of gradual changes in 
quaternary structure.
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Although a sequential model of the receptor function appears simple, in terms of kinetic 
measurements, it presents with several complexities. These complexities arise from the 
assumption of multiple intermediate states between several functionally recognizable 
confirmations of the protein; i.e., closed open and desensitized. In case of membrane 
bound receptors (as opposed to soluble enzymes), it is exceedingly difficult to 
experimentally detect the assumed intermediate confirmations and their associated kinetic 
rates.
Membrane bound receptors cannot be easily crystallized. For the same reason, various 
confirmations of these receptors cannot be easily ‘trapped’. The intermediate 
conformational changes assumed by the sequential model possibly occur at a very fast 
rate, further complicating any possible measurement of kinetic rates. For these reasons, 
sequential models of receptor action can be less easily validated compared to concerted 
models of receptor behavior.
There are no published sequential models of 5 -HT3R function.
2 1 0
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Figure A l.l:  Mechanistic models of 5-HT3R function
A l.l.A  A Concerted model for cooperative behavior of pentameric 5-HT3R
Five subunits of the 5-HT3aR are depicted in a pseudo-symmetric arrangement. Various 
reversible transitions between states are indicated by double arrows. Squares indicate 
basal closed state. Triangles indicate desensitized state, while circles indicate open state. 
Color indicates presence of ligand, while lack of color indicates absence thereof. 
According to this model, all five subunits can exist either in closed, open or desensitized 
state.
A1.2.B Sequential model for cooperative behavior of pentameric 5-HT3R
Five subunits of the 5-HT3AR are depicted in a pseudo-symmetric arrangement. Various 
reversible transitions between states are indicated by double arrows. Squares indicate 
basal closed state. Triangles indicate desensitized state, while circles indicate open state. 
Color indicates presence of ligand, while lack of color indicates absence thereof. 
According to this model, five sequentially pass from closed to the open and from open to 
the desensitized state
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Appendix 2: A vertical flow chamber for Xenopus oocyte
electroptiysiology and automated drug screening5 
A2.1 Abstract .
Xenopus laevis oocytes are used extensively in the study of ion channel coupled 
receptors. Efficient use of oocytes for ion channel characterization requires a system that 
is inherently stabile, reproducible, minimizes drug volumes, and maximizes of oocyte 
longevity. We have constructed a vertical flow oocyte recording chamber to address the 
aforesaid issues, where the oocyte is placed in a funnel-shaped chamber and perfused 
from the bottom of the funnel. The vertical rather than horizontal flow of perfusate results 
in an unusually stable environment for oocyte recording. Two-electrode voltage-clamp 
recordings from a single oocyte are acquired easily and routinely over several hours 
while maintaining stable baseline currents and reproducible response profiles. Chamber 
characteristics were tested using a serotonin ligand-gated ion channel receptor (5 -HT3R). 
Data obtained from this system corresponds well with published data. To further test the 
stability and reliability of this perfusion chamber, we constructed an automated oocyte 
perfusion system utilizing a commonly available HPLC autosampler. We were able to 
obtain dose response curves for various 5 -HT3A R ligands using the automated perfusion 
system with minimal user intervention. Such a system can easily satisfy need for
5 Published in the Journal o f Neuroscience Methods. (Citation: Joshi PR, Suryanarayanan 
A and Schulte MK (2004) A vertical flow chamber for Xenopus oocyte 
electrophysiology and automated drug screening. J  Neurosci Methods 132(l):69-79.)
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automated oocyte electrophysiology in academic settings, especially small to medium 
sized laboratories.
215
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
A2.2 Introduction
The Xenopus laevis oocyte, a heterologous expression system, has been successfully used 
to study various biological systems and ion channels including ligand-gated ion channels 
such as the nicotinic acetylcholine and serotonin type three receptors (5 -HT3R) (Bertrand 
et al, 1997; Maricq et al 1991). The functional aspects of these receptors can be studied 
electrophysiologically using two-electrode voltage-clamp. In this technique, oocytes are 
injected with cRNA (cytoplasmic) or cDNA (nuclear) coding for the ion channel receptor 
under study. After incubation at 19°C to 21°C for an appropriate length of time (usually 
24-48 hours), an oocyte expressing ion channel receptors is placed in a perfusion 
chamber and voltage-clamped. Rapid exposure of such an oocyte to an agonist results in 
inward currents with characteristic shapes and distinct desensitization characteristics.
In the conventional perfusion method, an oocyte is placed in a circular or 
elongated depression, with perfusion inlet from one end and drainage from the other end. 
Depending on specific requirements, the chamber volume can vary from small (-50-250 
pi) to large (~lml). Most of the conventional perfusion chambers involve a solution flow 
across the oocyte and the electrodes (fig.A2.1D). Such a flow results in a constant 
application of force to the oocyte at a direction that is perpendicular to its points of 
anchorage (base and the recording electrodes). Minute vibrations of the electrodes 
impaled in the oocyte may damage the oocyte membrane and increase the leak of 
electrode filling solution (usually 3M KCL). These effects may not be obvious in short 
term studies although may contribute towards oocyte mortality on a long-term basis.
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Additionally, many of the standard oocyte chambers, oocyte may not be exposed to the 
drug rapidly from all the sides, thus limiting rise times.
Oocyte electrophysiology is commonly employed in high throughput drug 
screening assays. These assay systems must meet certain requirements in order to 
produce reliable and reproducible data. Simplicity and rapidity of operation are important 
considerations, in addition to low drug volumes, rapid drug exchange rates, and stability. 
Among the various factors, stability appears to be of paramount importance to the 
successful execution of automation. An increase in the longevity of the oocyte will result 
in a highly productive system; where as reduced longevity will necessitate constant 
monitoring and intervention.
We describe a novel oocyte perfusion chamber where the oocyte is placed in a 
small volume funnel-shaped chamber on top of a wire mesh and perfused from an inlet at 
the bottom of the funnel. We have utilized ligand-gated ion channel coupled receptors, 
the 5 -HT3A and 5 -HT3 AB receptors (Maricq et al 1991; Davies et al 1999), to demonstrate 
various features of the funnel shaped chamber. A vertical flow as opposed to a sideway 
flow is expected to provide a stable environment to the oocyte. We show that an oocyte is 
stable for an extended period in the vertical flow chamber. The stability and reliability of 
the perfusion chamber have allowed us to construct an automated oocyte perfusion 
system utilizing a commonly available HPLC autosampler. We were able to obtain dose 
response curves for various 5-HTsa R ligands using the automated perfusion system with 
minimal user intervention.
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A2.3 Materials and Methods 
A2.3.1 Materials:
Sigma type II collagenase was purchased from Sigma-Aldrich (MO, US). mMESSAGE 
mMACHINE™ High Yield Capped RNA Transcription Kit was purchased from Ambion 
(TX, US). The OC-725C oocyte clamp and 7.5-150GT glass electrodes were purchased 
from Warner Instruments (CT, US). Datapac 2000 data acquisition software was 
purchased from RUN technologies (CA, US). Xenopus laevis frogs and frog food were 
purchased from Xenopus Express (FT, US). All other chemicals were obtained from 
Fisher Scientific (TX, US).
A2.3.2 Methods
A2.3.2.1 Chamber construction
Figure A2.1 provides with line diagrams of the chamber; a photograph is shown in figure 
A2.2A. We constructed the chamber apparatus using blocks of clear acrylic material. It 
consists of three parts: 1) A funnel shaped perfusion chamber 2) Chamber holding 
apparatus and 3) Fluid inlet and drainage system (Figure A2.1). The scheme shown in 
figure A2.1 refers to the manual operation of the system.
1) Funnel shaped perfusion chamber
The funnel shaped perfusion chamber (Figure A2.1C, Fc in Figure A2.1B) is a separable 
part of the perfusion system. Externally, it is cylindrical in shape with a funnel shaped 
interior at an angle of 30 degrees. The cylinder is 19 mm in diameter and 10 mm in 
height, with a 7 mm diameter circular inlet at the bottom, through which the fluid enters.
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The uppermost edge is the broadest part of the funnel with a diameter of 17 mm. Six 
drainage tubes are present in the funnel wall (Ex in Figure A2.1B). These tubes are 
arranged equidistant, tangentially to the perimeter of the funnel at a height of 2.1 mm 
from the top of the chamber. Each tube is 1 mm in diameter providing outlet for the 
perfusate. On the right side, an oblique tunnel (T) extends from the outer wall 1.5 mm 
from the upper rim, to a level 3 mm above the lower rim at the inner wall (Figure A2.1C). 
This oblique tunnel allows placement of an agar bridge that in turn is placed in a well 
containing the sense reference electrode (R2) in 3 M KC1. Another well contains a second 
reference electrode (Rl). The perfusion chamber holds a volume of 250 pi.
2) The chamber holding apparatus
The chamber holding apparatus consists of three concentric wells designated as ‘A’, ‘B’ 
and ‘C’ in Figure A2.1B. The outermost well ‘A’ is largest with a diameter of 30 mm and 
a depth of 4.5 mm and functions as the overflow drainage well. The volume in this well is 
maintained at -200 pi. The middle well ‘B’ functions as the perfusion chamber holder 
with a diameter 0.01 mm greater than the diameter of the perfusion chamber and a depth 
of 4.2 mm. A no. 40, 250 micron stainless mesh ( Small Parts Inc., Miami Lakes, FL) (M 
in Figure A2.1) is placed at the bottom of well ‘B’ and the perfusion chamber is pressed 
in place on top of the mesh. The innermost well ‘C’ is 8 mm in diameter and 2.1 mm in 
depth with an inlet connected from the bottom. The main inlet tube ‘D’ is 3.2 mm in 
diameter and runs down from well C for 4 mm before making a right angle turn and 
running parallel to the bottom of the chamber where it assumes a diameter of 1.3 mm.
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The two inlet tubes ‘E’ and ‘F’ (1.3 mm diameter) run from the top of the chamber and 
join tube ‘D’ at right angles. ‘E’ acts as drug inlet while ‘F’ acts as buffer inlet.
3) Fluid inlet and drainage system
All of the tubing used in the perfusion system is clear polyethylene PE 50 tubing. Since 
some drugs stick to the polyethylene tubing, a non-stick Teflon material can also be 
used. Drug inlet ‘E’ is connected via a 15 cm T tube to an 18-gauge syringe needle, 
which in turn can be connected to varying sizes of syringes to carry out drug perfusions. 
Drug perfusions are accomplished by using a perfusion pump. Buffer inlet ‘F’ is 
connected to the buffer reservoir and the flow adjusted to a rate of 20 ml /min. A flow 
rate of ~ 20 ml/min is faster than commonly reported (6-10 ml/min). However, other 
authors (e.g. Vijverberg et al, 1997) have previously reported such rates. The oocyte is 
exposed to the drug dissolved in ND96 recording buffer [96 mM NaCl / 2 mM KC1 / l .8 
mM CaCb / 1 mM MgCfe / 5 mM HEPES, titrated with NaOH to pH 7.4] at the rate of 
25 ml/min; this flow rate is used only during sample injection. The buffer flow need not 
be stopped during the sample injection. The drainage tube (‘P’ in Figure A2.1), placed in 
the holder, is positioned on the outermost well ‘A’ at a height 1mm below the level of 
exit tubes. Drainage is achieved with help of vacuum suction. All the described features 
can be identified in the photograph (figure A2.2A).
4) Automated perfusion system
The automated oocyte perfusion system utilizes a Gilson 231 XL auto sampling HPLC 
injector coupled with a keypad controller and a Gilson 401 dilutor. In order to minimize 
drug requirements the volume of the conical chamber was reduced to an effective
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chamber volume of 200 pi. Figure A2.3 shows the schematic arrangement of elements 
comprising the automated oocyte perfusion system. The autosampler injection valve (V) 
controls the traffic of fluids to the oocyte chamber (C). A 5ml syringe (S) mounted on the 
401 dilutor draws ND96 from either a reservoir (Rl) or the drug sample tube in the 
sample rack (SR). The injection port (IP) is connected to an injection loop (IL), which 
holds 2000 pi of fluid. The other end of the injection loop is attached to port 4 of the 
injection valve (V). Reservoir 2 (R2) is the default supplier of the ND96 buffer to the 
oocyte chamber, and is connected to port 2 of the injection valve. In the load position, the 
buffer from reservoir 1 flows through the valve then out port 3 to the chamber. The load 
position of the valve thus provides for a continuous flow of buffer to the chamber and is 
the default valve position. The contents of the injection loop are directed through port 5 
to the drain when the valve is in the load position. After withdrawing the sample from the 
tube in the sample rack, 2000 pi of the sample is injected through the injection loop. The 
valve is then switched to inject and 1000 pi of the buffer in reservoir 1 (Rl) is injected 
through the injection loop. In the inject position, the contents of the sample loop are 
injected through port 3 to the chamber and the buffer flow from R2 is stopped; thus 
directing the sample to the chamber. The flow rate during sample injection is set to 20 
ml/min. After the 1000 pi sample is injected into the chamber, the flow is stopped for a 
predetermined exposure time. Directly following drug exposure, the valve is switched 
back to load position and the buffer begins to flow to the chamber to wash out the 
sample. After washing the injection port and needle, the autosampler then draws up the 
next sample and the process repeats.
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Xenopus laevis ovarian lobes were surgically removed using sterile techniques. Ovarian 
lobes were washed twice in Ca+2 free Barth’s buffer [82.5 mM NaCl / 2.5 mM KC1 / 1 
mM MgCh / 5 mM HEPES, pH 7.4] under sterile conditions and gently shaken with 1.5 
mg/ml collagenase (Sigma type II, Sigma-Aldrich) for lhour at 20-25 °C. Stage IV and V 
oocytes were selected and prepared for micro injection. Selected oocytes were maintained 
at 10°C in Ca+2 free Barth’s medium.
cRNA synthesis and microinjection: Synthetic cRNAs for the mouse/ 5 -HT3A and human 
5 -HT3A / 5 -HT3AB receptors were prepared (mMESSAGE mMACHINE™ High Yield 
Capped RNA Transcription Kit).Approximately 50 nl cRNA solution injected into 
oocytes at a concentration of 0.2 mg/ml. Oocytes were incubated at 19°C for 24 to 48 hrs. 
At the end of the incubation period, healthy oocytes were selected for 
electrophysiological recording.
A2.3.2.3 Electrophysiological recordings
Data were acquired using an OC-725C oocyte clamp amplifier (Warner Instruments) 
coupled to online, computerized data acquisition system (Datapac 2000, RUN 
technologies). Data collection rates of 20 msec were used for all the recordings. The 
recording setup was prepared as follows. An agar bridge was placed in well ‘A ’ 
connecting it to the well containing a reference electrode (R1 in figure A2.1) in 3M KC1. 
A second agar bridge was placed in the wall of the perfusion chamber (T in Figure A2.1) 
connecting the interior of the perfusion chamber to the ‘sense’ reference electrode in 3M 
KC1 (R2 in Figure A2.1). An even flow of ND96, the recording buffer, was established.
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A2.3,2.2 Harvesting and maintenance of Xenopus laevis oocytes
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An oocyte was placed in the center of the perfusion chamber on the stainless mesh after 
stooping the buffer flow. Two Glass(7.5-150GT, Warner instruments, CT, US) 
electrodes(‘current’ and ‘voltage’) with resistance of 1-2 M ft were filled with 3M KC1 
and lowered until they converged on the oocyte placed on the mesh. The oocyte was thus 
held in place with three points of contact; two electrodes at the 10 and 2 o’clock positions 
and the mesh at the 6 o’clock position. The oocyte was voltage-clamped only if the 
resting membrane potential was -15 mV and above. The holding potential was -60 mV 
for all experiments unless stated otherwise.
The voltage-clamped oocyte was perfused with ND96 buffer solution at a 
constant rate of 20 ml/min by gravity feed through inlet ‘F’ and tube Ft. All the 
recordings involved switching from buffer perfusion to drug perfusion
The manual operation of the recording system is described first. Drugs (5-HT and 
otCPBG) constituted in ND96 buffer were applied through inlet ‘E’ connected to a 
syringe containing drug through tubing Et, using a motor driven pump (Harvard 
Apparatus) at a flow rate of 25 ml/min. Each drug application was followed by a buffer 
wash for 3 minutes. The duration of the drug application was four to five seconds at 
which time the perfusion was stopped (-1.6 ml drug per exposure) and the drug retained 
in the chamber until the desired washout time. No difference in the characteristics of 5- 
HT elicited currents was observed when longer drug exposures were performed. The drug 
was washed out of the chamber at the end of 108 seconds and the buffer flow continued 
for three additional minutes. At the end of each drug perfusion and after initiation of 
wash buffer, tubing Et is disconnected from the syringe containing the drug and lowered
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into a receptacle at a level lower than that of the chamber. This allows the running wash- 
buffer to purge tube Et resulting in complete clearance of the drug from the drug inlet 
tube Et.
To compare data generated from conventional side-flow chamber with that 
generated from the vertical-flow chamber, following protocol was followed. First, a 
conventional side-flow oocyte perfusion chamber (RC-1Z Oocyte Recording Chamber, 
Warner Instruments, Hamden, CT, approximate chamber volume 225 (il, with minor 
differences) was employed to elicit inward currents from oocytes expressing mouse 5- 
HT3AR. The perfusion system was set up exactly as described for the vertical-flow 
system, including two separate in-flows for drug and buffer. The voltage-clamped oocyte 
was perfused with ND96 buffer solution at a constant rate of 20 ml/min by gravity feed 
through inlet ‘F’ and tube Ft. The clamped oocyte was exposed to 30 pM 5-HT dissolved 
in the ND-96 buffer at a rate of 25 ml/min using the motor driven pump, and the inward 
currents were recorded. The procedure was repeated at least four times with the oocyte 
being used; at the end of which period the oocyte was removed from the side-flow 
chamber and stored for the future use. The side-flow chamber was then replaced with the 
vertical-flow chamber, while preserving the tubing, the recording electrodes, the agar 
bridges being used as well as rest of the recording setup. The agonist solution in use was 
also preserved. The entire operation of switching recording chambers was completed 
within 15 minutes. The oocyte used earlier was then placed in the vertical-flow chamber 
and was exposed to the agonist (30 pM 5-HT). The wash buffer as well as the agonist 
was perfused at rates 20 and 25 ml/min respectively. The whole experiment was repeated
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3 times, using three different oocytes. Figure A2.2C shows representative results obtained 
from these experiments.
To obtain IV curves, voltage was stepped up +10 mV at a time before agonist 
application, starting from -80 mV up to +30 mV. All the currents were normalized to the 
value obtained at -80 mV. Data represents a combination of three data sets obtained from 
three different oocytes.
A program written for the sampler keypad controller achieves automated 
perfusion. The sequence of events leading to a single drug exposure is as follows. Buffer 
from reservoir two (R2) is continuously flowing through the chamber (C) at a constant 
rate of 20 ml /min. When the sequence is initialized, the 5ml syringe (S) first draws 300 
pi of buffer from reservoir 1 .This buffer is then used to rinse the inside and outside of the 
injection needle (N). The syringe then draws 4500 pi of buffer and injects it into the 
injection port (IP) and the injection loop (IL) which drains out of the drain tube, thus 
rinsing the injection port and the injection loop. Drug sample (1 ml), stored in a 1.7 ml 
eppendorf tube is then collected by the syringe and injected into the injection loop. The 
next step involves loading of 1 0 0 0  pi of buffer in the syringe from reservoir 1 and 
initiation of recording trace in the data acquisition software (DataPac 2000), through an 
external pulse generated by the autosampler. This step is accompanied by a change in the 
default valve position, which shuts off the buffer flow from reservoir 2  and directs the 
contents of the injection loop to the chamber. The injection of 1000 pi of buffer into the 
injection loop injects 1000 pi of the drug sample into the chamber. This step is followed 
by a waiting period of 36 seconds, which ensures appropriate exposure of the oocyte to
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the drug. At the end of the waiting period, the valve shifts to its default position, 
reinitializing buffer flow from reservoir 2. Another waiting period of 1.5 minutes then 
commences before the cycle is repeated. The sampler has been programmed to collect 
samples from sequentially arranged eppendorf tubes in the sample rack.
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We utilized oocytes expressing 5-HT3A receptors to assess the functionality of the newly 
designed chamber. The characteristics of 5 -HT3A mediated inward currents recorded from 
microinjected oocytes are well established. (Davies et al, 1999; Dubin et al 1999; Yakel 
et al, 1996). Application of 5-HT to oocytes expressing 5 -HT3AB receptors resulted in 
characteristic inward currents. Figure A2.4A shows representative responses obtained 
from application of 0.3, 3, 10 and 30 pM 5-HT to such an oocyte. The inward currents 
show all critical parameters of 5 -HT3AB receptor-mediated currents. The onset of 
response corresponds with onset of drug application. The onset of inward current is rapid 
(10 to 90% of peak current within -400 msec), with a sharp ‘peak’. Drug exposure is 
terminated in five seconds, when the response is in the slow phase of desensitization. The 
chamber then functions as a static chamber. To rule out occurrence of artifacts due to 
shorter perfusions, we performed longer perfusions of 5-HT (from 24 to 36 seconds, data 
not shown). Recordings obtained with varying perfusion times were essentially identical. 
The slow phase o f desensitization is evident even in the continued presence of agonist. 
Wash buffer is started at 108 seconds when the trace has almost returned to the baseline 
during the non-desensitizing phase. Figure A2.4B shows the dose-response curve of 5- 
HT for the 5 -HT3 AB receptor, with an EC50 value of 7.6 + 0.46 pM. These results agree 
well with previously published data (Davies et al, 1999).
To compare the functionality of the vertical-flow chamber with the side-flow 
chamber, we compared data obtained from the two systems using a single oocyte 
expressing mouse 5-HT3A R. We used a small volume conventional side-flow chamber,
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A2.4 Results
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which was identical to the vertical-flow chamber in all the other aspects. However, 
dramatic differences were observed in the data obtained from the two chambers, an 
example of which is shown in figure A2.2C. The traces marked as (a) were obtained from 
the vertical flow chamber while those marked with (b) were obtained with the 
conventional side-flow chamber. The average rise time obtained using the side-flow 
chamber was 850 ms, while an average rise time of 400 ms was obtained using the 
vertical-flow. The response amplitudes also differed proportionately, with almost a 
double amount of current elicited when using the vertical-flow chamber. Differences 
were also observed in the characteristics of the desensitization. These results suggest that 
vertical flow results in better exposure of the oocyte to the drug solution, as compared to 
the side flow.
To further test the validity of the novel perfusion system, a current-voltage 
analysis was undertaken. Oocytes expressing 5 -HT3A receptor were clamped at holding 
potentials ranging from -80 mV to +30 mV (increments of 10 mV) and currents induced 
by application of 30 pM 5-HT were recorded for each holding potential. Currents were 
normalized to value obtained at -80 mV. The plot of normalized inward currents vs. 
holding potential is shown in Figure A2.4C (n=3). The current-voltage relationship is 
typical of an inwardly rectifying ion channel with a reversal potential near zero mV. 
These data agree well with reported values for the human 5-HTsa receptor ((Davies et al, 
1999).
To demonstrate the considerable stability achieved in oocyte perfusions, an 
oocyte expressing the mouse 5 -HT3A receptor was maintained in a funnel shaped chamber
228
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
for 10 hours and perfused with a fixed concentration of 5-HT every 45 minutes by 
following the protocol described above (Figure A2.5). The traces shown in figure A2.5 
are representative of two separate experiments. The oocyte was superfused with wash 
buffer at a constant rate of 2ml/min in intervals between two complete manual recording 
procedures. Over the 10-hour period, the baseline current (at approximately 0.4 pA) 
being injected into the oocyte showed no demonstrable change. Only minor changes in 
the maximum amplitude of the responses were observed. Gradual changes in the 
characteristics of the slow phase of desensitization were observed over the 10-hour period 
(see figure A2.5, traces D - O). The exact mechanism of these changes remains unknown. 
This decrease in desensitization rates is similar to the well-characterized “deceleration” 
phenomena commonly observed in whole-cell patch-clamp studies of 5 -HT3R.S (Yakel et 
al, 1991). While these effects are not commonly observed in Xenopus oocytes, it is 
possible that the prolonged recording time in these experiments produces a similar 
alteration in desensitization. Changes in levels of intracellular calcium or changes in 
second messenger systems are among the myriad of potential causes of these effects 
(Davies et al, 1999).
Automated oocyte recording systems are receiving attention due to their potential 
use in high throughput drug screening. The automated perfusion system described here 
was set up using a commonly available Gilson HPLC autosampler and injector. 
Continuous traces of inward currents elicited from an oocyte expressing human 5 -HT3A 
receptors by exposure to agonists 5-HT and mCPBG are shown in Figure A2.6A. Data 
obtained from the same traces was utilized for calculation of EC50 values for both
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agonists (Figure A2.6B). The characteristics of the responses as well as the EC50 values 
obtained (5-H T, 3.4 + 0.39 pM and twCPBG, 4.0 + 0.2 pM) agree well with previously 
published results (Davies et al, 1999). The use of a 200 pi chamber in these experiments 
resulted in faster response onrates (10 to 90% of peak current within -250 msec) when 
compared to the 450 ml chamber used in the manual perfusion system (~ 400 msec). As a 
result of the automation provided by this system, the recording procedure described 
above was completed in approximately 40 minutes without any user intervention.
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A reproduction of the established pharmacological profile for the 5 -HT3 receptor using 
the vertical flow apparatus validates our novel drug exposure method. Ligand affinities as 
well as other physiological characteristics (desensitization, voltage dependence) are in 
close agreement with previously reported values. The oocyte in a vertical flow chamber is 
suspended in the path of drug flow, achieving exposure to the complete oocyte surface 
area. This is akin to certain whole-cell patch-clamp techniques, where a mammalian cell 
is lifted up and then perfused to achieve maximum exposure. A similar chamber design 
was utilized for bath perfusion of brain slices (Koerner and Cotman, 1983). In a vertical 
flow system, drug solution flows over most of the oocyte surface before encountering the 
recording electrodes, thus minimizing turbulence. The decrease in turbulence even at 
high flow rates is apparently responsible for the high level of stability of this system. 
Multiple exit points at a fixed level above the oocyte hold the buffer level constant at all 
flow rates, avoiding cyclic rise and drop in solution levels. Lack of electrode movement 
as well as changes in the bath level at drug application, avoids agonist-application related 
artifacts, either at the onset of drug perfusion or at the onset of wash buffer. The solution 
exchange rates measured as a function of 5-HT induced response on-rates (~ 250- to 400 
msec) were adequately rapid, although faster rates have been obtained (200 msec) with 
other chambers, using mouse 5-HT3AR (Yakel, J.L 1993). Fast flow rate of 25 ml/min 
was necessary to obtain fast exchange rates. The flow rate was not altered due to the 
presence of the stainless steel mesh. A stainless steel mesh provides a solid support to the 
oocyte and hence is preferred to a nylon mesh. The mesh also plays an important role in
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A2.5 Discussion
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redistributing the flow of the drug around the oocyte. Despite fast flow rates, drug 
requirement was limited to 1,6 ml/exposure (up to 1 ml in case of the smaller chamber), 
as a result of the static exposure system. Although we could obtain faster onrates and 
lower drug requirements by further reducing the chamber volume (> 200 pi), it 
undermined the stability of the system.
Although data presented here consists mostly of relatively large currents, we have 
expressed and successfully characterized various mutant 5 -HT3R.S that generate small 
currents using the described system. Although we cannot specifically comment about 
other receptors or transporters, the relatively rapid drug exchange rates as well as low 
dead volume may result in increased sensitivity for detecting smaller currents.
Experiments involving the comparison of the vertical with the side-flow chamber 
clearly show that vertical flow system offers a distinct advantage over the conventional 
systems. Such a comparison at times could be misleading, since a number of minor 
differences collectively could result in large differences in the data obtained. We 
exercised utmost precaution in making such a comparison. To avoid any bias, the general 
setup was carefully preserved while changing only the perfusion chambers during these 
experiments. Since vertical flow results in half the rise times and double the current 
amplitudes, a strong argument could be made for the much improved drug exposure, in 
case of the vertical-flow perfusion system.
The stability of the perfusion system was demonstrated by the ability to record 
electrophysiological traces from single oocyte for more than ten hours. Although we see 
changes in the desensitization characteristics over a period of 10 hours, these changes
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only manifest prominently at the beginning of 4th hour of recording (trace marked “E” in 
Figure A2.5). In addition, the changes seen are very specific to the slower phase of 
desensitization, where as the base line current, the rise time as well as the fast phase of 
the desensitization remains largely unchanged. The slower phase of desensitization shows 
gradual changes (traces marked E to O in figure A2.5), where a progressive deceleration 
is observed over time. Moreover, these results could be reproduced in a second identical 
experiment. These changes could result from a variety of causes including effects 
introduced by the prolonged oocyte use. The specific nature of the changes however 
speaks against a generalized trauma to the oocyte as a cause. Any such trauma will result 
in increased baseline leak current, which did not change at all. To explain this 
phenomenon, an in-depth analysis of many possible causative factors needs to be 
undertaken.
The ability to a single oocyte over a period of ten and half hours represents 
regularly obtainable operational ability of the recording apparatus rather than specially 
designed and controlled conditions. We routinely record for a single oocyte over a period 
of 7-8 hours, with drug flow rates of 25 ml/min without any qualitative loss. The stability 
of the system actually permits recording from a single oocyte for as long as the operator 
wishes to use it. Similar studies may be employed that allow long-term measurement of 
receptor function, desensitization, modulation of receptor function by second messengers 
and receptor turnover. The design of the chamber also allows for placement of various 
probes (such as temperature, pH) vety close to the oocyte without obstruction to the flow 
of buffer.
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A simple experiment amply demonstrates stability offered by the vertical flow. 
The oocyte is placed at the centre of the mesh without the recording electrodes and 
perfused sequentially with wash buffer at 20ml/min and a dye at 25 ml/min. The oocyte 
retains its position on the mesh in the rapid buffer/dye flow even in absence of the 
recording electrodes. Serial images captured of such an experiment are shown in figure 
A2.2B. No such phenomenon was observed with a sideways buffer flow using a 
conventional chamber, where an oocyte cannot be retained in the recording chamber 
without being anchored by the recording electrodes. These experiments suggest that the 
vertical flow system provides a non-turbulent environment to the oocyte.
The automated system was primarily developed to assess the utility of the vertical 
flow chamber in automated settings. It should however be noted that any type of chamber 
can be adapted to the described automated perfusion system. The automated system 
described here uses a relatively inexpensive HPLC auto injector to provide a highly 
reproducible system requiring only small quantities of test compounds, low maintenance, 
and minimal human intervention. A number of automated oocyte recording systems have 
been recently introduced. OpusXpress™ (Axon Instruments, CA), offers many advanced 
features such as automated impalement, perfusion and data acquisition from up to eight 
Xenopus oocytes simultaneously. ALA Scientific offers Roboocyte™; a 96 well plate 
based automated system that allows both automated cRNA injections as well as 
recording. Automated system described here can only record from a single oocyte at a 
time and does not allow automatic impalement. Commercially available systems are 
primarily designed for industrial applications and are not easily available for academic
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laboratories. While it lacks certain advanced features present in the commercially 
available systems, the BDPLC pump based automated system offers a viable alternative, 
particularly for medium to small sized operations. HPLC based system is a relatively 
simple system requiring very little training. During the past two years, students at all 
levels o f expertise were successful in obtaining excellent quality recordings using this 
system.
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Figure A2.1: A schematic diagram of X. laevis oocyte perfusion chamber.
A-Top view, B- side view.
Fc: Funnel shaped chamber, Ex: Exit tube(s), T: Tunnel in the wall of funnel shaped 
chamber for the placement of Agar bridge, A: Outermost well, B: Middle well, C: 
Innermost well, M: Stainless mesh, D: Main inlet tube, E: Drug Inlet tube, F: Buffer inlet 
tube, Et: Tube connected to drug inlet, Ft: Tube connected to Buffer inlet, P: Drainage 
tube connected to vacuum suction, R1 and R2: Reference electrodes.
C- Funnel shaped inner chamber with an agar bridge in tunnel T is shown. AB: Agar 
bridge.
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D- Solution flow in sideways vs. vertical flow chamber. Sideways solution flow is 
perpendicular to the placement of the electrodes; vertical flow follows the same direction
as electrodes.
These connections are used for the manual operation of the system.
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Figure A2.2: The chamber design 
A2.2.A The vertical flow chamber
A photograph of the conical oocyte chamber with the agar bridges in position. Et: Tube 
connected to drug inlet, Ft: Tube connected to Buffer inlet, P: Drainage tube connected to 
vacuum suction, Rl and R2: Reference electrodes.
A2.2.B An experiment demonstrating non-turbulent flow in the vertical flow system
An oocyte was placed in the chamber without recording electrodes and sequentially 
perfused with buffer at a flow rate of 20 ml/min and with blue-dyed buffer at 25 ml/min 
(to simulate plain buffer and drug with buffer exposure). The sequential images were 
captured from a video recording of the experiment. All images clearly show an oocyte 
placed at the center of the recording chamber without recording electrodes. These 
sequential images are marked from A to D; A. Buffer flow at 20 ml/min B. No buffer 
flow C. Dyed buffer being perfused at 25ml/min D. Wash buffer being perfused at 20 
ml/min after the dyed buffer flow. During the entire experiment, the oocyte absolutely 
retains its position.
A2.2.C Inward currents elicited from a single oocyte using (a) the conventional 
chamber and (b) vertical-flow chamber, using 30 micromolar 5-HT.
Results shown are representative of four different experiments. The traces marked as (a) 
were obtained from the vertical flow chamber while those marked with (b) were obtained 
with the conventional side-flow chamber. Experimental conditions including the chamber 
fluid volume, perfusion apparatus, recording buffer preparation, 5-HT solution, buffer, 
and drug flow rates, electrodes, agar bridges, 3M KC1 solution, as well as the rest of the 
recording conditions were identical during use of both the conventional as well as the 
vertical flow chamber. Approximately half the rise times and double the maximal current 
amplitudes were obtained from the use of the vertical flow chamber as compared to the 
conventional side-flow chamber.
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Figure A2.3: The schematic arrangem ent of elements comprising the automated 
oocyte perfusion system.
V: The injection valve of the sampler (controls the traffic of fluids), C: oocyte chamber 
with an oocyte impaled by two electrodes, S: A 5ml syringe mounted on the dilutor 
pump, DP: dilutor pump, R l: reservoir one, SR: sample rack, IP: injection port, N: 
needle, NA: needle position in default position (needle with solid line) , NB: needle in 
load position (needle with dotted line), IL: injection loop, R2: Reservoir 2, D: drain tube 
draining into the waste receptacle. . Ports 2, 3, 4 and 5 of the valve V are also marked.
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The solid arrows indicate flow of fluids when the injection valve is in the default 
position. Needle marked with dotted lines indicates its position during drug perfusion. 
Dotted arrows indicate the pathway of drug flow through the valves 4 and 3 in load 
position.
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Figure A2.4: Validation of the apparatus
A2.4.A Currents elicited by rapid application of various concentrations of 5-HT to 
Xenopus laevis oocytes expressing human 5 -H T sa b  receptors.
The bar above each trace indicates the period of drug exposure. The traces recorded at 
higher concentrations (10 and 30 pM) characteristically show rapid onset with a sharp 
peak (10 to 90% of peak current within ~400msec, n=6 ), as well as multiphasic 
desensitization. The membrane potential was kept constant at -60  mV. Use of a smaller 
volume inner chamber (225 pi) leads to an rise time of 10-90% current in 250msec (data 
not shown).
A2.4. B. Dose-response curves for 5-HTsab R obtained from exposure to agonist 5- 
HT.
Normalized current amplitudes were plotted against concentrations of serotonin (5-HT). 
Experiments were performed in triplicate. Error bars indicate ±S.E. An EC50 value of 7.6 
+ 0.46 pM was obtained.
A2.4.C. Current-voltage (I-V) relationship curve generated from oocytes expressing 
human 5-HT3A receptor.
Currents were obtained by exposure of oocytes to 30 pM 5-HT at holding potentials 
ranging from -80 to +30 mV in increments of +10 mV. The voltage steps were applied 
before the application of the agonist. The data shown is a composite of three experiments 
at each holding potential.
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Figure A2.5: 5-HT induced traces recorded from single oocyte expressing human 5- 
HTsaR, over a period of 10.5 hours.
Traces were recorded by application of 30 pM 5-HT to an oocyte expressing human 
5-HT3AR, clamped at a holding potential of -60 mV. Traces are labeled from A to O (0 
-  10.5 hrs). Traces shown are representative of two separate experiments. The oocyte was 
washed for 43 min (2 ml/min) between sequential 5-HT exposures. Gradual changes in 
the slow phase of desensitization can be observed beginning with trace D (at 135 
minutes). The fast phase of desensitization in all the traces shows little change in 
characteristics. No changes in baseline current as well as response rise times were 
observed during the course of the 10.5 hours experiment.
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Figure A2.6: Validation of the automated drug perfusion system
A2.6. A Currents elicited from an oocyte expressing human S-HTsa receptors by 
exposure to agonists 5-HT and mCPBG utilizing the automated oocyte perfusion 
system.
The traces show sequential exposure of increasing concentrations of 5-HT (1, 3, 10, 30, 
100 pM). A and B represent traces recorded in that order. C and D show similar 
recordings performed utilizing increasing concentrations of mCPBG (1, 3, 10, 30, 100 
pM). All the recordings were obtained from a single oocyte.
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A2.6. B Dose response relationship curves obtained from automated drug perfusion 
experiments (human S-HTjaR).
Data obtained from two different experiments was combined (n=4). EC50 values: 5-HT;
3.4 ± 0.39 pM, m C P B G : 4.0 ± 0.2 pM. Hill coefficients: 5-HT; 1.4, biC P B G ; 2.3.
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